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INTRODUCTION 
 
Hieroglyphs of the ancient Egyptians provide the earliest known reference to the 
fact that, unlike the peripheral nervous system (PNS) the adult mammalian 
central nervous system (CNS) does not spontaneously regenerate after injury. 
The Edwin Smith surgical papyrus, which dates back to 1550 BC, states that “If 
you examine a man with a neck injury … and find he is without sensation in both 
arms and both legs, and unable to move them, and he is incontinent of urine … it 
is due to the breaking of the spinal cord caused by dislocation of a cervical 
vertebra. This is a condition which cannot be treated”. 
 
Damage to the central nervous system (CNS) of higher vertebrates, including 
humans, often results in devastating and persistent functional deficits. Hence, 
victims of stroke, trauma or neurodegenerative diseases suffer permanently from 
the losses in, e.g. movement, body functions, sensation, and thinking. In contrast 
to the peripheral nervous system (PNS) and the embryonic CNS, the capacity of 
the adult brain and spinal cord to repair lesions by axonal regeneration is 
extremely limited. Although injured axons can sprout spontaneously, this 
regeneration attempt is transitory and no significant regrowth occurs over long 
distances.1 However, this failure is not due to an intrinsic or irreversible lack of 
the ability of CNS neurons to regenerate, but rather to the non-permissive nature 
of the CNS environment. This was demonstrated by studies showing that many 
types of CNS neurons can extend long axons either by grafting pieces of 
peripheral nerves onto a lesion site,2,3 or by isolating neurons and growing them 
in culture.4,5  
What happens when there is a spinal cord injury (SCI)? There are two types of 
SCI, (a) Tetraplegics: Suffer impairment or loss in the arms as well as in the 
trunk, legs and pelvic organs and (b) Paraplegics: Have impairment or loss if 
motor and/or sensory function in the trunk, legs and pelvic organs, but have 
retained some or all of this fuction in the region of arms. 
The known therapie is to either immobilizing the spine, a surgery and a steroid 
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treatment or rehabilitation. However to date there is no cure for SCI. 
 
1. Inhibition of axonal regeneration in adult mammalian 
CNS: 
 
There are two main obstacles to regeneration after injury: inhibitors within the 
myelin sheets and formation of glial scars (figure 1).6 The scars are formed by 
reactive astrocytes, which change their morphology to act as a physical barrier to 
axonal outgrowth and also upregulate several extracellular-matrix-associated 
inhibitors after injury.7 However, since the glial scar formation takes a 
considerable time to become fully mature, immediately after injury the main 
impediments to regeneration are inhibitors in myelin. 
 
In the CNS and PNS, many axons are wrapped concentrically and tightly by a 
fatty sheath of myelin, which is produced by oligodendrocytes in the CNS and 
Schwann cell in the PNS.8 Behaving as an insulator, this multilamellar membrane 
is essential for rapid nerve conduction, as evidenced by debilitating 
demyelinating diseases in the CNS and PNS such as multiple sclerosis and 
Guillain Barré syndrome.9 The myelin sheath is interrupted at regular intervals by 
the nodes of Ranvier that are relatively small, unmyelinated regions of the axon. 
In the axonal membrane at these nodes, voltage-gated sodium channels are 
highly concentrated, thus allowing for the saltatory propagation of the action 
potential down the length of myelinated axons.10 Myelin in the adult mammalian 
CNS is also recognized as a major inhibitor for axonal regeneration from a 
variety of neurons both in vivo and in vitro.11-15 This inhibitory role was strongly 
confirmed by a study in which mice were immunized with myelin before a spinal 
cord injury was inflicted. A considerable axonal regeneration across the lesion 
was detected compared with the control mice that were immunized with liver 
tissue.16  
 15
 
Figure 1:   
Why does the regeneration capacity differ so dramatically between the PNS and 
CNS, while axons from both systems are wrapped by myelin sheaths? Actually, 
myelin in the PNS does inhibit neurite outgrowth. Shen’s study showed that 
myelin prepared from the CNS inhibits neurite outgrowth by 70% while PNS 
myelin inhibits by about 60%, relative to the control membranes.17 Nearly all the 
inhibitory molecules identified so far in the CNS myelin are present in the PNS 
myelin as well. However the permissive environment in the PNS for axonal 
regeneration is at least partly due to the different behavior of Schwann cells and 
oligodendrocytes. In the PNS, Schwann cells and macrophages rapidly clear 
myelin after injury, a process known as Wallerian degeneration.8 Regeneration 
takes place only after myelin debris has been cleared, Schwann cells have 
reverted into a non-myelinating phenotype and the expression of myelin proteins 
is downregulated.7 In contrast, removal of myelin in the CNS is much slower after 
injury, and takes several weeks or month to complete.18,19 Therefore, myelin–
associated inhibitors exposed from the damaged myelin sheath in the CNS are 
regarded to be the major obstacles for injured axonal regeneration followed by 
glial scar formation. 
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1.1. Inhibitors of regeneration in myelin: 
 
Following the discovery that myelin is adverse to axonal outgrowth, at least three 
myelin specific inhibitors MAG, Nogo, Omgp have been identified and 
characterized to date. Substantial progress towards the elucidation of the precise 
nature of these inhibitory molecules enhanced the understanding of the signaling 
mechanism involved in the inhibition of axonal regeneration in the adult 
mammalian CNS at molecular level. 
 
1.1.1. Nogo 
 
Schwab and his colleagues in the late 1980s gave a molecular insight into the 
mechanism of inhibition.20,21 The identification of IN-1 monoclonal antibody, 
which was raised against an inhibitory fraction of myelin A was the first indication 
that specific molecules in myelin were involved in neurite outgrowth. It allowed 
the axons to grow on myelin as shown both in vitro21 and in vivo.1 After a decade 
later, an antigen for the IN-1 antibody was cloned independently by three groups, 
which was named Nogo by Schwab for its inhibitory action on axonal growth 
(figure 2).22-24 Nogo belongs to the reticulon family, and is expressed as the 
distinct isoforms A, B, and C in CNS, but not in PNS.23 Among all three isoforms, 
Nogo-A is the only one that is expressed in oligodendrocytes, and therefore has 
been studied extensively. Although the topology of Nogo-A has not been clearly 
established, the model that is best supported by current evidence places Nogo-
66 on the intracellular surface, and amino-Nogo on the extracellular surface. As 
both segments are potent inhibitors of axonal outgrowth, the inhibitory amino 
terminus may only be exposed following damage to myelin and 
oligodendrocytes.7 Recombinant Nogo-A is recognized by the monoclonal 
antibody IN-1, and it inhibits neurite outgrowth from dorsal root ganglion (DRG) 
and spreading of 3T3 fibroblasts in an IN-1 sensitive manner,22 which showed 
that Nogo-A is a potent inhibitor of neurite outgrowth. 
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Figure 2: Nogo-A, B, and C. 
 
1.1.2. Myelin-associated glycoprotein 
 
Myelin-associated glycoprotein (MAG, figure 3), 0 kDa glycoprotein which was 
described in 1973,25 was the first protein of myelin to be characterized as an 
inhibitor of axonal outgrowth.26,27 It is a member of the siglec (sialic acid binding 
immunoglobulin-like lectin) family28 and contains five Ig-like domains in its 
extracellular sequence. The first Ig-domain adopts an unusual conformation by 
folding over the second Ig-domain. It has 8 to 9 potential N-linked glycosylation 
sites and consists of typically 30% carbohydrate by weight.29 It exists in two 
alternatively spliced isoforms, a large (L) and a small (S) form that differ only in 
their cytoplasmic sequences.30-32 In the CNS, MAG is located in the periaxonal 
myelin membrane, while in the PNS, it is found in the outermost membrane of the 
myelin sheath.33,34 
 
McKerracher et al.26 first observed MAGs inhibitory character of axonal 
regeneration by employing octyl glucoside to extract myelin from the CNS. After 
a chromatographic purification using a diethylaminoethyl (DEAE) anion exchange 
column, MAG was found to be a major component of the multiple neurite growth 
inhibitory proteins present in myelin of the CNS.  
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Figure 3: L-MAG and S-MAG. 
 
 
Interestingly, neurons early in their cell cycle are not inhibited by MAG, in fact 
their growth is promoted in most cases.27,35,36 Therefore, there is evidence that 
points to MAG is a bifunctional molecule, since all neurons studied to date switch 
their response to MAG from promotion to inhibition, depending on age and type. 
As a member of siglec family, MAG binds to neurons in a sialic-acid dependent 
manner regardless of whether neurite outgrowth is promoted or inhibited. A 
number of neurons respond to MAG by switching from promotion to inhibition 
during development.27,37 For retinal ganglion (RG) neurons and spinal neurons, 
the switch occurs by birth, while for dorsal root ganglion (DRG) neurons, the 
transition takes place sharply at post-natal day 3 (PND 3). 
 
To further elucidate the inhibitory role of MAG, MAG-/- mice were created by 
deletion of the MAG gene by homologus recombination.38,39 Surprisingly, tests 
both in vitro and in vivo showed no significant difference of axonal regeneration 
between MAG-/- and MAG+/+ mice.40 The most likely explanation might be that in 
response to the absence of MAG, other proteins may be upregulated to 
compensated for MAG, since MAG is just one of the inhibitory factors presented 
in myelin. In addition, it is possible that the effect of inhibitory molecules on 
regeneration is not additive; therefore the presence of any one inhibitor may be 
sufficient to prevent most regenerations. 
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As MAG is a sialic acid-binding protein, it specifically binds to sialo-glycoproteins 
and sialo-glycolipids (gangliosides). The Arg118 from the first Ig-domain of MAG 
was recently identified to be crucial for its sialic acid binding capability. When 
Arg118 of MAG is mutated, its sialic acid-binding capability is lost and as well as 
its ability to inhibit neurite outgrowth.41 Surprisingly, when a mutated MAG 
(R118A or R118D) was expressed from either Schwann cell or CHO cells, 
inhibition was as effective as with native MAG. Therefore, sialic acid binding by 
itself is not sufficient to effect inhibition of axonal regeneration. There must be a 
second, yet unknown site on MAG, distinct from the sialic acid binding site at 
Arg118 for inhibition. However, for soluble MAG, interaction of the inhibition site 
with the neuron is completely dependent on MAG’s inherent sialic acid binding 
capacity.  
 
1.1.3. Oligodendrocyte-myelin glycoprotein 
 
The existence of oligodendrocyte-myelin glycoprotein (OMgp, figure 4) was also 
known long before it was shown to be an inhibitor of axonal regeneration.42 
OMgp was also independently identified as an important myelin-associated 
inhibitor in a screen for glycosylphosphatidylinositol (GPI)-anchored CNS myelin 
proteins that mediate axonal outgrowth inhibition.43 In contrast to its name, OMgp 
is expressed not only by oligodendrocytes, but also at high levels in various 
neurons. It is a minor component of myelin with a relative abundance much lower 
than that of MAG, and is found largely in the paranodal loops, next to the node of 
Ranvier.44 OMgp contains a leucine rich repeat (LRR) domain, followed by a C-
terminal domain with serine/threonine repeats. In vitro Omgp induces growth 
cone collapse and potentially inhibits neurite outgrowth, but it’s function in vivo 
has not yet been reported.43 
 20
 
Figure 4: Oligodendrocyte-myelin glycoprotein (OMgp). 
1.2. Receptors for Myelin-associated inhibitors of axonal growth 
 
After the identification of these inhibitors, the next key step was to understand 
how axons respond to inhibitory influences. In particular, the receptors that 
transduce their inhibitory signals across the membrane to the neuron should be 
identified. In 2001, Strittmatter et al. cloned a binding partner of Nogo-66 which 
was termed as Nogo receptor (NgR).45 NgR is an 85 kDa GPI-linked protein that 
contains eight consecutive LRR domains followed by the C-terminal LRR. Direct 
interaction of Nogo-66 with NgR is required to induce growth cone collapse.45 
 
One of the most surprising and interesting findings was the discovery that NgR 
can also bind and mediate the inhibitory activity of MAG and OMgp.43,44,46 It is 
particularly striking, since there is no obvious sequence or domain similarity 
between Nogo-66, MAG and OMgp. A small peptide consisting of the first 40 aa 
residues of the Nogo-66 sequence, which is essential for binding to NgR but 
does not contribute to the inhibitory activity, has been found to enhance the 
majority of axons to regenerate over long distance.47 These observations suggest 
that this peptide could interfere with the ability of MAG and OMgp to bind to 
NgR.7 
 
As NgR is a GPI-linked protein it has no transmembrane or cytoplasmic domain. 
Consequently, even though NgR is essential for Nogo-66, MAG and OMgp to 
exert their inhibitory effects, it cannot tansduce the signal across the membrane 
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and depends on the support of a partner. Even before the discovery of NgR as a 
common receptor for all three inhibitors, the p75 neutrotropin receptor (p75NTR) 
was reported as the tranducer for MAG.48 The low-affinity p75NTR was identified 
as a co-receptor of NgR.49,50 It can be co-precipitated by MAG, Nogo-66 or 
OMgp, and NgR is present in the precipitate of each. It was also observed that 
after injury, upregulation of p75NTR has been shown in many axonal tracts.51,52 
Neurons from p75NTR-/- mice were not inhibited by either of the three inhibitors, or 
by myelin in general.7 Furthermore, a truncated p75NTR protein lacking the 
intracellular domain, when over expressed in primary neurons, attenuates the 
same set of inhibitory activities, suggesting that p75NTR is a transducer of 
inhibitory signals into the cytosol of responding neurons.49 
 
 
Figure 5: Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. 
 
After studying all the molecular aspects of the inhibitory effects of myelin, MAG, 
Nogo and OMgp were identified as the three main myelin-associated inhibitors 
which interact with the same receptor complex NgR-p75NTR to transduce the 
inhibitory signal across the membrane (figure 5). The transduced signal initiates 
a signaling cascade leading to the inhibition of axonal outgrowth after injury.53 
However, the postulated model implies that there is functional redundancy 
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between these inhibitors. This idea of redundancy could explain many confusing 
results of in vivo experiments in which either MAG or Nogo was blocked or 
absent. In the MAG-/- mouse, only a small amount of spontaneous axonal 
regeneration was recorded in one study,54 and none at all in another.24 Likewise, 
application of the antibody to Nogo (IN-1) after injury in wild-type mice allowed 
improved regeneration to occur, but only 5-10% of axon regrowth.26,55,56 
Presumably, in all of these situations, other ligands for NgR are presented or 
even upregulated to inhibit axonal regeneration, and the presence of any one 
inhibitor is sufficient to prevent regeneration by activating an inhibitory signal 
through a single receptor complex.57 
 
2. Gangliosides as functional ligands for MAG 
 
 
It has long been assumed that MAG mediates neurite outgrowth inhibition by the 
interaction with gangliosides (figure 5).53 However, the role of gangliosides was 
questioned after NgR was identified as the receptor of MAG. One opinion is that 
gangliosides can only potentiate and augment MAG-mediated inhibition of 
neurite outgrowth by facilitating the clustering of signaling molecules.6 In contrast 
many lines of evidence supports the hypothesis that the nerve cell surface 
gangliosides are specific functional ligands responsible for MAG-mediated 
neurite outgrowth inhibition.10,57,58 
 
Gangliosides, sialic acid-bearing glycosphingolipids, are the major glycans of 
nerve cells and the major sialic acid-containing glycoconjugates in the brain.59 
Brain gangliosides are characterized by their structural diversity, which derives 
primarily from the number and linkage position of N-acetylneuraminic acid 
(Neu5Ac, sialic acid) residues on the neutral sugar core, whereas the core itself 
shows only limited varieties. Indicated by a recent study, the major brain 
gangliosides have the physiological functions to maintain myelin stability, and to 
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control nerve regeneration. Notably, both functions may be mediated, at least in 
part, via their specific interactions with MAG.10  
 
Table 1: Established members of the siglec family.60,61 
Siglec Alternative 
name 
Tissue/Cell type distribution Minimal carbohydrate structure(s) 
recognized 
Siglec-1 Sialoadhesin Macrophages in spleen, 
lymph nodes, and bone 
marrow 
Neu5Ac-α(2-3)-Gal-β(1-3/4) GlcNAc-
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc- 
Siglec-2 CD22 B cells Neu5Ac-α(2-6)-Gal-β(1-4)-GlcNAc- 
Siglec-3 CD33 Myeloid cell lineage Neu5Ac-α(2-3)-Gal-β(1-3/4)-GlcNAc-
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc- 
Siglec-4a MAG Peripheral and central nerve 
system 
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc- 
Siglec-4b SMP Schwann cells in quail Neu5Ac-α(2-3)-Gal- 
Siglec-5  Granulocytes and monocytes Neu5Ac-α(2-3/6)-Gal- 
As previously mentioned, MAG belongs to the siglecs, a structurally and 
functionally related family of cell surface receptors that bind to sialic acid 
containing glycoproteins and glycolipids.28 To date, as many as eleven members 
have been identified, including sialoadhesin (Sn, siglec-1), CD22 (siglec-2), 
CD33 (siglec-3), MAG (siglec-4a), Schwann cell myelin protein (SMP, siglec-4b), 
and siglec-5~11 (Table 1).60,61 Each member contains two or more Ig-like 
domains: an amino-terminal V-set domain followed by one or more C2-set 
domains, a single transmembrane anchor, and a short cytoplasmic tail.62,63 The 
ligand recognition site has been localized in the amino-terminal V-set domain 
alone or the V-set domain and the adjacent C2-set domain (CD22).64,65 The first 
two domains share very high amino acid sequence similarity between MAG and 
SMP (>70%), and significant similarity across all siglecs (>30% in pairwise 
comparisons).62,66,67 Each siglec, by definition, recognizes a terminal sialic acid 
residue that is essential for binding, whereas significant differences in sialic acid 
linkage specificity are observed.68 For example, sialoadhesin binds terminal 
α2,3- or α2,8-linked sialic acid,69 CD22 recognizes solely α2,6-linked sialic 
acid,70 and MAG requires α2,3-linked sialic acid, preferentially, a 
Neu5Acα(2→3)Galβ(1→3)GalNAc terminus as implicated by initial specificity 
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study.57 As already reported 30 years ago, gangliosides carry 75-80% of the 
sialic acids content in the brain.59 Representative examples are the major brain 
gangliosides GD1a and GT1b (Figure 6). In addition, these gangliosides 
embedded in the neuronal cell surface and also along the axons and are placed 
directly apposed to MAG in vivo.10 The presence of the MAG binding glycan 
sequence on gangliosides, and their location on the axon surface led to the 
hypothesis that gangliosides may be endogenous ligands for MAG, and therefore 
may mediate MAGs physiological functions. 
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Figure 6: major brain gangliosides GD1a, GT1b. 
 
Substantial data are consistent with this hypothesis. Firstly, direct binding study 
showed that MAG binds to GD1a, GT1b and related gangliosides with high 
specificity and affinity in vitro.71 Secondly, the binding of MAG with gangliosides 
is blocked by mAb 513, a conformationally specific anti-MAG antibody that also 
blocks MAG-neuron binding.71 Finally, mice genetically lacking the 
Neu5Acα(2→3)Galβ(1→3)GalNAc terminus on gangliosides (but not on 
glycoproteins) suffer from axon degeneration and demyelination similar to that in 
MAG knockout mice.72  
 
Furthermore, evidence from extensive studies demonstrated that gangliosides 
are both necessary and sufficient to support MAG-mediated neurite growth 
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inhibition.58 In short gangliosides containing the Neu5Acα(2→3) 
Galβ(1→3)GalNAc terminus, are not only necessary to support MAG-mediated 
neurite outgrowth inhibition, but also sufficient to induce the same inhibition by 
multivalent clustering. In addition, GT1b was found to have specific association 
with P75NTR,48 implicating that, besides MAG-NgR-P75NTR, gangliosides and 
P75NTR may form a second type of receptor complex with MAG to transmit the 
inhibitory signals into neurons. 
 
2.1. Structural specificities of gangliosides for MAG binding 
 
Mammalian ganglioside-binding proteins have distinct structural specificities for 
their carbohydrate targets.57 To date, a number of structure-function studies of 
MAG-mediated cell adhesion to gangliosides and related glycosphingolipids have 
been performed to elucidate structural specificities of MAG-recognized 
carbohydrate (Table 2). 57,71,73 
 
Several points are note worthy upon consideration of the data in Table 2. First, it 
was observed that MAG only binds to gangliosides containing a terminal α-2,3-
linked sialic acid (compare GM1 to GD1a, GD1b to GT1b, entries 2 to 7 and 8 to 
11), but the adhesion was abrogated when it is capped by a α-2,8-linked sialic 
acid (compare GT1β to GQ1β, GT1b to GQ1b, entries 10 to 12 and 11 to 13).57 
 
 
Table 2: Adhesion of natural and modified gangliosides to MAG-transfected COS cell. 
 
Entry 
 
Ganglioside 
Conc. of ganglioside 
supporting half-maximal cell 
adhesion 
  [pmol/well] [Ref.] 
1 
Neu5Ac-α(2-3)-Gal-β(1-4)-Glc-β-Cer
GM3
>100a 71 
2 
Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-3) GM1
n.d.b 57,73 
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3 Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-6)
GM1α
n.d. 57,73 
4 
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
GM1b
80 57,73 
5 
Neu5Ac-α(2-8)-Neu5Ac-α(2-3)-Gal-β(1-4)-Glc-β-Cer
GD3
n.d. 71 
6 Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-6)
GD1α
 
19 
 
57,73 
7 
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-3) GD1a
50 57,73 
8 
Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-3) GD1b
n.d. 71 
 
9 Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-3)
Neu5Ac-α(2-6)
GT1aα
 
17 
 
57,73 
 
10 Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-6)
GT1β
50 57 
11 
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-3) GT1b
50 57,73 
12 Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-6)
GQ1βNeu5Ac-α(2-8)
n.d. 57 
13 
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-3) GQ1bNeu5Ac-α(2-8)
n.d. 57 
 
14 Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-3)
Neu5Ac-α(2-6)
GQ1bα
 
6.0 
 
57,73 
15 Neu5Ac-α(2-3)-Gal-β(1-3)-GlcNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer 240 57,73 
16 Neu5Ac-α(2-3)-Gal-β(1-6)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer 87 57,73 
17 
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
HO3S-(6)
22 57,73 
 
18 Neu5Ac-α(2-3)-Gal-β(1-4)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
HO3S-(6)
HO3S-(3)
1.5 57,73 
a low but statistically significant adhesion over background. 
b no detectable adhesion at >100 pmol/well. 
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Secondly, it is apparent from Table 2 that all but one member of an unique 
quantitatively minor family of gangliosides termed “Chol-1” gangliosides, GQ1bα 
(entry 14), displays enhanced potency for MAG-mediated adhesion except GM1α 
(entry 3).73 Chol-1 gangliosides are related to the major brain gangliosides, but 
have an additional α2,6-linked sialic acid on the GalNAc moiety of the 
gangliotetraose core, making them part of the “α-series” ganglioside family.74-76 
GQ1bα (0.5 mg/kg of brain) and GT1aα (0.9 mg/kg), defined as the two major 
Chol-1 gangliosides, are very minor species compared with GD1a, the major 
ganglioside of brain (1200 mg/kg).74-76 Nevertheless, their high binding affinities 
for MAG demonstrated the contribution of the additional α2,6-linked sialic acid, 
which by itself does not support MAG binding (GM1α has no detectable 
affinity).57,73 
 
GQ1bα, the most potent natural ganglioside identified so far, is about 10-fold 
more active in supporting MAG-mediated adhesion than GT1b, the closely 
related ganglioside lacking only the α2,6-linked sialic acid (entries 14 and 
11).57,73 Furthermore, the different affinity between GD1α and GD1a suggests 
that as an additional contributor, α-2,6-linked sialic acid is more significant than 
α-2,3-linked internal sialic acid, although both of them can enhance MAG-
mediated adhesion (entries 6 and 7).57,73 
 
Finally, in contrast to the marked binding effect of sialic acids attached on the 
neutral core, changes in the oligoaccharide core have only minor effects. The 
replacement of the core GalNAc with GlcNAc (entry 15) reduced the binding 
affinity about 3-fold as compared to GM1b (entry 4), suggesting a modest impact 
on recognition.57 Surprisingly, altering the Gal-GalNAc linkage from β-1,3 to β-1,6 
(entry 16), which might be expected to have a large conformational effect, did not 
influence MAG binding by comparing with GM1b (entry 4).57 This is consistent 
with a study by Kelm et al.77 where modifications on either monosaccharide 
residue of the neutral core (e.g. 4/6-deoxy, 6-O-methyl, 6-NH2 of Gal; various N-
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substituted glucosamines, Fuc instead of GalNAc) or the linkage between them 
did not cause significant difference for MAG-binding. These data indicate some 
tolerance for modifications of the neutral saccharide backbone. The core 
behaves more like a spacer to hold two sialic acids in the specific orientation 
needed for binding with MAG. 
 
In summary, the α-2,3-linked sialic acid on the terminal Gal is the primary 
determinant for MAG binding, while the additional α-2,6-linked sialic acid on 
GalNAc can measurably increase the binding affinity. Compared with the 
significant impacts of these two sialic acids, the disaccharide core is not 
comparably specific, which implies that it may be not greatly involved in the 
protein-binding site. According to the observations from the above SAR studies, 
tetrasaccharide Neu5Acα(2→3)Galβ(1→3)[Neu5Acα(2→6)]GalNAc, which is a 
partial structure of GQ1bα, can be deduced as the major pharmacophore for 
MAG binding (figure 7, in box). 
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Figure 7: Ganglioside GQ1bα with tetrasaccharide “Neu5Acα(2→3)Galβ(1→3)[Neu5Acα(2→6)] 
GalNAc” in box.  
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2.2. Functional groups of sialic acid interacting with MAG 
 
As previously discussed, the sialic acids of gangliosides are essential for MAG-
binding. Sialic acids occur on cell surfaces at exposed positions, mostly as 
terminal components with different linkages to the neutral core of 
glycoconjugates. A unique feature of sialic acids is their structural variability 
leading to more than 40 naturally occurring modifications. Therefore, sialic acids 
are thought to play important roles in cellular interactions.78,79. 
 
Sialic acids are the most complex monosaccharides in vertebrate 
glycoconjugates. They constitute a family of structures based on N-
acetylneuraminic acid, the most abundant sialic acid and precusor to diverse 
structures bearing modifications on the glycerol side chain, and/or hydroxyl at C-
4. To further investigate the contributions of substructural features of sialic acid 
for MAG-binding affinity, chemically synthesized and modified gangliosides were 
employed for an extensive structure-function study. 
 
Schnaar et al.57,58,71,73,80 studied the adhesion between natural and synthetic 
gangliosides adsorbed onto microwell plastic plates and full-length MAG 
expressed on the transiently transfected COS cell surface. Kelm et al.77,81 
employed a “hapten inhibition assay” to observe the binding between Fc-chimera 
containing N-terminal 3 or 5 domains of MAG (Fc-MAG1-3 or Fc-MAG1-5) and 
soluble natural and synthetic gangliosides in the presence of human 
erythrocytes.  
 
Since GD1a significantly supports adhesion of MAG, it was used as a basis for 
testing sialic acid modifications. Modifications of the carboxylic acid by 
esterification, amidation, or reduction, abolishe the MAG-binding, strongly 
demonstrating that the anionic charge is crucial for protein binding.71 Additionally, 
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this carboxylic acid needs to be in axial position, since only the α-anomer, the 
natural conformation in sialylated glycans supports MAG-binding.81 This 
orientation is in good agreement with the X-ray structure of the N-terminal 
immunoglobin-like domain of the sialoadhesin in complex with 2,3-sialyllactose. 
The structure shows the axial carboxylate of the terminal sialic acid forming a salt 
bridge with Arg97.82 It should be noted that this Arg is highly conserved in the 
first Ig-domain of other members of the siglec family (Arg97 in sialoadhesin 
corresponds to Arg118 in MAG).41  
 
The glycerol side chain of sialic acid was shown by Schnaar to be crucial for 
binding with a modified GD1a, whereas the binding affinity to MAG was 
abolished with truncated glycerol chain, 7/8-aldehydes, 7/8-alcohols, as well as 
deoxy and/or methoxy derivatives of the 7, 8 or 9-position of Sia(I) of GM3.71,80 
These results suggest that the intact glycerol chain is needed for binding and that 
eliminating or derivatizing any of its hydroxyls significantly diminishes binding. 
The role of the 9-OH attracts interest based on the X-ray of sialoadhesin co-
crystallized with sialyllactose, which implicates that a hydrogen bridge with a 
backbone carbonyl of the protein might exist.82  
 
From Kelm’s study of a series of methyl sialosides (Table 3),81 additional 
structural information was obtained demonstrating the requirement of 9-OH for 
binding (Figure 8). Replacement of 9-OH with hydrogen (entry 3) or halogens 
(entries 4 to 6) reduced affinity, while a 9-NH2-analogue (entry 8) showed a 3-fold 
increase in binding, suggesting 9-OH functions as a hydrogen bond donor for 
one or more amino acids in the binding pocket. The introduction of a thiol group 
resulted in much lower affinity (entry 7), either due to the weaker hydrogen bonds 
formed by –SH with the protein, or due to the steric constraints by the large sulfur 
atom. More recently, a systematic study based on C(9)-NH2 was carried out by 
differently substituting the amine.83  
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Figure 8: The influence of substituents at C-9 of sialic acid. 
 
Notably, acyl groups such as benzoyl, biphenylcarbonyl, naphthylcarbonyl 
(entries 9 to 11) increased the binding dramatically. Among them, methyl-α-9-N-
benzamido-9-deoxy-Neu5Ac enhanced the binding as much as 700-fold 
compared with the reference (entry 1). This indicates indeed an additional 
hydrophobic contact with the Tyr 44, 46 residues of MAG.84 
 
Based on the X-ray structure of sialoadhesin co-crystallized with sialyllactose, 
which showed that a Trp residue in the binding site interacts specifically with the 
methyl group of the N-acetyl moiety, Kelm et al.81 synthesized derivatives to 
investigate this position in greater detail (Figure 9).  
 
This analysis confirmed the crucial role of N-acetyl group for recognition (Table 
3). Halogenated acetyl groups showed a significant enhancement of binding to 
MAG. In Kelm’s study, the acetyl residue was replaced with propionyl (entry 12), 
aminoacetyl (entry 13), thioacetyl (entry 14) or halogenated acetyl groups 
(entries 15-17). Introducing a chlorine atom (entry 16) or a trifluoromethyl group 
(entry 17) enhanced the affinity for MAG by 7- and 4-fold, respectively. It should 
     Neu5AcαMe (1) 
 
     9-deoxy-Neu5AcαMe (3) 
     9-Iodo-Neu5AcαMe (6) 
     9-NH2-Neu5AcαMe (8) 
 
     9-Chloro-Neu5AcαMe (4) 
    9-Thio-Neu5AcαMe (7)
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be noted that N-fluoroacetyl sialic acid derivative (entry 15) binds nearly 17-fold 
better than the reference. 
 
 
 
 
 
Figure 9: The influence of substituents at C-5 of sialic acid. 
 
 
The enhanced affinity can be rationalized by additional halogen mediated 
contacts with the protein or by electronic effects on the amide. This would result 
in a weaker hydrogen bond acceptor quality of the carbonyl oxygen and a 
significantly increased hydrogen bond donor quality of the amino group. 81  
 
Table 3: Various substituted methyl sialosides. 
Entry Compound rIP [Ref.] 
1 Neu5Ac-α-Me 1.00 81 
2 Neu5Ac-α-Bn 9.80 81 
3 9-deoxy-Neu5Ac-α-Me n.a. 81 
4 9-Cl-Neu5Ac-α-Me n.a. 81 
5 9-Br-Neu5Ac-α-Me n.a. 81 
     Neu5AcαMe (1) 
 
     Neu5thioαMe (14) 
  Neu5propαMe (12) 
 
  Neu5NH2αMe (13) 
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6 9-I-Neu5Ac-α-Me n.a. 81 
7 9-thio-Neu5Ac-α-Me n.a. 81 
8 9-NH2-Neu5Ac-α-Me 2.98 81 
9 9-benzoyl-NH-Neu5Ac-α-Me 704 83 
10 9-bipheyl-4-carbonyl-NH-Neu5Ac-α-Me 218 83 
11 9-naphthyl-2-carbonyl-NH-Neu5Ac-α-Me 236 83 
12 Neu5Propyl-α-Me 1.56 81 
13 Neu5aminoAc-α-Me n.a. 81 
14 Neu5ThioAc-α-Me 3.85 81 
15 Neu5FAc-α-Me 16.94 81 
16 Neu5ClAc-α-Me 7.00 81 
17 Neu5F3Ac-α-Me 4.04 81 
n.a. = not applicable since less than 50% inhibition at the highest concentration tested. 
 
Based on the above SAR studies it was concluded that a hydroxy group at C-9 
and the N-acetyl residue at C-5 are essential structural features of for the binding 
of Sia by members of the siglec family (Figure 10). 
 
 
Figure 10: Functional groups of sialic acid interacting with siglecs 
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3. Carbohydrates Based Drug Discovery 
 
Traditionally, carbohydrates were considered to be solely of use for energy 
storage or as skeletal components. However this hypothesis was challenged in 
1963 when a protein was isolated from Canavalia ensiformis with a demonstrated 
ability to bind to carbohydrates on erythrocytes. In the mean time carbohydrates 
became a major focus of biological research. As ligands for proteins, 
carbohydrates play an important role in diverse cellular recognition and signaling 
events, such as cellular growth, adhesion, bacterial and viral infections, cancer 
metastasis, inflammation, and immune surveillance.85 As a result, the 
development of carbohydrate-based therapeutics86 appears to have great 
potential for the treatment of a myriad of human diseases. 
 
Carbohydrates have long been avoided by chemists and biologists because of 
their structural complexity, which makes them difficult to analyze and extremely 
difficult to synthesize. Now, recent advances in the synthetic tools offered by 
carbohydrate chemistry and in the understanding of their biological role, have put 
sugar-based drugs on medicine's menu, where they are garnering impressive 
early reviews. Carbohydrate compounds are currently in clinical trials aimed at 
targeting numerous therapeutic areas including inflammation, tissue rejection, 
hepatitis and cancer. 
 
3.1. Carbohydrate-based therapeutics 
 
The carbohydrate binding proteins have been termed as “lectins” and are found 
in varying densities on all cell-surface membranes.87-89 The lectins interact 
specifically with oligosaccharides and glycoconjugates on surrounding cells via 
H-bonding, metal coordination, Van der Waal’s forces and hydrophobic 
interactions.90,91 It is believed that favourable interactions between the hydroxyl 
groups of carbohydrates and the amino groups of the proteins aid molecular 
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recognition processes. These interactions are relatively weak, but their 
cumulative effects are so numerous that specific interactions occur.  
 
Diseases where carbohydrate-based drugs are making an impact include cancer, 
diabetes, AIDS; influenza, bacterial infections and rheumatoid arthritis.92 The 
carbohydrate-based therapeutics can be rationalized in following terms;  
 
3.1.1. Inhibition of carbohydrate-lectin interactions 
 
Many lectins on the surface of bacteria show specific binding to carbohydrates 
expressed on human cells and such interactions form an essential part of the 
infection pathway. Moreover, microbial enzymes can modify carbohydrate chains 
on host cells, resulting in an increased surface density of lectin ligands, which 
can enhance a bacterium’s virulence. For example, Pseudomonas aeruginosa (a 
respiratory virus) produces the enzyme neuraminidase in the lungs of cystic 
fibrosis patients, which cleaves sialic acid from a glycolipid,93 unmasking a 
carbohydrate receptor for the pathogen.  
 
Soluble forms of human cell surface oligosaccharide components are being 
investigated and developed for rational anti-infective drug design. Such 
compounds are excellent drug candidates as they are small (approximately 1 
kDa) and non-immunogenic. Anti-infective agents that are used clinically, or are 
undergoing clinical trials, include kanamycin (Figure 11), are of great interest 
when resistance to other antibiotics is observed. An analogue of kanamycin, 
dibekacin, has anti-tuberculosis properties as well as a broad spectrum of 
antimicrobial activity. Arbekacin, an aminoglycoside antibiotic that is currently on 
the market, has antibacterial activity against both Gram-positive and Gram-
negative bacteria and is stable in the presence of aminoglycoside-inactivating 
enzymes produced by methicillin resistant Staphylococcus aureus (MRSA). 
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Figure 11: Structure of kanamycin, dibekacin and arbekacin. 
 
Although lectin–carbohydrate interactions are essential for an efficient immune 
system, a more pernicious role is in the progression and metastasis of cancer 
cells.94,95 In clinical trials aimed at inhibiting metastasis have been reported that 
the administration of sialyl Lewisx mimetics that occupy the selectin binding sites 
offer a great therapeutic potential since they block the selectin–carbohydrate 
binding interactions (Figure 12). 
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Figure 12: Structure of Sialyl Lewisx. 
 
3.1.2. Inhibition of enzymes that synthesize disease-associated 
carbohydrates 
 
carbohydrates research has received particular attention for their potential to 
inhibit tumour growth and metastasis. The assembly of carbohydrates within 
biological systems occurs in the golgi apparatus and involves a number of 
glycosidase (carbohydrate trimming enzymes)- and glycosyl transferase 
(carbohydrate transfer enzymes)-mediated steps. For example, the biosynthesis 
of the cancer-associated sialyl Lewisx tetrasaccharide is accomplished by three 
glycosyl transferase enzymes. It has been demonstrated that carbohydrate 
analogues, that mimic their shape and electronic properties in transition state, 
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are capable of inhibiting specific enzymes involved in carbohydrate biosynthesis, 
offering the potential to disrupt the synthesis of disease-associated 
carbohydrates. As a result, interactions between the carbohydrates and the 
lectins would be disrupted and the disease will be unable to progress in the 
normal manner.  
 
Some examples of inhibitors of carbohydrate biosynthesis that show promise as 
therapeutic agents are shown in Figure 13. Examples of particular interest are 
highlighted in Table 4. 
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Figure 13: Some naturally occurring glycosidase (carbohydrate trimming enzyme) inhibitors. 
 
 
Table 4: Some aza-carbohydrate drugs under clinical investigation. 
Drug (Code) Target Company 
Swainsonine (GD0039) Renal, colorectal, breast 
cancer 
Glycodesign 
Vevesca 15 (OGT 918) 
(Zavesca) 
Fabry’s, Gaucher’s disease, 
HIV 
Oxford Glycoscience 
Celgosivir (MDL 28574, 
DRG-0202, BuCast) 
HIV/AIDS Hoechst Marion Roussel 
 
 
Swainsonine, is currently in phase II clinical trials for cancer therapy. It is 
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administered orally and has been shown to reduce solid tumours and 
haematological malignancies.96,97 Zavesca (Vevesca) (Figure 14) is an orally 
active imino sugar that is a potent inhibitor of glucosylceramide 
glucosyltransferase, the enzyme responsible for converting ceramide to 
glucosylceramide during glycosphingolipid (GSL) biosynthesis. 
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Figure 14: Structure of some aza-sugar drugs. 
 
Diabetics can also benefit from administration of glycosidase inhibitors and a 
number of carbohydrate-derived therapies have been developed (Figure 15, 
Table 5). For example, acarbose is an α-glucosidase inhibitor blocking the 
digestion of carbohydrates in the small intestine.98 
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Figure 15: Structure of some current anti-diabetic drugs. 
 
Table 5: Some anti-diabetic drugs. 
Drug (Code) Target Company 
Acarbose (Glucobay,Precose, Prandase) 
Voglibose (AO-128, Basen, Glustat) 
Miglitol (BAY M 1099, Glyset) 
Diabetes (Type I and II) 
Diabetes (Type II) 
Diabetes 
Bayer AG 
Takeda/Abbott 
Bayer 
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Carbohydrate analogues have also been developed as potential treatments for 
influenza (Figure 16). As mentioned previously, the influenza virus possesses 
surface proteins that complex with specific membrane-bound oligosaccharides 
on human cells. Neuraminidase protrudes from the surface of the influenza virus 
The glycomimetic drugs bind to the neuraminidase, which stops the virus from 
exiting the host cell, reducing the amount of virus that is released to infect other 
cells. 
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Figure 16: Structure of some anti-influenza drugs.  
Zanamivir is a transistion state mimic that selectively inhibits influenza A and B 
virus neuraminidases, which are essential for the release of the virus from 
infected host cells.99 A recent review describes the development of new anti-
influenza drugs.100 
3.1.3. Carbohydrate-based anti-thrombotic agents 
 
Heparin was the first polysaccharide-based drug to find widespread use in man 
since 1937 for the treatment of thrombosis. It is isolated from mammalian tissues 
as a complex mixture of glycosaminoglycans (GAG) and demonstrates powerful 
anticoagulant activity. It enhances the ability of antithrombin to inactivate 
thrombin and factor Xa, which are enzymes that promote coagulation. A number 
of carbohydrate-based drugs have been developed via chemical101 and 
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enzymatic102 methods as alternative anti-thrombotic agents. For example, Table 
6 portrays low-molecular-weight heparin-based drugs that have been approved 
for the treatment of thrombosis. 
 
Table 6: Examples of low-molecular-weight heparin-based drugs currently on the market 
Drug Target Company 
Dalteparin Sodium (Fragmin) Thrombosis, anticoagulant Pfizer 
Nadroparin calcium (Fraxiparin) Thrombosis, anticoagulant Sanofi-Synthelabo 
Enoxaparin sodium (Clexane) Thrombosis, anticoagulant Aventis 
Ardeparin (Normiflo) Thrombosis, anticoagulant Wyeth 
Danaparoid (Orgaran) Thrombosis, anticoagulant Organon 
Fondaparinux (Arixtra) Thrombosis, anticoagulant Organon/Sanofi-Synthelabo 
3.2. Drawbacks of carbohydrates as drugs: 
 
In spite of the structural diversity and the broad range of biological functions, 
there have been only a relatively small efforts in developing new mimetics or 
drugs. There are series of obstacles that make carbohydrates a problematic 
class of lead structures for drug development, specifically their complicated 
synthetic availability, poor bioavailability, and low binding affinity for target 
proteins.103-105 
 
3.2.1. Synthetic difficulties 
 
Due to the structural complexity resulting from various regio- and stereospecific 
linkages of oligosaccharides, carbohydrates are rarely chosen as lead structures. 
Moreover, to synthesize peptides or oligonucleotides, automated synthesizers 
are available for an iterative formation of a single bond type (peptide or 
phosphodiester bond, respectively). However, the synthesis of specific glycosidic 
linkages is much more difficult, as carbohydrates are densely functionalized with 
hydroxyl groups of similar reactivity. Cubersome protection and deprotection 
steps leads to synthese with a large number of synthetic steps. Despite recent 
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advances in solid phase synthesis,106-108 efficient regio- and stereoselective 
synthese of oligosaccharides remains a considerable challenge.  
3.2.2. Low bioavailability 
 
Many natural saccharides are rapidly degraded in vivo. Most glycosides are 
hydrolyzed either  under the acidic conditions in the stomach or by glycosidases 
in the small intestine.109 This is the reason that oligosaccharides are generally 
not orally available. In addition, various glycosidases are present in body fluids, 
which limits a carbohydrate-based drugs plasma half-life to just a few minutes, 
depending on its structure.105 Finally, the hydrophilic character of carbohydrate 
leads to their fast renal excretion. 
 
3.2.3. Low binding affinity 
 
Carbohydrate-protein interactions show typically low affinities, where the 
dissociate constant is most often in the mM to µM range (KD≈10-3 to 10-6 M). By 
contrast the general requirements for pharmaceutical applications is much lower 
(KD≈10-9 M).110 Despite their low-affinity, the binding processes that 
carbohydrates display are highly specific. Hydrogen bonding is expected to play 
an important role in carbohydrate-protein recognition processes. Since the 
directionality of hydrogen bonds is critical, they contribute predominantly to the 
specificity of carbohydrate recognition. Their energetic contributions are rather 
small and have been extensively debated.110-112 The lack of hydrophobic groups 
in carbohydrate moieties, which are often dominant in high-affinity receptor-
ligand interactions is also responsible for their low affinity. 
3.3. Carbohydrate mimics 
 
To overcome these drawbacks, various strategies and approaches were applied. 
Research on multivalent carbohydrate ligands that increase the affinity through 
multiple simultaneous binding events has been reported.113-116 In addition 
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numerous studies have been devoted to developing and optimizing carbohydrate 
mimics.103,117 There are two main strategies for the design of carbohydrate 
mimics. 
• The substitution of the O-glycosidic bond with non-natural linkages or 
replacement of ring oxygen by N, S or C.118 
• The replacement of the entire glycosidic scaffold by a small, non-
carbohydrate scaffold bearing the required functional groups in the 
same spatial orientation as the parent sugar structure.119  
 
3.3.1. O-glycosidic bond substituted mimics 
 
For mimics such as C-glycosides, S-glycosides or carba-sugars, substitution 
would ideally increase the resistance to endogenous enzymatic hydrolysis and 
chemical degradation, while conserving the global geometry of the native 
oligosaccharide.118 
 
3.3.2. Mimics based on non-carbohydrate scaffolds 
 
These type of mimics are generally based on different core structures, while 
maintaining the functions of the carbohydrate lead structure by retaining the 
essential functional groups required for recognition. Additionally, by virtue of the 
rational design based on structural details of the protein binding site, higher 
affinities and selectivities can be achieved by additional interactions with 
hydrophobic or charged groups of their cognate receptors.103 
 
An example of the strategy described above is demonstrated with CGP69669, a 
mimic of the tetrasaccharide sLex, a natural ligand for E-selectin (Figure 17). 
CGP69669 was designed based on the information that anionic charge is the 
only pharmacophore of the terminal sialic acid and the GlcNAc behaves merely 
as a spacer to hold Gal and Fuc in the appropriate spatial orientation. For this 
mimic, sialic acid was replaced by the much simpler cyclohexane L-lactic acid 
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and GlcNAc by cyclohexane 1,2-diol. The resulting IC50 was about 12-fold better 
than that of sLex from a in vitro biological assay.120  
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Figure 17: sLeX and its mimic CGP69669. 
 
As mentioned earlier, another famous example is the development of anti-
influenza agents (Figure 18).121 Zanamivir was designed to mimic the transition 
state of sialic acid (Neu5Ac2en) in the hydrolysis reaction by neuraminidase. The 
carboxylic acid, glycerol side chain and N-acetyl functions that are essential for 
the binding were retained. In addition the basic guanidinyl group was attached on 
4-position, offering the formation of an optimal salt bridge with Glu 119 and Glu 
227 identified by X-ray crystal analysis.121 Notably, Ki of Zanamivir is 4,000 times 
better than the parent compound Neu5Ac2en.122 However, due to its poor 
bioavailability of only 2% (logD7.4≈ -6), Zanamivir cannot be applied orally and 
was developed as a nasal spray. By further modification based on a prodrug 
concept, Oseltamivir with 78% bioavailability (logD7.4≈ 0.5) and similar activity (Ki 
≈ 1 nM) was obtained. This mimic is now on the market as an orally administered 
drug to block influenza virus infection.123-125 
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Figure 18: Neu5Ac2en, Zanamivir and Oseltamivir at physiological pH. 
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4. Fluorescent hapten inhibition assay (in collaboration with 
Prof. S. Kelm, University of Bremen): 
 
To analyze the inhibitory potentials of the partial structures of GQ1bα and 
derivatives and mimics thereof, a chimeric protein consisting of the Fc-portion of 
human IgG and the N-terminal 3 or 5 domains of MAG (Fc-MAGd1-3 or Fc-MAGd1-
5) was produced in COS cell and purified.77,81 The fluorescent hapten inhibition 
assay (figure 19) employed in this project is a successor of the previous one 
which was based on radio-labeled MAG and erythrocytes as target cells.77,81 
 
 
Figure 19: Fluorescent hapten inhibition assay. 1. The inhibitor is added to the sialic acid 
coated microtitre plates; 2. Fc-MAG complexed with polyclonal goat anti human IgG(Fc) coupled 
with alkaline phosphatase is added; 3. After incubation, unbound complexes are removed; 4. By 
treating with fluorescein diphosphate (FDP), the resulting fluorescence intensity that is 
proportional to the amount of bound complexes can be determined. 
 
In order to simplify the analyses, microtitre plates with covalently attached sialic 
acids instead of erythrocytes have been used as ligands for MAG. For the 
quantification of bound MAG, Fc-MAG is complexed with alkaline phosphatase-
labeled anti-Fc antibody. During incubation, inhibitors occupy the protein-binding 
site and competitively inhibit the binding with the sialic acids coated plate. After 
washing for the removal of inhibitor-Fc-MAG complexes, the amount of Fc-MAG 
bound to the sialylated plates is determined by the initial velocity of fluorescein 
released from fluorescein phosphate. This method proved to be more reliable 
and easier to handle than the former assay relying on radiolabels. The inhibitory 
potencies obtained for several reference compounds were similar in both 
systems. 
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The concentrations required for 50% inhibition  (IC50) are determined from 
inhibition curves obtained from titration experiments. Since IC50 may vary 
depending on the condition from assay to assay, relative inhibitory potencies 
(rIPs) are calculated by dividing the IC50 of the reference compound by the test 
compound.77,81 It is notable that rIP values are consistent, thus allowed a reliable 
comparison among different assays as long as the same reference is used. 
 
 IC50 (reference compound)
IC50 (analyte)
rIP     =
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RESULTS AND DISCUSSION 
 
5. Sialic acid derivatives modified at 2 and 9-position 
 
Kelm et al. reported that Neu5AcαBn has a ten-fold higher affinity for MAG than 
the corresponding methyl glycoside.81 Substituting the 9-hydroxy group of sialic 
acid by an amino group enhances binding, while substitution by halogens 
decreases the binding drastically, suggesting the necessity of a hydrogen donor 
at the 9-position. It was also shown that, introducing an amide group at 9-position 
of sialic acid increases the binding to MAG dramatically.126,83 Based on these 
results, several benzyl sialosides (Scheme 1) were synthesized with a wide 
range of amide residues at the 9-position. 
 
Starting from neuraminic acid 1, sialyl donor 3 was synthesized according to a 
reported procedure.127 The reaction of compound 3 with benzyl alcohol in the 
presence of NIS/TfOH yielded the isomeric mixture of benzyl sialosides 4α (41 
%) and 4β (18 %).128 Subsequent saponification of 4α and 4β gave the benzyl 
sialosides 5α and 5β. O-Deacetylation of 4α (→6) followed by selective p-
tosylation at 9-position afforded compound 7.129 The azido group was introduced 
using sodium azide and crown ether 18-C-6.130 Subsequent saponification of 
azide 8 afforded the sodium salt 10. Acetylation of 8 using acetic anhydride and 
pyridine gave compound 9. Amidation with a wide range of aromatic and aliphatic 
acyl chlorides under modified Staudinger conditions131 afforded the 9-amido-
substituted sialosides 11a-g in 54%-70% yeild. Final saponification of yielded the 
target substances 12a-g for the bioassay studies. 
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Scheme 1: i) a. MeOH, Amberlyst 15, b. Ac2O, DMAP, pyr, 81%; ii) TMSSMe, TMSOTf, MS 3Å, 
DCE 82%; iii) PhCH2OH, NIS/TfOH MeCN, 41% α, 18 % β; iv) a. 10% NaOH, MeOH, b. Dowex 
50X8 (Na+), 70-95%; v) NaOMe, MeOH, 2 h, 82%; vi) p-TsCl, pyr, 56%; vii) NaN3, DMF, 18-C-6, 
75%; viii) Ac2O, DMAP, pyr, 73%; ix) RCOCl, PPh3, DCM, 54-70%. 
 
 
The inhibitory potencies of the benzyl sialosides 5α, 10 and 12a-g (Table 7) 
towards MAG were measured using a fluorescent hapten inhibition assay.77,81 
(see p45)  
 
The inhibition assay indicated that the introduction of amide group at 9-position 
strongly increased the affinity compared to that of the 9-hydroxy sialoside 5α. 
Another interesting observation was that, the aromatic moieties (compounds 12a-
c) were found to be significantly more active than the aliphatic moieties 
(compounds 12e-g). Compound 12a showed the most promising affinity for MAG 
with a rIP of 690. The insertion of sterically more demanding biphenyls (12b and 
12c) or a hydrophilic orotinoyl residue (12d) led to a decrease in the affinity. The 
observation that 9-azido compound 10 turned out to be inactive may be due to 
the lack of a hydrogen donor at 9-position. 
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Table 7: Relative inhibitory potencies (rIPs) of sialosides with respect to trisaccharide A 
Entry Compound R1 R2 rIP 
1 A Gal-β(1-3)-GalNAc-OSE OH 1 
2 5α OBn OH 0.6 
4 10 OBn N3 0.05 
 
5 
 
12a 
 
OBn O
H
N
 
 
690 
6 12b OBn 
O
H
N
 
165 
7 12c OBn 
O
H
N
 
68 
8 12d OBn 
O
H
N
NH
N
H
O
O
 
6 
9 12e OBn 
O
H
N
 
10 
10 12f OBn 
O
H
N
 
12 
11 12g OBn 
O
H
N
 
9 
 
The relative inhibitory potencies (rIPs) were calculated by dividing the IC50 of the 
reference compound by the IC50 of the compound of interest. The higher the rIP, 
stronger the binding of compound. Trisaccharide A was choosen as a reference 
compound due to its easy availability via chemo-enzymatic synthesis.132 
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After optimizing the substituent at the 9-position of sialic acid and achieving a 
higher affinity, we decided to explore the influence of a benzamido substituent on 
the activity of the reference compound A. Towards this end trisaccharide B was 
synthesized and tested against the reference compound A. 
 
In addition, benzyl ether functionality at C-9 position (C) was introduced to 
evaluate the necessity of an amide group for the higher activity. This group is 
more flexible than the amide group while the phenyl is retained for possible 
hydrophobic interactions.  
 
Using the fluorescent hapten inhibition assay, compounds B and C were tested 
together with compound A as a reference. The resulting rIPs are listed in Table 
8, which also includes compounds 12a and 5α for comparison. According to the 
rIP values, trisaccharide B with the benzamido substituent at the 9-position of the 
sialic acid residue showed a 203-fold enhanced affinity over the reference 
compound A. However, B was approximately 3 fold weaker than its 
monosaccharide analogue 12a with a benzyl group as aglycon instead of the 
disaccharide core. This finding was surprising since previous studies 
demonstrated the existence of additional contacts of the subterminal saccharides 
with the protein.81 It is possible that, this dramatical improvement in affinity of 12a 
might be caused by “induced fit” of the protein on binding. This line of reasoning 
may also explain the low binding affinity of compound B, in which the 
disaccharide core is hindered from binding by the change of the protein 
conformation. It was also seen that monosaccharide C had only 3.7 times higher 
affinity than 5α. This demonstrates that the effect of the substitution by benzyl 
ether is not comparable to the dramatic enhancement by a benzoylamide 
replacement of 9-hydroxy seen with 12a. It is likely that the hydrogen bond 
interaction is crucial for binding since one difference between benzoylamide and 
benzyl ether is that the former can serve as a hydrogen bond donor and acceptor 
while the latter acts only as an acceptor. 
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Table 8: Relative inhibitory potencies (rIPs) of mimics with C-9 modified sialic acid: 
Entry Compound Structure rIP 
rIC50 
(M) 
1 12a O
BzHN
AcHN
HO
OHOH CO2Na
O
 
690 0.001 
2 5α O
HO
AcHN
HO
OHOH CO2Na
O
 
0.62 1.61 
3 Cx OAcHN
HO
COONaOHOHBnO
O
 
2.3 0.43 
4 Bx O
HO
O
OH
O
HO
O
OH
OSE
OHOH
O
BzHN
AcHN
OH
OH
HO
CO2Na
203 0.004 
5 Ay OO
OH
OSE
HO
O
OHHO
OH
OH
OO
CO2Na
HO
AcHN
OH OH
OH  
1 1 
 
(x) Synthesized by Dr. Ganpan Gao at the Institute of Molecular Pharmacy, University of Basel 
(y) Synthesized by Dr. Oliver Schwardt at the Institute of Molecular Pharmacy, University of Basel 
 
 
6. 2-O-Benzyl Sialic Acid derivatives modified at C-9 
position 
6.1. Topliss operational scheme: 
 
The rIP’s indicated that the aromatic substitution at the 9-position was more 
beneficial for increasing the affinity for MAG compared to aliphatic substitution 
(Table 7). Using the Topliss Operational Scheme (TOS) a systematic 
investigation of the influence of aromatic substitution on the inhibitory activity of 
sialic acid analogues was therefore initiated.133 The TOS is a non-mathematical 
application of the Hansch analysis, designed to guide the synthesis towards the 
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most active analogue of a lead compound. Lipophilic, electronic and steric 
parameters of the substituents are taken into account. The compounds 12h-12o 
(Figure 20) containing the aromatic substituents proposed by TOS were 
synthesized as described in Scheme 1. For this investigation the unsubstituted 
benzamide 12a, is used as the new reference compound. The choice of a 
reference with higher affinity is necessary to obtain better accuracy for the new 
generation of MAG antagonists. According to the TOS the next compound to be 
synthesized was p-Cl-benzamide 12h. This was found to be more active than the 
compound 12a (rIP=1 Vs. rIP=1.84). All other derivatives (see figure 20) showed 
lower affinity compared to 12h. These bioassay data indicated that other 
electron-withdrawing substituents than chloride were not tolerated, probably 
because of electronic and steric reasons.  
 
With this study, we could show that substituted mono-sialosides were better 
ligands for MAG than the natural oligosaccharides. A strong enhancement in 
binding potency was achieved by a systematic design. Specifically, starting from 
trisaccharide A, we discovered compound 12h that exhibits a 1300-fold improved 
affinity. Furthermore, these compounds (e.g. 12h) have improved 
pharmacokinetic properties due to the presence of aromatic moieties, lower 
molecular weight and a reduced number of hydrogen bond donors and 
acceptors. 
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Figure 20: Sialosides 12a-12o synthesized according to the Topliss Operational Scheme. 
 
 
6.2. Sialic acid derivatives with triazole substitution at 9-
position 
 
Huisgen 1,3-dipolar cycloadditions134-136 leads to the formation of heterocycles 
starting from two unsaturated reactants. It provides fast access to a large variety 
of five-membered heterocycles.137-139 The cycloaddition reaction of azides and 
alkynes yeilding triazoles is particularly noteworthy. The triazole moieties is an 
often used element in drug discovery. Due to the concept of ‘click chemistry’ 
triazoles have attracted a considerable interest.140-142 Apart from their easy 
sythetic availability, triazoles can interect with their biological targets by hydrogen 
bonding and dipole interactions. A further advantage is that, triazoles do not 
undergo hydrolytic cleavage reactions and are merely metabolized by oxidative 
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or reductive processes. 
 
Rostovtsev et al.143 reported a very safe and efficient stereoselective synthesis of 
anti-1,4-disubstiutted triazoles through ‘click chemistry’. We decided to use this 
reported procedure for the identification of MAG antagonists with improved 
affinity. The synthesis of several compounds with substituted-triazoles at the 9-
position of sialic acid is outlined in Scheme 2. The biological data are 
summarized in Table 9.  
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Scheme 2: i) Na-ascorbate, CuSO4.5H2O, tertBuOH:H2O (1:1), r.t. 32%-81%. ii) a) 10% NaOH, r.t 
3 hr, b) 10% HCl, Dowex 50X8 (Na+), 73%-99%. 
 
For all triazole derivatives, dissppointingly low affinities were found in the hapten 
inhibition assay. Nonetheless, these results further confirmed the importance of 
hydrogen bond donor in 9-position of sialic acid for the formation of a hydrogen 
bond with the MAG. 
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Table 9: 9-triazole substituted sialic acid derivatives. 
No. Compound rIP 
 
12a 
OO
H
N
AcHN
HO
OH
OH
O
CO2Na
 
1.00 
 
14a 
O
OH
N OH COONa
OAcHN
HO
N
N
N  
0.03 
 
14b O
OH
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N
N
N
N
N
 
 
0.0008 
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N
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O
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N
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0.29 
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7. Biosensor Analysis: 
(The Biacore studies were performed by Daniel Strasser from Institute of Molecular Pharmacy, 
University of Basel)  
 
For the development of new pharmaceuticals, the elucidation of the dynamics of 
the ligand/protein interaction is of fundamental interest. Surface plasmon 
resonance biosensor technology provides the possibility to measure 
ligand/protein interactions without labeling ligand or protein and in real-time.144 
The kinetic parameters obtained are the association and dissociation rate 
constants (kon, koff), which enables a closer insight into the binding process. 
Since kinetic data have been shown to be useful when selecting a lead 
structure145 or correlating a pharmacological effect to interaction data,146-148 the 
application of this kinetic information to lead optimization will sustainably 
influence the drug discovery process.147.145 
 
In addition to the rIPs measured by the hapten inhibition assay, the equilibrium 
binding constants for the compounds 12a, 12h, 12k, 21 and A were determined 
by surface plasmon resonance experiments. For all ligands, the experimental 
data was best fitted to a 1:1 binding model. The obtained KD values were in very 
good agreement with the relative affinity values (Table 10). In particular, the 
ligand with the highest rIP, compound 12h, had the best KD (KD=11.8 µM). The 
equilibrium binding constants enabled a more detailed understanding and 
discussion of the results obtained in the STD-NMR and molecular modeling 
studies by elucidating the exact quantitative contributions of structural features 
for binding affinity.  
 
For all ligand-MAG interactions, fast association and dissociation was observed 
(Table 11). The half-life times (t1/2) of the complexes were in the range of 
seconds. The obtained kinetics were in good agreement with documented kinetic 
properties for other carbohydrate-protein interactions. 
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Table 10: Comparision of equilibrium binding constants obtained by biosensor analysis together  
                 with the corresponding rIP value. 
 
Compound KD +/- SEM (µM) n rIP 
12h 11.8 +/- 1.3 3 1074 
12a 20.3 +/- 3.1 3 690 
12f 749.3 1 8.62 
B 32.6 +/- 3.3 3 203 
A 131.5 +/- 3 1 
 
 
 
Table 11: Kinetic data obtained for the selected MAG ligands. Fast association and dissociation 
of the complex was observed for all measured compounds as discussed 
Compound kon +/- SEM (M-1•s-1) koff +/- SEM (s-1) t1/2 (s) n 
12h 26744 +/- 3571 0.3292 +/- 0.0447 2.1 3 
12a 29916 +/-  0.5591 +/-  1.2 3 
B 30589 +/-  1.0253 +/-  0.7 3 
A 67264 +/-  9.1845 +/-  0.1 3 
 
 
For the further improvement of binding affinities, the prolongation of the 
dissociation time is crucial. Unfortunately, the correlation between structural 
features and the dissociation rate constant Koff has not yet been properly defined 
yet. Nevertheless, using kinetic data, it would be possible to improve the lead 
optimization process by choosing those modifications showing slower 
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dissociation rather than faster association. For the MAG-project, we planned to 
improve lipophilic interactions starting from 12h and to identify the corresponding 
contributions to Kon and Koff. 
 
8. STD NMR: 
(were performed by Dr. Brian Cutting from Institute of Molecular Pharmacy, University of Basel) 
 
The difference between two NMR spectra of a ligand/receptor mixture, where in 
one spectrum the protein is selectively saturated, is referred to as Saturation 
Transfer Difference (STD) NMR spectroscopy. 149 The STD experiment provides 
a tool to screen compound libraries for binding to the protein as well as to map 
the binding epitopes of the ligand.  
 
The protein is saturated in the presence of the ligand by the application of 
selective irradiation through a train of weak radio-frequency pulses, which do not 
directly affect the resonances of ligand. The magnetization is spread over the 
entire protein by intramolecular Overhauser processes and spin-diffusion, which 
is more efficient with larger proteins. Ligands interacting with the saturated 
protein are distinguished from non-binding compounds based on intermolecular 
Overhauser processes. Ligands which had received magnetization from the 
protein dissociate back into solution where they are detected.149 Short half-lives, 
with respect to longitudinal relaxation, of the ligand-protein complex result in a 
higher sensitivity compared to monitoring the protein. This sensitivity 
improvement is due to the rapid mixing of the bound and free forms and 
extended memory due to slow relaxation. The STD experiment allows the 
identification of the binding epitope of a respective ligand since the size of the 
STD-signal depends on the intensity of the local ligand/protein interactions.  
 
The intensity of STD NMR signals is easily measured provided the binding is 
between 10-3 and 10-8 M, which corresponds with affinities generally found for 
carbohydrate/protein interactions. In contrast to methods such as SAR by NMR, 
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there is no limit to the size of the protein. In fact, the increase of sensitivity goes 
parallel to the size of the protein due to a more efficient inter- and intramolecular 
saturation transfer.150  
 
To investigate the structural elements of the ligands interacting with MAG, three 
structurally related compounds (12a, D and B) were measured using the STD 
technique. The structures of the three compounds analyzed by STD-NMR with 
corresponding STD-values are depicted in Figure 21. The common core to all 
three antagonists consists of the sialic acid residue. Depending on the 
“decorations” at the reducing end, modifications of the binding mode could be 
determined by STD-NMR. Whereas compound 12a contains an O-benzyl 
substituent at the reducing end, compound D is a O-methyl glycoside and B a 
trisaccharide. 
 
The STD reference and STD spectra, respectively, for each of the three 
compounds analyzed by NMR are displayed in Figure 22. To aid in the visual 
comparison of the epitope, each spectrum is shown with equivalent vertical 
scaling of the N-acetate methyl resonance. Additionally, in the STD spectra, 
dotted lines are drawn above the meta-hydrogens of the benzoate present within 
all three compounds. The heighted lines represents the STD effect found for the 
meta-hydrogens of 12a. 
 
The largest, and most easily quantified STD effects for the three compounds are 
collected in Table 12. The enhancement of the resonances for the hydrogens of 
the benzoate were comparable in size for compounds 12a and D, however 
noticeably reduced for compound B. According to Figure 21, it becomes evident 
that the aromatic substituents exhibit strong enhancements and are thus 
hypothesized to be crucial for binding. For compound B, they turned out to 
remarkably smaller. 
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Figure 21: Group epitope mapping of compounds 12a, D and B; the figure indicates the STD-
effect for the corresponding hydrogens; the STD-values are normalized to the N-acetate (100%). 
 
 
 
 60
 
 
 
 
 
Figure 22: STD 
reference and STD 
spectra for compounds 
12a (a, b), D (c, d) and 
B (e, f), respectively; 
Each spectrum is 
vertically scaled to have 
identical intensities for 
the methyl group of the 
N-acetate moiety 
resonance at 1.95 ppm) 
 
 
The relative error among the three types of benzamide hydrogens was largest for 
the para position since this signal is due to only one hydrogen, and consequently 
has a lower signal to noise ratio. Inspection of other STD enhancements, as seen 
in Figure 22, yields relatively small STD enhancements for hydrogens bound to 
the sugar rings. 
 
The size of the STD enhancement of the various substituents provides insight 
into the origin of the affinities of different ligands determined by biosensor 
analysis. For compound 12a, the benzoate experienced a strong enhancement 
and had the strongest binding affinity. Compound D displayed enhancements 
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similar to compound 12a for resonances in the common core fragment, and was 
therefore hypothesized to have a similar binding mode. 
 
Table 12: Summary of the STD effects for compounds 12a, D and B. 
Compound STD 
Hpara/HNAc 
STD 
Hmeta/HNAc 
STD 
Hortho/HNAc 
Biosensor 
determined 
KD (µM) 
12a 3.1 2.7 2.0 20 
D 3.6 2.5 1.9 131 
B 1.6 1.6 1.6 33 
 
 
However, the replacement of a methyl group for a benzyl group reduced the 
affinity by a factor of 6.5. The weaker binding of compound D was manifested in 
the STD spectrum by a reduction in the enhancement factor of the methyl group 
by a factor greater than two. The reduced affinity of D and the smaller STD effect 
of the methyl group may be due to a smaller hydrophobic contact area of the 
methyl group compared to the benzyl group or a weaker binding to the receptor 
due to the absence of pi-stacking interactions. Interestingly, the mode of binding 
of compound B appeared different than for compounds 12a and D. The change 
in the STD enhancement of the common fragments may be attributed to a 
necessary chance of the binding mode caused by steric effects of the larger 
disaccharide substituent. In fact, the disaccharide moiety did not show any 
significant STD signal. The only other side chain of B that received an 
observable STD enhancement was the TMS group. Since the affinity constant for 
compound B (KD = 33 µM), was far closer to the stronger binding 12a (KD = 20 
µM), than the weaker D (KD = 131 µM), the observation that the TMS group 
received measurable STD may indicate the presence of a second potential 
binding region for MAG inhibitors. 
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9. Molecular Modelling: 
(were performed by Dr. Michele Porro from Institute of Molecular Pharmacy, University of Basel) 
 
To gather more information about the binding modes, in parallel with the 
information from the STD-NMR experiments, the most active compound, 12h, 
was docked onto the MAG-model. Heiko Gaithe from University of Bremen 
developed the homology model of MAG from the amino acid sequence of MAG. 
The ligands were manually docked on to the homology model of MAG. This 
approach assumed a similar ligand-docking mode as that found for Methyl αN-
benzoyl-amino-9-deoxy-Neu5Ac in the crystal structure of Siglec-1a, protein with 
high homology with respect to MAGThe result is presented in Figure 23 and 
Figure 24. The proposed docking mode showed that the carboxylic group of the 
ligand forms a salt bridge with Arg118. Additionally, the hydrophobic 
modifications at the 2-(OBn) and 9-(NHC(=O)Ph) position of the sialic acid 
scaffold found ideal partners for hydrophobic interactions in the sidechains of the 
amino-acids Phe129 and Glu131. A further hydrophobic contact between the 
methyl group of acetyl-moeity at position 5 and Trp22 as well as a hydrogen 
bond between the 5-NH-group and the backbone carbonyl group of Gln126 were 
observed. 
 
The crucial hydrogen bond (see Table 8 for affinity difference between 
compounds 5α, 12a and C) between the NH (donor) at the 9-position of the 
ligand and its protein partner was found to be the carbonyl backbone of Phe129. 
The docking mode presented seems to be very plausible, because of the 
similarity to the observed binding mode for methyl αN-benzoyl-amino-9-deoxy-
Neu5Ac in a homology model based on the crystal structure of Siglec-1, a protein 
with high homology to MAG.84 
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Figure 23: The docking mode obtained for ligand 12h. The ligand is presented in green. 
 
Figure 24: View of the stacking of aromatic groups of 12h in binding pocket of MAG. 
 
The docking mode presented is in strong agreement with the STD-NMR results. 
In particular, the STD signals measured by NMR that indicated strong 
interactions between the hydrophobic moieties of the MAG-ligands and the 
protein could be explained. These contacts might be rationalized as interactions 
between the modifications at the 9-position and the sidechains of Phe129 and 
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Glu131, the methyl group of the acetate at the 5-position with Trp22 and the 
substituents at the anomeric center with Phe129. The docking mode also 
explains the reduction in binding affinity observed for ligand A (KD =131 µM) 
compared to that of ligand 12a (KD=20 µM). This loss in affinity seemed ideally 
explained by the loss of the strong interaction with Phe129, a hypothesis 
substantiated by a less intense signal in the STD-NMR. The proposed docking 
mode enabled further insight into the SAR of the different modifications at the 9-
position of the ligands. It is evident that modifications such as those in ligands 
12c, 12k and 12n compared to our best compound 12h are not ideally 
accommodated into the shallow pocket between Phe129 and Glu131. 
 
Finally a second docking experiment with MAG was performed with the 
tetrasaccharide A. This docking mode was overlapps with the docking mode of 
the best ligand (12h). 
 
Figure 25: Overlapped docking modes of 12h (red) and the tetrasaccharide A (green) 
 
From the superimposition, it is obvious that the benzyl group at the reducing end 
is differently orientated than the disaccharide moiety (Figure 25). Based on this 
information, the design of a next generation of mimics is planned. 
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10. Pharmacokinetic evaluation of MAG Ligands 
(were performed by Dr. Michele Porro from Institute of Molecular Pharmacy, University of Basel) 
 
In addition to the detailed kinetic studies of the binding properties of MAG ligands 
by NMR, molecular modeling and Biacore analysis, profiling of the best ligand 
12h, and the tetrasaccharide A, was performed for the evaluation of their 
pharmacokinetic properties. The data is presented in Table 13. For good 
bioavailability of a compound, a molecular weight lower than 500 Da, a PSA 
lower than 150 Å2, and a ClogP between zero and five are desired. 
 
Table 13: pK properties of compounds 12h and A. 
12h Tetrasaccharide A “Rule of 5” 
MW ≅ 537 
PSA ≅ 175 Å 
ClogP = 1.47 
HBALipinksi = 12 
HBDLipinksi = 5 
MW ≅ 979 
PSA ≅ 466 Å 
ClogP = -9.752 
HBALipinksi = 29 
HBDLipinksi = 16 
MW ≤500 
LogP ≤5 
HBD ≤5 
HBA ≤10 
 
From the above pK data, it can be seen that the physicochemical properties of 
tetrasaccharide A is far from drug-like, since it is expected to have an extremely 
short half lives due to fast renal excretion. In contrast, improved drug-like 
molecular properties were achieved with 12h which approaches the criteria 
defined by Lipinski’s “Rule of 5”. 
 
11. NMR based screening 
 
 
NMR spectroscopy has long been used to detect the binding of small molecules 
to biomolecular targets, and has more recently been employed to screen libraries 
of compounds for drug discovery. A variety of well known NMR techniques have 
been used for screening, including the nuclear Overhauser effect (NOE),151-155 
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chemical shift perturbation,156 diffusion,157-159 relaxation160 and saturation 
transfer.149,161,162 NMR screening can be used to detect binders with affinities 
ranging from nanomolar to millimolar, and recent method improvements have 
drastically reduced the protein consumption and increased the throughput. 
 
11.1. Fragment based screening 
 
An important aspect of NMR screening is the discovery of fragments that bind in 
proximity of a first binding site ligand, thereby offering the possibility to combine 
them with a short linker causing only a minimal loss in entropy. Provided a 
structure of the protein, and its assigned HSQC spectrum, these fragments can 
be found using chemical shift mapping of affected chemical shifts.156,163 There 
are several general strategies by which information about weakly binding 
molecular fragments can be used to construct more potent molecules. One is a 
fragment-linking approach, in which an attempt is made to link molecules that 
individually bind to the target (Figure 26). In a pioneering technique termed “SAR 
by NMR”,156 NMR screening152,155,160,164 is used to identify a ligand binding to the 
target through the use of an isotopically enriched protein and structural 
information. At saturating concentrations of this first ligand, a second round of 
NMR screening is then used to discover a second ligand that binds to the target 
simultaneously and in the vicinity to the first ligand (“second-site screening”). The 
fragments that bind in proximity are identified using chemical shift perturbation, 
and the ligands of the two binding site are linked with various length of linkers. 
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Figure 26: Fragment-Based Screening. 
 
As a ligand for the first binding site in MAG was identified (compound 12h) which 
showed a decent affinity (KD=20 µM) for MAG, a second site screening approach 
was used to identify a proximate second binding site and ligands thereof by using 
the spin label advocated by Jahnke.163 
 
11.2. Second-Binding Site Screening 
 
Jahnke et al.163 described an elegant method of second site screening through 
the use of a spin labeled first ligand. This method exploits transverse relaxation 
to detect ligand binding, thus the variation between the bound and free state 
relaxation rates of the second site ligand should be as large as possible. Since 
the gyromagnetic ratio of an unpaired electron is a factor of 658 times larger than 
that of a proton, transverse relaxation effects on a second ligand, binding 
simultaneously and in the vicinity of the spin labeled first ligand, will be 
significant.165  
 
All the second site ligands will exhibit quicker relaxation due to binding to the 
protein. In addition, if the second site ligand binds in the vicinity of the unpaired 
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electron (radius of ≈ 20Å), its relaxation will as well be enhanced from 
paramagnetic interactions. This potential contribution from the later effect is 
distinguishable from the former by reducing the spin label and therefore knowing 
its effect. 
 
11.2.1. Second site NMR screening with a spin-labeled first ligand 
 
After identifying a first site ligand, for MAG and gathering information regarding 
the binding modes (e.g. 12h, A, B, D) by STD NMR and molecular modeling, we 
further decided to investigate the possibility of a nearby second binding site to 
further enhance the activity. 
 
As shown in our previous report,166 the tetrasaccharide core in GQ1bα,  Neu5Ac-
α(2→3)-Gal-β(1→3)-[Neu5Ac-α(2→6)]-GalNAc, with two terminal sialic acid 
moeities is an important epitope for binding to MAG. The terminal α-2,3-linked 
sialic acid is the more important pharmacophore. In contrast to the important 
contribution of the two sialic acids to binding, several SAR studies have indicated 
that the disaccharide core Gal-β(1→3)-GalNAc, acts predominantly as a linker 
holding the two sialic acid moieties in the appropriate spatial orientation.57,77 This 
hypothesis was based on in-house STD-NMR studies, from which only small 
STD effects the disaccharide core were observed.  
 
The spin-labeled derivative 12a* which is based on the ligand 12a for the first 
binding site was synthesized. The rIP=0.15 and rIC50=2.98 values of the spin-
labeled derivative 12a* (Figure 27), clearly shows that the activity was not 
considerably reduced compared to the reference compound 12a, suggesting a 
similar mode of binding. This result also demonstrates that the addition of the 
TEMPO moiety did not significantly disturb the binding, thus allowing compound 
12a* to be used for screening second site ligands.  
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Scheme 3: i) 1 M NaOMe, MeOH, 2 h, Amberlyst H+, 68%; vi) p-TsCl, pyr, 56%; vii) NaN3, DMF, 
18-C-6, 89%; viii) Ac2O, DMAP, pyr, 90%; vi) NIS, TfOH, Cbz-amino propanol, ACN, -40°C to –
30°C, 14 h, v) PhCOCl, PPh3, DCE, r.t. 14 h, 95%. vi) a) 1 M NaOMe, MeOH, r.t. 2 h. b) H2O, 2 h, 
52%. vii) [H]2, Pd/C, MeOH, 2 h, 95%. viii) a) Dhbt, DIC, THF, O°C, 2 h. b) 4-carboxy-TEMPO, 
DMF, r.t. 2 h, 57%. 
 
The synthesis of compound 12a* (scheme 3) was started from a building block 
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18. Compound 3 was deprotected (→15) and selectively p-tosylated under 
standard conditions to give 16. Introducing azide (→17) and further acetylation 
afforded compound 18. Sialidation of Cbz-amino propanol with 18 under 
standard NIS/TfOH conditions gave an anomeric mixture of compound 19 (α:β 
1:0.4) together with approximately 10% of glycal. The benzamide group was 
introduced by modified Staudinger conditions131 to get 20 with 95 % yield. Further 
selective deprotection under the Zemplen conditions afforded after 
chromatographic purification with α-isomer 21 in 52%. The β-isomer and glycal 
were isolated as impurities. Hydrogenation of compound 21 in methanol gave 
compound 22 in 95% yield.  
 
The next step towards the synthesis of spin-labeled compound was the coupling 
of compound 22 with the spin-label. 1-Oxyl-4-carboxyl-2,2,6,6-
tetramethylpiperidine (23) was activated with 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-
benzotriazine (Dhbt-OH) in the presence of diisopropyl carbodiimide (DIC) and 
the intermediate 23a (Scheme 4) was condensed with the free amine of 
compound 22 according to the reported procedure.167 The final product was 
purified by reversed phase chromatography which yeilded compound 12a* in 
52% yield. 
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11.3.  Library Design for NMR screening 
 
The next step towards finding a second site ligand was to design an appropriate 
library for NMR screening. In an academic enviroment, the size of the library to 
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be screened has to be smaller than in large pharmaceutical companies, 
indicating need to compose small libraries with optimizes components. Four 
principal criteria for library design were taken into account: diversity, drug-like 
character, solubility and synthetic accessibility. 
 
A popular approach for designing screening libraries is to bias the selection of 
compounds towards drug-like molecules. The library is built from components, 
which possess desirable properties of the drugs such as low toxicity, high oral 
absorption and permeability, resistance to metabolic degradation and the 
absence of rapid excretion. In contrast to other methods for compound 
classification, an appealing approach is to construct a library around molecular 
scaffolds that occur frequently in known drugs.155 
 
Despite the emphasis on drug-like molecules, the goal of primary screening is to 
produce good leads, not drugs. As described by Teague and coworkers,168 it is 
no sufficient that drug-like leads fulfill Lipinski’s ‘Rule of 5’. Such leads are not an 
optimal starting points for optimization because the addition of lipophilic groups 
that increase potency can MW and logP. Therefore drug-like leads are smaller 
(MW=100–350 Da) and more polar (clogP 1–3).168 The implication is that libraries 
biased towards small, polar molecules are inherently superior. This is 
advantageous for NMR screening, which benefits from both high solubility and 
relatively weak binding. 
 
Properties used to select drug-like compounds: 
Rule of 5’ criteria169 
• Molecular weight ≤500 Da 
• LogP ≤5 
• Hydrogen bond donors (OH/NH) ≤5 
• Hydrogen bond acceptors (O/N) ≤10 
Other criteria170-172 
• Number of heavy atoms 10–70 
• Rotatable bonds 2–8 
• Number of rings 1–6, aromatic ≤3
• Molar refractivity 40–130 
 
A complementory advantage of small, simple molecules are that they can 
penetrate deep into active sites without steric hindrance. Of particular interest in 
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academic settings is that, the number of compounds necessary to represent the 
scaffolds of interest is relatively small. Taking the above literature findings, the 
SHAPES strategy was applied to identify the molecules to be compiled in the 
library to identify second site hits by NMR. 
 
11.3.1. The  SHAPES strategy:  
 
Design of the SHAPES library is based to a large extent on previously published 
work, in which commercially available therapeutics were examined for common 
chemical features that made these compounds ‘drug-like’.173 In this study, all 
drug molecules were broken down into systems consisting of rings, linkers and 
side chains. The library is composed largely of molecular shapes that represent 
frameworks most commonly found in known drugs. 173 A set of frameworks from 
which the ‘SHAPES’ Library was derived is shown in figure 28. 
 
For NMR screening, the compounds used in the library also must yield a simple, 
well-resolved 1H NMR spectrum. After a thorough literature search on library 
design, common occurring scaffolds in drugs were identified and were ordered 
from commercial sources. 
 
 73
N
N
N N
N
N N
O
N
S
X
N
X
X
X
NN
N
N
O
N O N N
N N
H
NH
N N
N
O
O
N
O
N
O
N
N
N
SO2
NH
 
Figure 28: Molecular frameworks used for library selection. Attachment points forside chains are 
indicated by single electrons or lone pairs. ‘X’ represents C, N, O or S atom. 
 
 
A small library of approximately 40 compounds (Figure 29) was identified and 
used for NMR screening. The library was divided into mixtures containing ≈ 6-8 
compounds each. The mixtures were designed to minimize the intermolecular 
reactions and to show at least some separation of peaks on the spectra to allow 
each compound to be identified.  
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Figure 29: A library of compounds for NMR screening. 
 
 
11.4. Library Screening 
(were performed by Dr. Brian Cutting from the Institute of Molecular Pharmacy, University Of 
Basel) 
 
After the synthesis of the TEMPO derivative of sialic acid (12a*) and the 
optimization of second site library, the next step was the identification of second 
site ligands. The first step in the screening process was to cross validate the 
binding of 12a* and the conditions for its reduction. The hapten inhibition assay 
confirmed that the binding affinities of 12a* and 12a (section 11.2.1) are not 
significantly different. The binding of 12a* observed in the hapten inhibition assay 
was also observed with NMR as depicted in Figure 30-C. 
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Figure 30: Reduction and hit validation of compound 12a* for occupying first binding site. A) 0.5 
mM spin-label 12a*. B) 0.5 mM spin-label 12a*, 16 mM ascorbic acid. C) 30 µM compound 12a*, 
1 mM ascorbic acid and 3 µM MAG protein. 
 
To validate the paramagnetic activity and conditions for the reduction, several 
spectra were required. First, two spectra were recorded with 0.5 mM of spin-label 
12a* in D2O using a Shigemi tube. The spectra were recorded at T2 relaxation 
delay of 10 ms and 200 ms to verify the large decay in intensity due to 
paramagnetic relaxation (Figure 30-A). These two experiments were repeated 
after reducing the radical with 16 mM solution of ascorbic acid. The excess of 
ascorbic acid was used to ensure a complete reduction of the radical. The line 
narrowing and reduction of signal decay for the 200 ms decay proves that 12a* is 
in its diamagnetic state (Figure 30-B). To verify the binding of reduced 12a*, 3 
µM of MAG was mixed with 30 µM of 12a* and 300 µM of ascorbic acid. As seen 
in Figure 30-C there is a larger signal decay after 200 ms than in the absence of 
MAG (Figure 30-C), thus confirming the binding of 12a* to MAG. 
 
After optimizing NMR conditions for observing the binding of compound 12a* to 
MAG, the next step was to screen various mixture of ligands to identify second 
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binding site ligands. For second site NMR spectroscopic screening, MAG and 
spin-labeled ligand 12a* were mixed with various sublibraries. Binding to a 
second site is observed by an enhancement in the transverse relaxation rate of 
the compounds in the library. The enhanced relaxation is potentially due to two 
sources. Any compound in the library, which binds to MAG will experience 
quicker relaxation due to the longer rotational correlation time of the bound 
complex. In addition, if the second binding site is in the vicinity (r ≈ 20Å) of the 
unpaired electron in 12a*, additional relaxation enhancement is due to 
paramagnetic relaxation. Paramagnetic relaxation enhancement effects from 
12a* to any of the compounds were investigated by T1ρ relaxation 
experiments.163 The proximity of the simultaneously binding compounds was 
evaluated by analyzing the same mixture with a sufficient amount of ascorbic 
acid to ensure that 12a* is in its completely reduced form. Among the various 
mixtures screened, nine compounds were found to bind to MAG.  
 
From these screening hits, three compounds with indole scaffolds (Figure 31) 
were found to bind in close vicinity of first binding site. The other six compounds 
were found to bind too far from 12a* since they did not show a reduced rate of 
relaxation upon addition of ascorbic acid. The most promising second site hit 
identified was found to be 5-nitro-1H-indole (marked in circle below).  
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Figure 31: Identified Hits from NMR screening. 
 
Figure 32 shows the resonances of the most promising hit (5-nitro-1H-indole) 
that binds in close proximity to the first binding site. As seen in Figure 32, a 
comparison of the spectra of a sublibrary shows that most compounds did not 
experience relaxation enhancement. However, the resonances of one 
compound, highlighted within dotted boxes, are completely quenched on binding 
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in the presence of the oxidized form of 12a*. This compound was judged to be in 
close vicinity of 12a*, since the peaks recovered when the spin label was 
reduced with ascorbic acid. This compound was therefore unambiguously 
identified as a second-site ligand. 
 
In a typical experimental procedure for screening second site ligands, a spectrum 
is recorded for a sublibrary containing 500µM of each of the 6 to 8 ligands with 
short and long relaxation decay (10 ms and 200 ms). These two experiments are 
repeated with a second sample containing 6 µM of MAG, 180 µM of spin-label 
12a* and the sublibrary containing at 60µM for each ligand to a Shigemi 5 mm 
NMR tube. Finally, the two experiments were again repeated after the addition of 
1,800 µM ascorbic acid to ensure the complete reduction of the radical and 
estimate the proximity of the two binding ligands. 
 
In order to more confidently observe the effects of paramagnetic relaxation on 
the hit identified (Figure 31), the ratio of ligand to protein was increased. 
Increasing the ratio from 10:1 to 20:1 (ligand:protein) prevented the resonances 
of the test compound from being completely quenched on binding by decreasing 
the molar fraction of bound ligand (Figure 33). The binding of the best hit 
identified was confirmed through a separate analysis, in which the non-binding 
ligands were not added to the Shigemi tube, by T1ρ as well as STD experiments. 
As shown in Figure 33 and Figure 34, the identified screening hit binds 
simultaneously in close proximity to first binding site and thus is a confirmed 
second binding site ligand. 
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Figure 32: Mixture analysis showing the best hit identified by T1ρ experiments. A) A 
mixture of 8 compounds (500µM each). B) MAG (6µM in binding site), spin-label 12a* (180µM), a 
mixture of 8 compounds (60µM each). C) MAG (6µM in binding site), spin-label 12a* (180µM), a 
mixture of 8 compounds (60µM each) and ascorbic acid (1,800µM). 
 
STD measurements were used as a complementary approach to verify the 
simultaneous and proximate binding to MAG of the screening hit and 12a*. The 
STD of the screening hit binding to MAG was measured without (Figure 34-A) 
and in the presence of 12a*. In the presence of 12a*, the STD intensities of the 
screening hit are measurably reduced (Figure 34-B). The STD signal reduction 
could arise from several sources, such as a modification of the KD of the 
screening hit caused by structural changes in MAG or an increase in the 
relaxation rate of the screening hit due to the paramagnetic influence of 12a*. To 
evaluate if the reduced STD intensities are indeed due to paramagnetic 
relaxation, a third STD was measured with reduced 12a* (Figure 34-C). 
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Figure 33: Individual analysis of identified hit by T1rho method. A) Mixture of 8 compounds 
at 500µM each. B) MAG (6uM in binding site), spin-label (180µM) and hit (120µM). C) MAG (6µM 
in binding site), spin-label (180µM), hit (120µM) and ascorbic acid (1800µM). 
 
The STD intensities of the screening hit and 12a* in its reduced form in the 
presence of MAG showed a value between its STD measured with 12a* in its 
oxidized form and its STD measured in the absence of 12a*, thus substantiating 
the claim that the two compounds bind in close proximity to each other.  
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Figure 34: Individual analysis of the identified hit by STD NMR method. A) STD of second 
binding site hit and MAG. B) STD of second binding site hit, spin-label 12a* (oxidized) and MAG. 
C) STD of second binding site hit, spin-label 12a* (reduced) and MAG. 
 
12. Linker design 
 
In general, both, the first-site ligand and the second-site ligand are generally low-
affinity ligands with dissociation constants in the µM or mM range. They need to 
be chemically linked in order to obtain a high-affinity, nanomolar ligand. The 
optimal linker should satisfy three criteria. First, it should allow the two individual 
components to occupy in the same binding site in the same orientation in the 
linked compound as they do as in the unlinked fragments. Second, while allowing 
the two components to have sufficient flexibility to adopt optimal binding 
orientations, the linker should be as rigid as possible in order to reduce the 
entropic cost of binding.174 Thirdly, the linker should not have unfavorable 
interactions with the protein;  
 
The atoms on both fragments to which the linker should be attached can be 
identified by observing the quenching effects of each ligands. In the case of 
second site screening with a spin-labeled first ligand, the paramagnetic relaxation 
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enhancement depends on the inverse sixth power of the distance. This 
mechanism leads to differential quenching effects on the second ligand, 
depending on its proximity to the paramagnetic center. Those resonances of the 
second ligand that are most strongly affected are located nearest to the first 
ligand and are therefore primary candidates for linker attachment. 
 
As the crystal structure of MAG is not known till to date, we decided to identify 
the appropriate linker by using the in-situ click chemistry approach.140-142,175-177  
 
13. In-situ click chemistry 
 
The in-situ click chemistry approach to target-guided synthesis (TGS) employs 
the completely bioorthogonal [1,3] dipolar cycloaddition reaction between azides 
and acetylenes which was pioneered by Rolf Huisgen.134 This process is self-
contained, hence there are no external reagents, catalysts, or byproducts that 
might interfere, and the reactants themselves are “invisible” in biological milieu. 
Most importantly, the cycloaddition reaction, which is slow at room temperature, 
is accelerated tremendously when azide and acetylene groups are held together 
in close proximity to lead to irreversible formation of triazoles.178-180 Sharpless et 
al.140-142,175-177 successfully employed this approach to assemble 
acetylcholinesterase (AChE) and carbonic anhydrase inhibitors (CA). A 
femptomolar inhibitor175 for AChE was identified by in-situ click chemistry 
approach. 
 
13.1. Synthesis of precursors for first binding site and second 
binding sites 
 
For the in-situ click chemistry, the azide and alkyne moieties have to be 
introduced into the ligands to be linked. We decided to incorporate the azide 
group on 5-nitro indole and the alkyne groups on the sialic acid. The alkynols 
 82
were selected with varying spacer lengths and the azide group with a varying 
spacer lengths on the 5-nitro-1H-indole in order to identify an optimum spacer 
length and orientation of ligands in respective binding site pockets.  
 
13.1.1. Precursors for first binding site: (SA1-4) 
 
The sialidation with various alkynols was performed as described in literature.181 
As shown in scheme 5, alkynol (n= 1,2,3,4) was coupled with 2-chloro-sialic acid 
derivative 24182 to give compound 25a-d as a mixture of α and β isomers in 1:1 
ratio. This mixture was O-deacetylated to give compound 26a-d from which α 
and β isomers could be separated. The α-isomer of compound 26a-d was further 
selectively p-tosylated at 9-position to yeild compound 27a-d. After the 
introduction of an azide group (→ 28a-d) and acetylation compound 29a-d were 
obtained in good yields. Amidation under the modified Staudinger reaction131 
gave compound 30a-d. A final deprotection with 10% NaOH in methanol, 
neutralization with 10% HCl and finally passing it through a Dowex 50X8 (Na+) 
afforded the Na-salts of compound 31a-d. 
 
 
Cl
O
AcO
AcHN
AcO
OAc
OAc
CO2Me OO
AcO
AcHN
AcO
OAc
OAc CO2Me
(CH2)n
OO
TsO
AcHN
HO
OH
OH CO2Me
(CH2)n OO
N3
AcHN
AcO
OAc
OAc CO2Me
(CH2)n
OO
H
N
AcHN
AcO
OAc
OAc CO2Me
(CH2)nO
OO
H
N
AcHN
HO
OH
OH CO2Na
(CH2)nO
24 25a-d
27(α)a-d 29a-d 30a-d
31a-d
i) ii)
iv) v)
vi)
OO
HO
AcHN
HO
OH
OH CO2Me
(CH2)n
26a-d
iii)
 
Scheme 5: i) AgOTf, CH3CN, MS 3 Å, r.t. alkynol, . ii) 1M NaOMe, MeOH, Amberlyst 15 H+, r.t. 2 
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h. iii) pTsCl, pyr, 0°C. iv) a. NaN3, DMF, 60°C, 24 h. b. Ac2O, pyr, DMAP. v) PhCOCl, PPh3, DCE, 
r.t. 16 h. vi) 10%NaOH, MeOH, Dowex 50X8 (Na+). 
 
13.1.2. Precursors for the second binding site: (NI1-3) 
 
The introduction an azide group with different spacer length on 3-position of 5-
nitro-1H-indole followed different synthetic routes. The 3-(azidomethyl)-5-nitro-
1H-indole 39 was synthesized from commercially available 5-nitro-1H-indole 32 
(scheme 6). 32 was formylated at the 3-position to get 5-nitro-1H-indole-3-
carboxaldehyde 33.183 After reduction with NaBH4 in methanol to  5-nitro-1H-
indole-3-carbinol 34 was isolated. Due to the high reactivity of NH of indole, the 
nitrogen was protected by a tBOC group to yeild compound 35 with 62% yield. 
The other side product was the di-BOC derivative. By SN2 substitution 
compound 35 was transformed into corresponding bromide 37 (62%) with bromo-
alkene 36184,185. Substitution of the bromide with an azide group yeilded 
compound 38 in 95% yield. The deprotection of the nitrogen in TFA afforded 
compound 39 as a yellowish solid with 71% yield. 
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Scheme 6: i) POCl3, DMF, 92%. ii) NaBH4, MeOH, 93%. iii) Boc2O, DMAP, DCM, 14 h, 62%. iv) 
19, CHCl3, r.t. 6 h, 62% v) NaN3, 15-C-5, DMF, r.t. 16 h, 95%. vi) TFA, DCM, 70%. 
 
As reported186, 3-(3-azidopropyl)-5-nitro-1H-indole 43 was also synthesized from 
5-nitro-1H-indole 32 (scheme 7). The 5-nitro-1H-indole 32 was treated with 
Meldrum’s acid, formaldehyde and proline in ACN to give the compound 5-[(5-
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nitro-1H-indol-3-yl)methyl]-2,2-dimethyl -1,3-dioxane-4,6-dione as a yellowish 
solid. Without further purification, the crude product was heated to reflux in 
ethanol in presence of pyridine and copper to give ethyl 5-nitro-3-(1H-
indole)propionate 40. Compound 40 was then reduced with LiAlH4 in THF to give 
5-nitro-3-(3-hydroxypropyl)-1H-indole 41 in 82% yield. Treatment of 41 with 
bromoenamine 36184,185 in CHCl3 yeilded 3-(3-bromopropyl)-5-nitro-1H-indole 42 
(62%). Treatment of 42 with NaN3 in DMF gave 3-(3-azidopropyl)-5-nitro-1H-
indole 43 as a yellowish solid in 96% yield. 
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Scheme 7: i) a. MA, HCHO, proline, CH3CN, r.t. 20 h. b. Cu, pyr, EtOH, reflux, 2 h. ii) LiAlH4, 
THF, 82%. iii) 36, CHCl3, r.t. 6 h. iv) NaN3, 15-C-5, DMF, r.t. 16 h, 96%. 
13.2. In-situ click chemistry experiments 
 
After the synthesis of the first and second site ligand, in-situ click chemistry 
reactions (scheme 8) were conducted in Eppendorff vials.  
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Scheme 8. 
 
Each Eppendorff vial contained a mixture of MAG (8.77 µM), the acetylenes 31a-
d (380 µM), and the azides 39/43 (760 µM) in phosphate buffer solution (pH 7.4). 
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For a simple understanding of abbreviations, the acetylenes were named as 
SA1-4 and azido-nitro-indoles as NI1,3, with the numericals indicating the 
number of carbon atoms in C-chain. The formation of the product was monitored 
by LC-MS-SIM analysis. Two sets of control experiments were conducted in 
parallel to check the false positives, one with a bovine serum albumin (BSA) in 
place of MAG and another in the absence of any protein. Each mixture was 
stirred at 37°C for 3 days.  
 
13.3. Analysis of the in-situ click chemistry reactions 
 
 
Figure 35. The in-situ product SA1NI3 compared by LC-MS-SIM analysis to authenticate sample 
from the Cu(I)-catalysed reaction. A) Authentic sample of anti-SA1NI3 synthesized by Cu(I)-
catalyzed reaction. B) SA1-4 and NI3 incubated at 37°C at 48 hr in the presence of MAG. C) 
SA1-4 and NI3 incubated at 37°C for 48 hr in the presence of BSA. D) SA1-4 and NI3 incubated 
at 37°C for 48 hr in the absence of any protein. 
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The analysis of each mixture by LC-MS-SIM revealed the exclusive formation of 
a triazole product in the presence of MAG. The formation of this triazole product 
was neither observed in presence of BSA, nor in absence of protein. This 
observation validates the fact that the identified product is an in-situ hit and its 
formation required both binding sites to be easily accessible. Figure 35 illustrates 
the results for identified SA1NI3 combination. 
 
For the determination of binding affinities, all 8 anti-triazoles were synthesized 
(Scheme 9) from their respective acetylene/azide precursors using the copper-
catalyzed reaction conditions developed by Sharpless/Kolb143 and Meldal.187 The 
bioaffinites of these compounds were measured in the Biacore assay that was 
developed in house. 
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Scheme 9. 
 
13.4. Bioassay 
(Biacore assay was performed by Daniel Strasser from Insititute of Molecular Pharmacy, 
University of Basel) 
 
As shown in Table 14, repeated measurements from the Biacore assay show 
high binding affinity for the in-situ hit SA1NI3 (KD = 190 nm). This value is 
significantly stronger than either the acetylene precursor SA1 (KD = 76.5 µM) or 
azide precursor NI3 (KD = >100 mM) from which they are derived (Table 15).  
 
This shows that the in-situ click chemistry can be used to selectively identify the 
strongest binding inhibitors for MAG, in which only one of the components binds 
well to the target. 
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Table 14: KD values for triazole-linked compounds. (NA = Not active) 
x = 1 x = 3  
n KD SD KD SD 
1 NA - 0.19 µM +/- 0.01 
2 NA - 1.00 µM +/- 0.41 
3 NA - 1.74 µM +/- 0.31 
4 NA - 3.63 µM +/- 0.40 
 
 
As shown in Table 15, the SA1-4 compounds were found to reasonably active in 
Biacore assay. The increase in the chain length of the spacer decreases the 
activity. In case of NI1,3 it was observed that the activity of NI3 is  
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Table 15: KD values for the precursors SA1-4 and NI1-3 precursors. 
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KD 
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x(H2C)
N
H
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(NI) 
 
KD 
(µM) 
 
n = 1 
 
76.5 
 
x = 1 
 
 
n = 2 63.9 x = 3  
n = 3 47.0   
n = 4 39.6   
 
 
The other combinations, SA1-4NI1, which were not identified by in-situ click 
chemistry, were found to be inactive against MAG. This illustrates the potential of 
applying the in-situ click chemistry approach to selectively identify a potent hit. 
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The best hit SA1NI3 (KD= 0.19 µM) was found to be 60 times more active than 
the previously best known compound 12h (KD=11.8 µM). 
 
 
In order to cross check whether the triazole just acts as a linker between two 
binding sites or contributes to the binding, we synthesized the (N-unsubstituted 
1,2,3-triazole) sialic acid derivative 42 (Scheme 10) by a recently reported 
literature method.188 
 
The synthesis of (N-unsubstituted 1,2,3-triazole) sialic acid derivative 42 was 
non-trivial, since the copper (I) catalyzed click chemistry reactions did not work 
with sodium azide. Other methods of using TMS-azide and/or only sodium azide 
as the azide component for the click reactions were unsuccessful. Finally 
applying the reported method188 from the Sharpless group resulted in a 
successful synthesis of the N-unsubstituted-1,2,3-triazole sialic acid derivative 
42. 
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Scheme 10. 
 
Treating chloro-methyl pivaloate with aqueous sodium azide under heterogenous 
conditions, afforded azido-methyl pivaloate 40 in analytical pure form upon 
workup. A facile cycloaddition between azido-methyl pivaloate 40 and sialic acid 
precursor 31a was achieved using the standard click chemistry parameters and 
reagents, resulting in 1,4-disubstituted-[1,2,3]-triazole 41 in good yield. The 
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pivaloate group was easily removed using dilute aqueous sodium hydroxide 
solution for few minutes to give the 4-Methyl-(5-acetamido-9-benzamido-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulo-pyranoside)-NH-1,2,3-triazole 42. 
 
Table 16: KD of the unsubstituted triazole 42. 
Compound KD 
 
OO
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11.72 µM 
 
The KD value of 11.72 µM for 42 indicate that the triazole moiety interacts with 
the MAG and then thereby contributing to an improved affinity of SA1NI3 
compound. 
 
14. STD-NMR study of SA1NI3:  
(were perormed by Dr. Brian Cutting from the Institute of Molecular Pharmacy, University of 
Basel) 
 
 
After the identification of SA1NI3 as a ligand with a nanomolar affinity for MAG, a 
STD-NMR study was performed to elucidate the binding epitope. As seen in 
Figure 36, both aromatic moieties contribute a large STD effect as compared to 
the sugar moieties. As expected and shown in our previous STD studies with 
compound 12a, the benzamide group in both cases is an important epitope 
binding epitope.  
 
The most interesting information obtained concernes the contribution from the 5-
nitro-indole and triazole moieties. The STD values show that the 5-nitro-indole 
group contributes to a similar extent as the benzamide group. Furthermore it can 
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be stated that the triazole forms a contact with the MAG probably similar to the 
reducing end benzyl group as in 12a. This information on the binding epitopes 
will be highly valuable for the design of the next generation of mimics. 
 
Figure 36: Group epitope mapping and STD-NMR spectra of SA1NI3. 
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CONCLUSION AND OUTLOOK: 
 
15. CONCLUSION 
 
From this study it can be concluded that the substituted mono-sialosides were 
better ligands for MAG than the natural oligosaccharides. These compounds also 
have better pharmacokinetic properties due to the presence of aromatic moieties, 
a low molecular weight, and a reduced number of polar hydroxy functions.  
 
We achieved a strong enhancement in binding potency by a systematic 
approach. Specifically, starting from trisaccharide A, we discovered compound 
12a that exhibits a 700-fold improved affinity (rIP value) for MAG. The necessity 
of an amide group at the 9-position of sialic acid was proved by the low rIPs for 
compounds 10 (Table 7), C (Table 8) and the triazole derivatives 13a-f (Table 
9). By applying the Topliss operational scheme we could identify the lead 
compound 12h, which was found to be 1000-fold (rIP value) more active than the 
trisaccharide A.  
 
For mimicking trisaccharide A the disaccharide moiety was replaced by a benzyl 
group and the 9-position of sialic acid was substituted by a benzamide group. 
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The next generation of ligands was identified by a fragment-based NMR 
screening and in-situ click chemistry. We have termed this approach as a 
“Receptor-mediated Approach”. Using the second binding site screening method 
by NMR with spin-label 12a*, we could successfully identify a ligand for a second 
binding site in the vicinity of the first binding site.  
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The linking of these two ligands was efficiently achieved using the concept of in-
situ click chemistry. Finally, the nanomolar compound SA1NI3 was identified 
from the in-situ click chemistry experiments. The identified compound was scaled 
up by a copper-catalysed procedure. With the Biacore assay, the compound 
SA1NI3 showed an affinity of 190 nM for MAG.  
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16. OUTLOOK 
 
Future directions will be based on the current research work. Replacing the 
benzamide moiety in SA1NI3 with the p-chloro benzamide moiety, as identified 
by our TOS study, should further improve affinity. 
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Furthermore, the nitro group in SA1NI3, has to be replaced, since it is usually 
avoided in medicinal chemistry due to its reactivity and instability in a 
physiological environment, leading e.g. to the formation of a nitroso group. 
Replacing the nitro functionality with its isosteres will lead to MAG-antagonists 
with an improved drug-like character.  
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The STD-NMR and Biacore studies indicate that the role of triazole is more than 
just as a linker. This offers the opportunity to improve bidning with derivatized 
aromatic moieties. 
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Finally, combining all the optimizations at various, it is possible to design the new 
generation of MAG anatagonists as shown below. The hydroxamic acid 
substituion would be interesting from medicinal chemistry point of approach. 
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EXPERIMENTAL 
 
Chemistry. NMR spectra were recorded on a Bruker Avance DMX-500 (500 
MHz) spectrometer. Assignment of 1H and 13CNMR spectra was achieved using 
2D methods (COSY, HSQC, TOCSY). Chemical shifts are expressed in ppm 
using residual CHCl3, CHD2OD and HDO as references. Optical rotations were 
measured using a Perkin-Elmer Polarimeters 241 and 341. MS analyses were 
carried out using a Waters Micromass ZQ Detector system. The spectra were 
recorded in positive ESI mode. Reactions were monitored by TLC using glass 
plates coated with silica gel 60 F254 (Merck) and visualized by using UV light 
and/or by charring with a molybdate solution (a 0.02 M solution of ammonium 
cerium sulfate dihydrate and ammonium molybdate tetrahydrate in aqueous 10% 
H2SO4). Column chromatography was performed on silica gel (Uetikon, 40-60 
mesh). Methanol was dried by refluxing with sodium methoxide and distilled 
immediately before use. Pyridine was freshly distilled under argon over KOH. 
Dichloromethane (DCM), dichloroethane (DCE), acetonitrile (ACN), toluene, and 
benzene were dried by filtration over Al2O3 (Fluka, type 5016 A basic). Molecular 
sieves (3 Å) were activated in vacuo at 500°C for 2 h immediately before use. 
 
Methyl (5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-D-
galacto-2-nonulopyranosid)onate (2).  
O
OAcAcO OAc CO2Me
OAcAcHN
AcO  
N-Acetyl neuraminic acid 1 (6.18 g, 20.0 mmol) and Amberlyst 15 (5.00 g) were 
stirred at r.t. in MeOH (300 mL) for 16 h. TLC analysis (DCM/MeOH 7:3) showed 
completion of the reaction. The reaction mixture was filtered and the residual 
solid thoroughly washed with MeOH. After evaporation of the solvent, the methyl 
ester (5.50 g) was obtained and taken as such for the acetylation step. The 
above product was dissolved in dry pyridine (68 mL) and stirred at 0°C for 15 min 
under argon before DMAP (323 mg, 2.70 mmol) and Ac2O (76.6 mL, 715 mmol) 
were added simultaneously at 0°C. After stirring at r.t. for 14 h, TLC analysis 
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showed completion of the reaction. After evaporation of solvents, 
chromatography on silica gel (DCM/MeOH 20:1) yielded 2 as a white foam (7.25 
g, 81%). 
1H NMR (500 MHz, CDCl3): δ 1.90 (s, 3H, NHAc), 2.04 (m, 10H, H-3a, 3OAc), 
2.14 (s, 3H, OAc), 2.15 (s, 3H, OAc), 2.66 (dd, J = 5.0, 13.5 Hz, 1H, H-3e), 3.79 
(s, 3H, CO2CH3), 4.12 (m, 3H, H-5, H-6, H-9a), 4.49 (dd, J = 2.5, 12.4 Hz, 1H, H-
9b), 5.08 (m, 1H, H-8), 5.26 (m, 1H, H-4), 5.38 (m, 2H, H-7, NH),  
 
Methyl (methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2-thio-3,5-dideoxy-D-
glycero-D-galacto-2-nonulopyranosid)onate (3).  
O
OAcAcO OAc CO2Me
SAcHN
AcO  
To a stirred solution of 2 (7.20 g, 13.5 mmol) in 1,2-dichloroethane (100 mL) 
containing activated mol. sieves (3Å) (5.00 g), TMSSMe (2.26 g, 18.9 mmol) and 
TMSOTf (2.24 g, 10.1 mmol) were added simultaneously. The mixture was 
stirred under argon at 50°C for 5 h and then for 16 h at r.t. After dilution with 
DCM (25 mL) the reaction mixture was subsequently washed with sat. aqueous 
NaHCO3 (100 mL) and water (100 mL), dried over Na2SO4, filtered and 
concentrated. Purification by column chromatography on silica gel (DCM/MeOH 
40:1) yielded 3 (5.75 g, 82%) as a fluffy solid. This was taken as such in the next 
step. 
 
Methyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α- 
and β-D-galacto-2-nonulopyranosid)onate (4α and 4β).  
O
OAcAcO OAc CO2Me
OAcHN
AcO  
Compound 3 (5.20 g, 10.0 mmol), benzyl alcohol (1.62 g, 15.0 mmol) and 3Å 
molecular sieves (5 g) were suspended in dry MeCN (100 mL) and stirred under 
argon with cooling until temperature reached –40°C. NIS (2.68 g, 12.0 mmol) and 
trifluoromethane sulfonic acid (600 mg, 4.00 mmol) were added successively. 
After stirring for 30 min, the reaction was warmed to –30°C and stirring was 
continued at this temperature for additional 14 h. The mixture was diluted with 
 97
DCM and filtered through a pad of Celite. After subsequent washing with 20% 
aqueous Na2S2O3 (200 mL) and sat. aqueous NaHCO3 (200 mL), the organic 
layer was dried over Na2SO4, filtered and concentrated to give a syrup. 
Purification by column chromatography on silica gel (petrol ether/DCM/2-
propanol 8:4:1) yielded α-isomer 4a (2.40 g, 41%) and β-isomer 4b (1.04 g, 
18%). 
1H NMR (500 MHz, CDCl3): 4a: δ 1.90 (s, 3H, NHAc). 2.03 (s, 3H, OAc), 2.03 (m, 
4H, H-3a, OAc), 2.05 (s, 3H, OAc), 2.14 (s, 3H, OAc), 2.17 (s, 3H, OAc), 2.66 
(dd, J = 4.6, 12.9 Hz, 1H, H-3e), 3.67 (s, 3H, CO2CH3), 4.09–4.15 (m, 3H, H-5, 
H-6, H-9a), 4.33 (dd, J = 2.7, 12.4 Hz, 1H, H-9b), 4.43, 4.82 (A, B of AB, J = 12.0 
Hz, 2H, CH2Ph), 4.87 (m, 1H, H-4), 5.21 (d, 1H, NH), 5.35 (dd, J = 2.1, 8.5 Hz, 
1H, H-7), 5.47 (m, 1H, H-8), 7.25–7.37 (s, 5H, Ar-H). 4b: 1.87 (s, 3H, NHAc), 
1.96 (m, 4H, H-3a, OAc), 2.01 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.16 (s, 3H, OAc), 
2.56 (1H, H-3e), 3.73 (s, 3H, CO2CH3), 3.99 (dd, J = 2.2, 10.5 Hz), 1H, H-9a), 
4.10-4.15 (m, 3H, H-5, H-9b), 4.52 (A, B of AB, J = 11.9 Hz, 2H, CH2Ph), 4.84 
(dd, J = 2.5, 12.5 Hz, 1H, H-6), 5.28-5.41 (m, 4H, H-4, H-7, H-8, NH), 7.36 (m, 
5H, Ar-H). 
 
Methyl (benzyl 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosid)onate (6): 
O
OHHO OH CO2Me
OAcHN
HO  
A solution of 4a (2.38 g, 3.95 mmol) in dry methanol (90 mL) was treated with 1 
M methanolic NaOMe (10.5 mL) at r.t. for 2 h. The reaction mixture was 
neutralized with Amberlyst 15 (H+) ion-exchange resin and filtered through a pad 
of Celite. The Celite was washed thoroughly with methanol (3 × 5 mL), and the 
combined filtrates were evaporated to dryness to give 6 as colorless foam (1.40 
g, 82%). 
1H NMR (500MHz, CD3OD): δ 1.85 (t, J = 12.6 Hz, 1H, H-3a), 2.05 (s, 3H, 
NHAc), 2.78 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 3.58 (dd, J = 1.6, 11.0 Hz, 1H, H-
9a), 3.67–3.74 (m, 3H, H-4, H-6, H-9b), 3.81 (s, 3H, CO2CH3), 3.83–3.95 (m, 4H, 
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NH, H-5, H-7, H-8), 4.56, 4.86 (A, B of AB, J = 11.6 Hz, 2H, CH2Ph), 7.28–7.33 
(m, 5H, Ar-H). 
 
Methyl [benzyl 5-acetamido-3,5-dideoxy-9-O-(4-toluenesulfonyl)-D-glycero-
α-D-galacto-2-nonulo-pyranosid]onate (7): 
O
OHTsO OH CO2Me
OAcHN
HO  
To a solution of 6 (1.20 g, 2.90 mmol) in pyridine was added p-TsCl (608 mg, 
3.20 mmol) at 0°C. After 2 h, p-TsCl (220 mg, 1.16 mmol) was added and stirring 
continued for 16 h at 5°C. The reaction mixture was warmed to r.t., diluted with 
methanol (40 mL) and stirring continued for 30 min. After removal of the solvents 
the remaining syrup was purified by chromatography on silica gel (DCM/MeOH 
19:1) to yield 7 as a fluffy solid (929 mg, 56%). 
1H NMR (500MHz, CD3OD): δ 1.80 (t, J = 12.7 Hz, 1H, H-3a), 2.04 (s, 3H, 
NHAc), 2.45 (s, 3H, CH3), 2.74 (dd, J = 4.6, 12.8, Hz, 1H, H-3e), 3.52 (dd, J = 
1.5, 8.5 Hz, 1H, H-7), 3.65 (dd, J = 1.5, 10.4 Hz, 1H, H-6), 3.69 (m, 1H, H-4), 
3.77 (m, 1H, H-5), 3.79 (s, 3H, CO2CH3), 4.05 (ddd, J = 2.1, 6.4, 9.4 Hz, 1H, H-
8), 4.13 (dd, J = 6.4, 10.1 Hz, 1H, H-9a), 4.40 (dd, J = 2.2, 10.1 Hz, 1H, H-9b), 
4.49, 4.77 (A, B of AB, J = 11.6 Hz, 2H, CH2Ph), 7.33, 7.45, 7.83 (m, 9H, Ar-H). 
 
Methyl (benzyl 5-acetamido-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-
nonulo-pyranosid)onate (8): 
O
OHN3 OH CO2Me
OAcHN
HO  
A mixture of 7 (910 mg, 1.60 mmol), crown ether 18-C-6 (169 mg, 0.64 mmol) 
and NaN3 (520 mg, 8.00 mmol) was stirred in DMF (30 mL) at 60°C for 24 h. TLC 
analysis (DCM/acetone 1:1) showed completion of the reaction. The mixture was 
filtered through a pad of Celite and the filtrate was evaporated to dryness. 
Purification by column chromatography on silica gel (DCM/acetone 7:3) yielded 8 
as a white solid (525 mg, 75 %). 
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1H NMR (500 MHz, CD3OD): δ 1.84 (t, J = 12.6 Hz, 1H, H-3a), 2.06 (s, 3H, 
NHAc), 2.77 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 3.43 (dd, J = 6.2, 12.9 Hz, 1H, H-
9a), 3.54 (dd, J = 1.4, 8.9 Hz, 1H, H-7), 3.60 (dd, J = 2.5, 12.8 Hz, 1H, H-9b), 
3.75 (m, 2H, H-4, H-6), 3.81 (s, 3H, CO2CH3), 3.83 (m, 1H, H-5), 4.06 (m, 1H, H-
8), 4.57, 4.85 (A, B of AB, J = 11.6 Hz, 2H, CH2Ph), 7.36 (m, 5H, Ar-H). 
 
Methyl (benzyl 5-acetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid)onate (9).  
O
OAcN3 OAc CO2Me
OAcHN
AcO  
Compound 8 (480 mg, 1.09 mmol) was dissolved in dry pyridine (4.29 g, 54.3 
mmol) and stirred at 0°C for 15 min under argon before DMAP (21.4 mg, 0.175 
mmol) and Ac2O (4.93 g, 46.0 mmol) were added simultaneously at 0°C. After 
stirring at r.t. for 14 h, TLC analysis showed completion of the reaction. After 
evaporation of the solvents, chromatography on silica gel (DCM/MeOH 20:1) 
yielded 9 as a white foam (470 mg, 73%). 
1H NMR (500 MHz, CDCl3): δ 1.89 (s, 3H, NHAc), 2.03 (s, 3H, OAc), 2.04 (t, J = 
12.6 Hz, 1H, H-3a), 2.17 (s, 3H, OAc), 2.19 (s, 3H, OAc), 2.67 (dd, J = 4.6, 12.9 
Hz, 1H, H-3e), 3.28 (dd, J = 5.9, 13.5 Hz, 1H, H-9a), 3.59 (dd, J = 3.0, 13.5 Hz, 
1H, H-9b), 3.70 (s, 3H, CO2CH3), 4.12 (m, 1H, H-5), 4.44, 4.80 (A, B of AB, J = 
11.9 Hz, 2H, CH2Ph), 4.87 (m, 1H, H-4), 5.19 (m, 1H, NH), 5.36 (m, 3H, H-6, H-7, 
H-8), 7.31 (m, 5H, Ar-H). 
 
General method I for the synthesis of 9-substituted amides (11a–g): To a 
solution of 9 (1 eq.) and acid chloride (4 eq.) in toluene, DCM or DCE was added 
a solution of triphenyl phosphine (2.2 eq.) in DCM, DCE or toluene. After stirring 
for 1-3 h, the solvent was evaporated. Purification by column chromatography on 
silica gel (DCM/MeOH 100:1 to 20:1) yielded 12a-12g as solids. 
 
Methyl (benzyl 5-acetamido-4,7,8-tri-O-acetyl-9-benzamido-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid)onate (11a): 
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O
OAcHN OAc CO2Me
OAcHN
AcO
O
 
According to the general method I, compound 9 (42.0 mg, 0.071 mmol) was 
reacted with benzoyl chloride (20.0 mg, 0.142 mmol) and triphenyl phosphine 
(24.0 mg, 0.091 mmol) in toluene (2 mL) for 1 h. After workup 11a was obtained 
as a solid (25.0 mg, 54%). 
1H NMR (500 MHz, CDCl3): δ 1.99 (s, 3H, NHAc), 2.05 (m, 4H, H-3a, OAc), 2.15 
(s, 3H, OAc), 2.27 (s, 3H, OAc), 2.67 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 2.96 (dd, J 
= 3.3, 11.5 Hz, 1H, H-9a), 3.65 (s, 3H, OCH3), 4.06 (d, J = 10.7 Hz, 1H, H-6), 
4.21 (q, J = 10.7 Hz, 1H, H-5), 4.39 (m, 1H, H-9b), 4.44, 4.83 (A, B of AB, J = 
12.0 Hz, 2H, CH2Ph), 4.85 (m, 1H, H-4), 5.17 (m, 2H, NH-5, H-7), 5.33 (m, 1H, 
H-8), 7.09 (m, 1H, NH-9), 7.33–7.44, 7.84 (m, 10H, Ar-H). 
 
Methyl [benzyl 5-acetamido-4,7,8-tri-O-acetyl-9-(4-biphenylcarboxamido)-
3,5,9-trideoxy-glycero-α-D-galacto-2-nonulopyranosid]onate (11b).  
O
OAcHN OAc CO2Me
OAcHN
AcO
O
 
According to the general method I, compound 9 (50.0 mg, 0.084 mmol) was 
reacted with biphenyl-4-carbonyl chloride (26.2 mg, 0.10 mmol) and triphenyl 
phosphine (36.7 mg, 0.17 mmol) in toluene (2 mL) for 2 h. After workup 11b was 
obtained as a solid (14.0 mg, 24%). 
1H NMR (500 MHz, CDCl3): δ 1.91 (s, 3H, NHAc), 2.06 (m, 3H, H-3a, OAc), 2.16 
(s, 3H, OAc), 2.28 (s, 3H, OAc), 2.67 (dd, J = 4.6, 12.7 Hz, 1H, H-3e), 2.98 (m, J 
= 1H, H-9a), 3.65 (s, 3H, OCH3), 4.07 (dd, J = 2.0, 10.8 Hz, 1H, H-6), 4.22 (dd, J 
= 10.3, 10.8 Hz, 1H, H-5), 4.41 (m, 1H, H-9b), 4.45, 4.85 (A, B of AB, J = 12.0 
Hz, 2H, CH2Ph), 4.86 (m, 1H, H-4), 5.20 (m, 2H, H-7, NH-5), 5.35 (m, 1H, H-8), 
7.15, (m, 1H, NH-9), 7.33, 7.39, 7.47, 7.62, 7.67, 7.91 (m, 14H, Ar-H). 
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Methyl [benzyl 5-acetamido-4,7,8-tri-O-acetyl-9-(2-biphenylcarboxamido)-
3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid]onate (11c). 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
 
According to the general method I, compound 9 (50.0 mg, 0.084 mmol) was 
reacted with biphenyl-2-carbonyl chloride (72.5 mg, 0.336 mmol) and triphenyl 
phosphine (48.0 mg, 0.183 mmol) in DCM (2 mL) for 1 h. After workup 11c was 
obtained as a solid (40.0 mg, 66%). 
1H NMR (500 MHz, CDCl3): δ 2.02 (m, 1H, H-3a, NHAc), 2.08 (s, 3H, OAc), 2.15 
(s, 3H, OAc), 2.17 (s, 3H, OAc), 2.63–2.70 (m, 2H, H-3e, H-9a), 3,69 (s, 3H, 
OCH3), 3.94 (dd, J = 2.3, 10.7 Hz, 1H, H-6), 4.06-4.15 (m, 2H, H-5, H-9b), 4.39, 
4.79 (A, B of AB, J = 12.0 Hz, 2H, CH2Ph), 4.67 (dd, J = 2.2, 9.4 Hz, 1H, H-7), 
4.83 (m, 1H, H-4), 4.99 (d, 1H, NH-5), 5.12 (m, 1H, H-8), 5.99 (m, 1H, NH-9), 
7.31–7.59 (m, 1H, Ar-H). 
 
Methyl (benzyl 5-acetamido-4,7,8-tri-O-acetyl-3,5,9-trideoxy-9-
orotinoylamido-D-glycero-α-D-galacto-2-nonulopyranosid)onate (11d). 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
HN
N
H
O
O
 
According to the general method I, compound 9 (50.0 mg, 0.084 mmol) was 
reacted with orotinoyl chloride (63.8 mg, 0.336 mmol) and triphenyl phosphine 
(48.0 mg, 0.183 mmol) in DCM (2 mL) for 1 h. After workup 11d was obtained as 
a solid (40.0 mg, 70%). 
1H NMR (500 MHz, CDCl3): δ 1.92 (s, 3H, NHAc), 2.05 (m, 4H, H-3a, OAc), 2.13 
(s, 3H, OAc), 2.26 (s, 3H, OAc), 2.67 (dd, J = 4.6, 12.7 Hz, 1H, H-3e), 2.93 (m, 
1H, H-9a), 3.99 (s, 3H, OCH3), 4.03 (dd, J = 2.0, 10.7 Hz, 1H, H-6), 4.21 (m, 1H, 
H-5), 4.27 (m, 1H, H-9b), 4.41, 4.79 (A, B of AB, J = 12.0 Hz, 2H, CH2Ph), 4.84 
(m, 1H, H-4), 5.04 (dd, J = 2.0, 9.9 Hz, 1H, H-7), 5.32 (m, 2H, NH-5, H-8), 6.08 
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(s, CH=C), 6.40 (s, C=CH) 7.32 (s, 5H, Ar-H), 7.49 (m, 1H, NH-9), 8.65 (m, 1H, 
allylic NH), 8.82 (s, 1H, NH). 
 
Methyl (benzyl 5-acetamido-4,7,8-tri-O-acetyl-9-butyrylamido-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid)onate (11e) 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
 
According to the general method I, compound 9 (50.0 mg, 0.084 mmol) was 
reacted with butyryl chloride (35.8 mg, 0.336 mmol) and triphenyl phosphine 
(48.0 mg, 0.183 mmol) in DCM (2 mL) for 3 h. After workup 11e was obtained as 
a solid (43 mg, 84%). 
1H NMR (500 MHz, CDCl3): δ 0.96 (t, J = 8.3 Hz, 3H, H-4´), 1.63–2.68 (m, 2H, H-
3´), 1.91 (s, 3H, NHAc), 2.04 (m, 4H, H-3a, OAc), 2.13 (s, 3H, OAc), 2.17 (t, J = 
7.4 Hz, 2H, H-2´), 2.21 (s, 3H, OAc), 2.66 (dd, J = 4.5, 12.8 Hz, 1H, H-3e), 2.78 
(m, 1H, H-9a), 3.66 (s, 3H, CO2CH3), 4.04–4.20 (m, 3H, H-5, H-6, H-9), 4.42, 
4.82 (A, B of AB, J = 12.0 Hz, 2H, CH2Ph), 4.86 (m, 1H, H-4), 5.09 (d, J = 10.6 
Hz, 1H, H-7), 5.23 (m, 2H, H-8, NH-5), 6.17 (m, 1H, NH-9), 7.32 (m, 5H, Ar-H), 
 
Methyl (benzyl 5-acetamido-4,7,8-tri-O-acetyl-3,5,9-trideoxy-9-
hexanoylamido-D-glycero-α-D-galacto-2-nonulopyranosid)onate (12f). 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
 
According to the general method I, compound 9 (50.0 mg, 0.084 mmol) was 
reacted with caproyl chloride (45.6 mg, 0.336 mmol) and triphenyl phosphine 
(48.0 mg, 0.183 mmol) in DCM (2 mL) for 3 h. After workup 11f was obtained as 
a solid (26 mg, 49%). 
1H NMR (500 MHz, CDCl3): δ 0.90 (t, J = 6.9 Hz, 3H, H-6´), 1.30 (m, 4H, H-4´, H-
5´), 1.62 (m, 2H, H-3´), 1.91 (s, 3H, NHAc), 2.04 (m, 4H, H-3a, OAc), 2.13 (s, 3H, 
OAc), 2.18 (t, J = 6.9 Hz, 2H, H-2´), 2.21 (s, 3H, OAc), 2.56 (dd, J = 4.6, 12.8 Hz, 
1H, H-3e), 2.79 (m, 1H, H-9a), 3.66 (s, 3H, CO2CH3), 4.09 (m, 2H, H-6, H-9b), 
4.18 (q, J = 10.4 Hz, 1H, H-5), 4.42, 4.82 (A, B of AB, J = 12.0 Hz, 2H, CH2Ph), 
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4.86 (ddd, J = 5.7, 6.5, 10.4, Hz, 1H, H-4), 5.01 (dd, J = 2.1, 9.7 Hz, 1H, H-7), 
5.24 (m, 2H, H-8, NH-5), 6.14 (m, 1H, NH-9), 7.26–7.33 (m, 5H, Ar-H). 
 
Methyl (benzyl 5-acetamido-4,7,8-tri-O-acetyl-9-decanoylamido-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate (11g). 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
 
According to the general method I, compound 9 (50.0 mg, 0.084 mmol) was 
reacted with decanoyl chloride (65.2 mg, 0.336 mmol) and triphenyl phosphine 
(48.0 mg, 0.183 mmol) in DCM (2 mL) for 3 h. After workup 11g was obtained as 
a solid (30 mg, 51%). 
1H NMR (500 MHz, CDCl3): δ 0.87 (t, J = 6.8 Hz, 3H, H-10´), 1.26–1.31 (m, 14H, 
H-4´, H-5´, H-6´, H-7´, H-8´, H-9´), 1.60 (m, 2H, H-3´), 1.91 (s, 3H, NHAc), 2.04 
(m, 4H, H-3a, OAc), 2.13 (s, 3H, OAc), 2.18 (t, J = 7.9 Hz, 2H, H-2´), 2.21 (s, 3H, 
OAc), 2.66 (dd, J = 4.5, 12.7 Hz, 1H, H-3e), 2.79 (m, 1H, H-9a), 3.65 (s, 3H, 
CO2CH3), 4.06–4.20 (m, 3H, H-5, H-6, H-9b,), 4.42, 4.82 (A, B of AB, J = 12.0 
Hz, 2H, CH2Ph), 4.86 (ddd, J = 4.9, 6.2, 10.3 Hz, 1H, H-4), 5.09 (d, J = 8.8 Hz, 
1H, H-7), 5.18–5.25 (m, 2H, H-8, NH-5), 6.13 (m, 1H, NH-9), 7.27–7.33 (m, 5H, 
Ar-H). 
 
Methyl [benzyl 5-acetamido-4,7,8-tri-O-acetyl-9-(4-chlorobenzamido)-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (11h). 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
Cl
 
According to the general method I, compound 9 (40.0 mg, 0.070 mmol) was 
reacted with p-chloro benzoyl chloride (49.0 mg, 0.280 mmol) and triphenyl 
phosphine (40.3 mg, 0.154 mmol) in DCE (2 mL) for 14 h. After workup 11h was 
obtained as a solid (32.0 mg, 68%). 
 104
1H NMR (500 MHz, CDCl3): δ 1.89 (s, 3H, NHAc), 2.04 (m, 4H, H-3a, OAc), 2.14 
(s, 3H, OAc), 2.26 (s, 3H, OAc), 2.67 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 2.96 (m, 
1H, H-9a), 3.64 (s, 3H, OCH3), 4.06 (dd, J = 2.0, 10.7 Hz, 1H, H-6), 4.20 (q, J = 
10.4, 1H, H-5), 4.35 (m, 1H, H-9b), 4.43 (A of AB, J = 12.0 Hz, 1H, CH2Ph), 4.83 
(m, 2H, H-4, B of AB CH2Ph), 5.15 (dd, J = 2.0, 9.9 Hz, 1H, H-7), 5.27 (d, J = 
10.1 Hz, 1H, NH-5), 5.34 (m, 1H, H-8), 7.09 (m, 1H, NH-9), 7.25-7.43, 7.77 (m, 
9H, Ar-H). 
 
Methyl [benzyl 5-acetamido-4,7,8-tri-O-acetyl-3,5,9-trideoxy-9-(4-
methoxybenzamido)-D-glycero-α-D-galacto-2-nonulopyranosid] onate (11i). 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
O
 
According to the general method I, compound 9 (40.0 mg, 0.070 mmol) was 
reacted with p-anisoyl chloride (47.6 mg, 0.280 mmol) and triphenyl phosphine 
(40.3 mg, 0.154 mmol) in DCE (2 mL) for 14 h. After workup 11i was obtained as 
a solid (25.0 mg, 53%). 
1H NMR (500 MHz, CDCl3): δ 1.89 (s, 3H, NHAc), 2.04 (m, 4H, H-3a, OAc), 2.14 
(s, 3H, OAc), 2.25 (s, 3H, OAc), 2.67 (dd, J = 4.6, 12.7 Hz, 1H, H-3e), 2.95 (m, 
1H, H-9a), 3.64 (s, 3H, CO2CH3), 3.84 (s, 3H, PhOCH3), 4.06 (dd, J = 2.1, 10.7 
Hz, 1H, H-6), 4.21 (q, J = 10.4, 1H, H-5), 4.35 (m, 1H, H-9b), 4.44 (A of AB, J = 
11.9 Hz, 1H, CH2Ph), 4.84 (m, 2H, H-4, B of AB CH2Ph), 5.18 (dd, J = 2.0, 9.8 
Hz, 1H, H-7), 5.26 (d, J = 10.1 Hz, 1H, NH-5), 5.33 (m, 1H, H-8), 6.92 (m, 2H, Ar-
H), 6.96 (m, 1H, NH-9), 7.247.34, 7.79 (m, 7H, Ar-H). 
 
Methyl [benzyl 5-acetamido-4,7,8-tri-O-acetyl-3,5,9-trideoxy-9-(4-
methylbenzamido)-D-glycero-α-D-galacto-2-nonulopyranosid] onate (11j). 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
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According to the general method I, comound 9 (40.0 mg, 0.070 mmol) was 
reacted with p-toluyl chloride (43.1 mg, 0.280 mmol) and triphenyl phosphine 
(40.3 mg, 0.154 mmol) in DCE (2 mL) for 14 h. After workup 11j was obtained as 
a solid (26.0 mg, 56%). 
1H NMR (500 MHz, CDCl3): δ 1.89 (s, 3H, NHAc), 2.04 (m, 4H, H-3a, OAc), 2.14 
(s, 3H, OAc), 2.26 (s, 3H, OAc), 2.39 (s, 3H, Ph-CH3), 2.67 (dd, J = 4.6, 12.8 Hz, 
1H, H-3e), 2.96 (m, 1H, H-9a), 3.64 (s, 3H, CO2CH3), 4.06 (dd, J = 1.9, 10.8 Hz, 
1H, H-6), 4.20 (q, J = 10.4, 1H, H-5), 4.36 (m, 1H, H-9b), 4.43 (A of AB, J = 12.0 
Hz, 1H, CH2Ph), 4.84 (m, 2H, H-4, B of AB CH2Ph), 5.17 (dd, J = 1.9, 9.8 Hz, 1H, 
H-7), 5.24 (d, J = 10.1 Hz, 1H, NH-5), 5.33 (m, 1H, H-8), 7.04 (m, 1H, NH-9), 
7.22-7.33, 7.73 (m, 9H, Ar-H). 
 
Methyl [benzyl 5-acetamido-4,7,8-tri-O-acetyl-9-(3,4-dichlorobenzamido)-
3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (11k). 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
Cl
Cl
 
According to the general method I, compound 9 (40.0 mg, 0.070 mmol) was 
reacted with m,p-dichlorobenzoyl chloride (58.5 mg, 0.280 mmol) and triphenyl 
phosphine (40.3 mg, 0.154 mmol) in DCE (2 mL) for 14 h. After workup 11k was 
obtained as a solid (31.0 mg, 63%). 
1H NMR (500 MHz, CDCl3): δ 1.91 (s, 3H, NHAc), 2.04 (m, 4H, H-3a, OAc), 2.14 
(s, 3H, OAc), 2.27 (s, 3H, OAc), 2.67 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 2.95 (m, 
1H, H-9a), 3.65 (s, 3H, OCH3), 4.06 (d, J = 2.0, 10.7 Hz, 1H, H-6), 4.22 (q, J = 
10.4, 1H, H-5), 4.35 (m, 1H, H-9b), 4.43 (A of AB, J = 12.0 Hz, 1H, CH2Ph), 4.85 
(m, 2H, H-4, B of AB, CH2Ph), 5.14 (dd, J = 2.1, 9.9 Hz, 1H, H-7), 5.25 (d, J = 
10.1 Hz, 1H, NH-5), 5.33 (m, 1H, H-8), 7.12 (m, 1H, NH-9), 7.33, 7.51, 7.62, 7.94 
(m, 8H, Ar-H). 
 
Methyl [benzyl 5-acetamido-4,7,8-tri-O-acetyl-9-(3-chlorobenzamido)-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (11l). 
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O
OAcHN OAc CO2Me
OAcHN
AcO
O
Cl
 
According to the general method I, compound 9 (40.0 mg, 0.070 mmol) was 
reacted with m-chlorobenzoyl chloride (49.0 mg, 0.280 mmol) and triphenyl 
phosphine (40.3 mg, 0.154 mmol) in DCE (2 mL) for 14 h. After workup 11l was 
obtained as a solid (28.0 mg, 59%). 
1H NMR (500 MHz, CDCl3): δ 1.84 (s, 3H, NHAc), 1.99 (m, 4H, H-3a, OAc), 2.07 
(s, 3H, OAc), 2.19 (s, 3H, OAc), 2.60 (dd, J = 4.6, 12.9 Hz, 1H, H-3e), 2.87 (m, 
1H, H-9a), 3.57 (s, 3H, CO2CH3), 3.99 (d, J = 10.7 Hz, 1H, H-6), 4.14 (q, J = 10.7 
Hz 1H, H-5), 4.29 (m, 1H, H-9b), 4.36 (A of AB, J = 12.0 Hz, 1H, CH2Ph), 4.77 
(m, 2H, H-4, B of AB, CH2Ph), 5.09 (d, J = 9.9 Hz 1H, H-7), 5.22 (m, 2H, H-8, 
NH-5), 7.04 (m, 1H, NH-9), 7.14-7.41, 7.60, 7.76 (m, 9H, Ar-H). 
 
Methyl [benzyl 5-acetamido-4,7,8-tri-O-acetyl-3,5,9-trideoxy-9-(4-
trifluoromethylbenzamido)-D-glycero-α-D-galacto-2-nonulopyranosid] 
onate (11m). 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
F3C
 
According to the general method I, compound 9 (40.0 mg, 0.070 mmol) was 
reacted with p-trifluoromethyl-benzoyl chloride (58.2 mg, 0.280 mmol) and 
triphenyl phosphine (40.3 mg, 0.154 mmol) in DCE (2 mL) for 14 h. After workup 
11m was obtained as a solid (30.0 mg, 60%). 
1H NMR (500 MHz, CDCl3): δ 1.82 (s, 3H, NHAc), 1.97 (m, 4H, H-3a, OAc), 2.07 
(s, 3H, OAc), 2.20 (s, 3H, OAc), 2.60 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 2.92 (m, 
1H, H-9a), 3.57 (s, 3H, CO2CH3), 3.99 (m, 1H, H-6), 4.14 (q, J = 10.4, 1H, H-5), 
4.29 (m, 1H, H-9b), 4.36 (A of AB, J = 12.0 Hz, 1H, CH2Ph), 4.76 (m, 2H, H-4, B 
of AB, CH2Ph), 5.08 (dd, J = 2.1, 9.9 Hz, 1H, H-7), 5.29 (m, 2H, H-8, NH-5), 7.13-
7.26, 7.63, 7.86 (m, 10H, NH-9, Ar-H). 
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Methyl [benzyl 5-acetamido-4,7,8-tri-O-acetyl-9-(2,4-dichlorobenzamido)-
3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (11n). 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
Cl
Cl
 
According to the general method I, compound 9 (40.0 mg, 0.070 mmol) was 
reacted with o,p-dichlorobenzoyl chloride (58.5 mg, 0.280 mmol) and triphenyl 
phosphine (40.3 mg, 0.154 mmol) in DCE (2 mL) for 14 h. After workup 11n was 
obtained as a solid (31.0 mg, 62%). 
1H NMR (500 MHz, CDCl3): δ 1.82 (s, 3H, NHAc), 1.97 (m, 4H, H-3a, OAc), 2.09 
(s, 3H, OAc), 2.15 (s, 3H, OAc), 2.60 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 2.87 (m, 
1H, H-9a), 3.59 (s, 3H, CO2CH3), 4.01 (dd, J = 2.0, 10.8 Hz, 1H, H-6), 4.11 (q, J 
= 10.4 Hz, 1H, H-5), 4.29 (m, 1H, H-9b), 4.37, 4.76 (A, B of AB, J = 12.0 Hz, 2H, 
CH2Ph), 4.80 (m, 1H, H-4), 5.11 (dd, J = 1.9, 9.7 Hz 1H, H-7), 5.23 (m, 2H, H-8, 
NH-5), 6.84 (m, 1H, NH-9), 7.18-7.26, 7.35, 7.49 (m, 8H, Ar-H).  
 
Methyl [benzyl 5-acetamido-4,7,8-tri-O-acetyl-3,5,9-trideoxy-9-(4-
nitrobenzamido)-D-glycero-α-D-galacto-2-nonulopyranosid] onate (11o). 
O
OAcHN OAc CO2Me
OAcHN
AcO
O
N+
OŠ
O
 
According to the general method I, compound 9 (40.0 mg, 0.070 mmol) was 
reacted with p-nitrobenzoyl chloride (51.8 mg, 0.280 mmol) and triphenyl 
phosphine (40.3 mg, 0.154 mmol) in DCE (2 mL) for 14 h. After workup 11o was 
obtained as a solid (28.0 mg, 58%). 
1H NMR (500 MHz, CDCl3): δ 1.82 (s, 3H, NHAc), 1.99 (m, 4H, H-3a, OAc), 2.08 
(s, 3H, OAc), 2.20 (s, 3H, OAc), 2.60 (dd, J = 4.6, 12.7 Hz, 1H, H-3e), 2.93 (m, 
1H, H-9a), 3.58 (s, 3H, CO2CH3), 3.99 (dd, J = 2.0, 10.7 Hz, 1H, H-6), 4.15 (q, J 
= 10.4 Hz, 1H, H-5), 4.30 (m, 1H, H-9b), 4.36 (A of AB, J = 11.9 Hz, 1H, CH2Ph), 
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4.76 (m, 2H, H-4, B of AB, CH2Ph), 5.08 (dd, J = 2.0, 9.8 Hz 1H, H-7), 5.27 (m, 
2H, H-8, NH-5), 7.18-7.30, 7.91, 8.20 (m, 10H, NH-9, Ar-H). 
 
General method II for the saponification of final compounds (5, 6, 11, 12a-
g). 
To a solution of protected compounds 4a/b, 9, 11a-g (25-50 mg) in methanol (2 
mL) was added 10% aq. NaOH (0.2 mL). The mixture was stirred at r.t. for 3 h. 
The solution was concentrated and the residue was purified by reversed phase 
chromatography (RP-18 column, 5% gradient MeOH in water), Dowex 50X8 ion-
exchange chromatography (Na+ type), and P2 size exclusion chromatography to 
afford 5, 6, 11, and 12a-12g as colorless solids after a final lyophilization from 
water. 
 
Sodium (benzyl 5-acetamido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-
nonulopyranosid)onate (5). 
O
OHHO OH CO2Na
OAcHN
HO  
According to the general method II, compound 4a (50.0 mg, 0.086 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After workup and purification 
5 was obtained as a fluffy solid (47 mg, 94%). 
α[ ]D25  = - 4.3 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.60 (t, J = 11.9 Hz, 1H, 
H-3a), 1.89 (s, 3H, NHAc), 2.68 (dd, J = 3.5, 12 Hz, 1H, H-3e), 3.49-3.77 (m, 7H, 
H-4, H-5, H-6, H-7, H-8, H-9), 4.42, 4.65 (A, B of AB, J = 11.0 Hz, 2H, CH2Ph), 
7.30 (m, 5H, Ar-H); 13C NMR (125 MHz, D2O): δ 22.4 (NHCOCH3), 40.9 (C-3), 
52.2 (C-5), 62.9 (C-9), 67.5 (CH2Ph), 68.5 (C-7), 68.7 (C-4), 72.0 (C-8), 73.1 (C-
6), 101.3 (C-2), 128.7, 129.0, 129.1, 137.4 (6C, C6H5), 173.9, 175.4 (2XCO). 
 
Sodium (benzyl 5-acetamido-3,5,9-trideoxy-D-glycero-β-D-galacto-2-
nonulopyranosid)onate (6). 
 109
O
OHHO OH
CO2Na
O
AcHN
HO  
According to the general method II, compound 4b (50.0 mg, 0.086 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After workup and purification 
6 was obtained as a fluffy solid (34 mg, 94%). 
α[ ]D25  = - 1.3 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.68 (t, J = 12.1 Hz, 1H, 
H-3a), 1.90 (s, 3H, NHAc), 2.38 (dd, J = 4.7, 13.1 Hz, 1H, H-3e), 3.57 (d, J = 9.6 
Hz, 1H, H-7), 3.67 (dd, J = 6.5, 12.0 Hz, 1H, H-9a), 3.83-3.97 (m, 4H, H-5, H-6, 
H-8, H-9b), 4.02 (m, 1H, H-4), 4.27, 4.60 (A, B of AB, J = 10.1 Hz, 2H, CH2Ph), 
7.39 7.47 (m, 5H, Ar-H); 13C NMR (125 MHz, D2O): δ 23.6 (NHCOCH3), 40.3 (C-
3), 52.4 (C-5), 63.9 (C-9), 65.3 (CH2Ph), 67.4 (C-4), 68.6 (C-7), 70.3 (C-8), 70.6 
(C-6), 100.5 (C-2), 128.7, 129.1, 129.2, 137.5 (6C, C6H5), 175.1, 181.9 (2XCO). 
 
Sodium (benzyl 5-acetamido-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-
nonulopyranosid)onate (10). 
O
OHN3 OH CO2Na
OAcHN
HO  
According to the general method II, compound 8 (25.0 mg, 0.045 mmol) was 
deprotected by treatment with 10% NaOH (0.1 mL). After the workup and 
purification 10 was obtained as a fluffy solid (17 mg, 85%). 
α[ ]D25  = - 3.6 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.67 (t, J = 12.2 Hz, 1H, 
H-3a), 2.03 (s, 3H, NHAc), 2.76 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.46 (dd, J = 
6.1, 13.2 Hz, 1H, H-9a), 3.57 (dd, J = 1.8, 9.1 Hz, 1H, H-7), 3.63 (dd, J = 2.6, 
13.2 Hz, 1H, H-9b), 3.68 (ddd, J = 4.1, 4.6, 11.8 Hz, 1H, H-4), 3.74 (d, J = 10.4 
Hz, 1H, H-6), 3.79-3.83 (m, 2H, H-5, H-8), 4.53, 4.72 (A, B of AB, J = 11.0 Hz, 
2H, CH2Ph), 7.41 (s, 5H, Ar-H); 13 C NMR (125 MHz, D2O): δ 20.5 (NHCOCH3), 
39.1 (C-3), 50.4 (C-5), 51.5 (C-9), 65.8 (CH2Ph), 66.8 (C-4), 67.4 (C-7), 68.8 (C-
8), 71.0 (C-6), 99.6 (C-2), 126.8, 127.2, 127.2, 135.7 (6C, C6H5), 172.0, 173.6 
(2XCO).  
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Sodium (benzyl 5-acetamido-9-benzamido-3,5,9-trideoxy-D-glycero-α-D-
galacto-2-nonulopyranosid)onate (12a). 
O
OHHN OH CO2Na
OAcHN
HO
O
 
According to the general method II, compound 11a (25.0 mg, 0.038 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12a was obtained as a fluffy solid (19 mg, 95 %). 
α[ ]D25  = - 2.0 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.65 (t, J = 11.8 Hz, 1H, 
H-3a), 1.99 (s, 3H, NHAc), 2.77 (dd, J = 3.5, 11.8 Hz, 1H, H-3e), 3.46-3.52 (m, 
2H, H-7, H-9a), 3.68 (m, 1H, H-4), 3.75-3.84 (m, 4H, H-5, H-6, H-8, H-9b), 4.53, 
4.70 (A, B of AB, J = 11.2 Hz, 2H, CH2Ph), 7.27-7.39, 7.52, 7.60, 7.78 (m, 10H, 
Ar-H); 13 CNMR (125 MHz, D2O): δ 21.5 (NHCOCH3), 40.1 (C-3), 42.1 (C-9), 51.4 
(C-5), 66.9 (CH2Ph), 67.8 (C-4), 69.4 (C-7), 69.8 (C-8), 72.2 (C-6), 101.0 (C-2), 
126.6, 127.7, 128.2, 128.3, 131.7, 133.2, 136.8 (12C, 2C6H5), 170.7, 172.5, 
174.6 (3XCO). 
 
Sodium [benzyl 5-acetamido-9-(4-biphenylcarboxamido)-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid]onate (12b). 
O
OHHN OH CO2Na
OAcHN
HO
O
 
According to the general method II, compound 11b (14.0 mg, 0.019 mmol) was 
deprotected by treatment with 10% NaOH (0.1 mL). After the workup and 
purification 12b was obtained as a fluffy solid (7.0 mg, 64%). 
α[ ]D25  = - 4.8 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.69 (t, J = 12.2 Hz, 1H, 
H-3a), 2.01 (s, 3H, NHAc), 2.77 (dd, J = 4.6, 12.2, Hz, 1H, H-3e), 3.44 (dd, J = 
8.5, 14.7, Hz, 1H, H-9a), 3.54 (d, J = 8.5 Hz, 1H, H-7), 3.68 (m, 1H, H-4), 3.81 
(m, 4H, H-5, H-6, H-8, H-9b), 4.48, 4.68 (A, B of AB, J = 11.2 Hz, 2H, CH2Ph), 
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7.22-7.32, 7.39, 7.54, 7.72 (m, 14H, Ar-H); 13C NMR (125MHz, D2O): δ 22.3 
(NHCOCH3), 40.5 (C-3), 42.5 (C-9), 52.2 (C-5), 67.5 (CH2Ph), 68.6 (C-4), 70.4 
(C-7), 70.8 (C-8), 73.0 (C 6), 101.5 (C-2),127.3, 127.9, 128.4, 128.6, 128.8,  
128.9, 129.4, 132.5, 137.4, 139.6, 144.2 (18C, 2XC6H5, C6H4), 171.5, 174.6, 
176.3 (3CO). 
 
Sodium [benzyl 5-acetamido-9-(2-biphenylcarboxamido)-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid]onate (12c). 
O
OHHN OH CO2Na
OAcHN
HO
O
 
According to the general method II, compound 11c (40 mg, 0.055 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification, 12c was obtained as a fluffy solid (32 mg, 97%). 
α[ ]D25  = - 2.7 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.51 (t, J = 11.4 Hz, 1H, 
H-3a), 1.92 (s, 3H, NHAc), 2.63 (dd, J = 4.3, 10.5 Hz, 1H, H-3e), 2.97 (dd, J = 
9.0, 13.9 Hz, 1H, H-9a), 3.27 (d, J = 9.1 Hz, 1H, H-7), 3.47 (m, 1H, H-8), 3.57 (m, 
4H, H-4, H-5, H-6, H-9b), 4.36, 4.58 (A, B of AB, J = 10.7 Hz, 2H, CH2Ph), 6.93, 
7.02 7.07, 7.18-7.34 (m, 14H, Ar-H); 13C NMR (125 MHz, D2O): δ 22.4 
(NHCOCH3), 40.7 (C-3), 43.5 (C-9), 52.2 (C-5), 67.5 (CH2Ph), 68.6 (C-4), 70.2 
(C-8), 70.4 (C-7), 72.8 (C-6), 101.2 (C-2), 127.9, 128.0, 128.1, 128.7, 128.9, 
129.0, 129.3, 130.5, 130.9, 135.1, 137.2, 129.9, 140.1 (18C, 2C6H5, C6H4), 
173.5, 173.8, 175.4 (3CO). 
 
Sodium (benzyl 5-acetamido-3,5,9-trideoxy-9-orotinoylamido-D-glycero-α-D-
galacto-2-nonulopyranosid)onate (12d). 
O
OHHN OH CO2Na
OAcHN
HO
O
N
H
O
O
HN
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According to the general method II, compound 11d (40 mg, 0.059 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12d was obtained as a fluffy solid (32.0 mg, 96%). 
α[ ]D25  = - 3.7 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.69 (t, J = 12.1 Hz, 1H, 
H-3a), 2.01 (s, 3H, NHAc), 2.76 (dd, J = 4.5, 12.4 Hz, 1H, H-3e), 2.97 (m, 1H, H-
9a), 3.44–3.52 (m, 2H, H-7, H-9b), 3.66–3.84 (m, 4H, H-4, H-5, H-6, H-8), 4.54, 
4.69 (A, B of AB, J = 11.3 Hz, 2H, CH2Ph), 6.07, 6.22(2s, 2H, orotinoyl-H), 7.31-
7.41 (m, 5H, Ar-H); 13C NMR (125 MHz, D2O): δ 23.6 (NHCOCH3), 42.1 (C 3), 
44.9 (C-9), 52.2 (C-5), 67.7 (CH2Ph), 68.6 (C-4), 70.1 (C-7), 70.4 (C-8), 72.9 (C-
6), 98.2 (HN-C=C-), 100.8 (HN-C=C-), 128.5, 128.9, 128.9, 129.0, 129.1, 137.7 
(6C, C6H5), 161.4, 166.7, 174.0, 176.0, 182.0 (5CO). 
 
Sodium (benzyl 5-acetamido-9-butyrylamido-3,5,9-trideoxy-D-glycero-α-D-
galacto-2-nonulopyranosid)onate (12e). 
O
OHHN OH CO2Na
OAcHN
HO
O
 
According to the general method II, compound 11e (42 mg, 0.069 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12e was obtained as a fluffy solid (32 mg, 96%). 
α[ ]D25  = - 1.2 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 0.88 (t, J = 7.4 Hz, 3H, 
H 4´), 1.59 (m, 2H, H-3´), 1.68 (t, J = 12.2 Hz, 1H, H-3a), 2.01 (s, 3H, NHAc), 
2.24 (t, J = 7.3 Hz, 2H, H-2´), 2.75 (dd, J = 4.7, 12.4 Hz, 1H, H-3e), 3.30 (dd, J = 
7.1, 14.2 Hz, 1H, H-9a), 3.45 (dd, J = 1.7, 9.0 Hz, 1H, H-7), 3.53 (dd, J = 2.8, 
14.1 Hz, 1H, H-9b), 3.68 (ddd, J = 2.9, 4.7, 11.8 Hz, 1H, H-4), 3.72-3.82 (m, 3H, 
H-5, H-6, H-8), 4.51, 4.70 (A, B of AB, J = 12.0 Hz, 2H, CH2Ph), 7.38 (s, 5H, Ar-
H); 13C NMR (125 MHz, D2O): δ 12.1 (C-4´), 18.4 (C-3´), 22.6 (NHCOCH3), 37.0 
(C-2´), 39.8 (C-3), 41.0 (C-9), 51.2 (C-5), 66.5 (CH2Ph), 67.6 (C-4), 68.9 (C-7), 
69.3 (C-8), 71.9 (C-6), 100.4 (C-2), 127.6, 128.0, 128.0, 136.5 (6C, C6H5), 174.3, 
176.7, 180.8 (3CO). 
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Sodium (benzyl 5-acetamido-3,5,9-trideoxy-9-hexanoylamido-D-glycero-α-D-
galacto-2-nonulopyranosid)onate (12f). 
O
OHHN OH CO2Na
OAcHN
HO
O
 
According to the general method II, compound 11f (26 mg, 0.040 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12f was obtained as a fluffy solid (20 mg, 96%). 
α[ ]D25  = -1.15 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 0.81 (t, J = 7.0 Hz, 3H, 
H-6´), 1.25 (m, 4H, H-4´, H-5’), 1.57 (m, 2H, H-3´), 1.66 (t, J = 12.2 Hz, 1H, H-
3a), 2.02 (s, 3H, NHAc), 2.25 (t, J = 7.4 Hz, 2H, H-2´), 2.75 (dd, J = 4.7, 12.5 Hz, 
1H, H-3e), 3.22 (dd, J  = 7.7, 14.2 Hz, 1H, H-9a), 3.46 (dd, J = 1.7, 9.0 Hz, 1H, H-
7), 3.58 (dd, J = 7.7, 14.1 Hz, 1H, H-9b), 3.68 (ddd, J = 6.6, 9.8, 12.8 Hz, 1H, H-
4), 3.72-3.80 (m, 3H, H-5, H-6, H-8), 4.50, 4.70 (A, B of AB, J = 11.0 Hz, 2H, 
CH2Ph), 7.40 (s, 5H, Ar-H); 13C NMR (125 MHz, D2O): δ 20.1 (C-6´), 20.6 (C-5´), 
21.8 (NHCOCH3), 23.7 (C-4´), 28.9 (C-3´), 34.2 (C-2´), 39.0 (C-3), 40.3 (C-9), 
50.4 (C 5), 65.8 (CH2Ph), 66.8 (C-4), 68.2 (C-7), 68.7 (C-8), 71.1 (C-6), 99.6 (C-
2), 126.8, 127.2, 127.3, 135.6 (6C, C6H5), 173.6, 176.1, 180.1 (3CO). 
 
Sodium (benzyl 5-acetamido-9-decanoylamido-3,5,9-trideoxy-D-glycero-α-D-
galacto-2-nonulopyranosid)onate (12g). 
O
OHHN OH CO2Na
OAcHN
HO
O
 
According to the general method II, compound 11g (30 mg, 0.043 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12g was obtained as a fluffy solid (24 mg, 97%). 
α[ ]D25= - 4.1 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 0.56 (t, J = 6.8 Hz, 3H, 
H-10´), 0.92-1.00 (m, 12H, H-4´, H-5´, H-6´, H-7´, H-8´, H-9´), 1.32 (m, 2H, H-3´), 
1.46 (t, J = 12.2 Hz, 1H, H-3a), 1.81 (s, 3H, NHAc), 2.01 (t, J = 7.2 Hz, 2H, H-2´), 
2.55 (dd, J = 4.5, 12.2 Hz, 1H, H-3e), 2.94 (dd, J = 8.3, 14.1 Hz, 1H, H-9a), 3.25 
(d, J = 11.1 Hz, 1H, H-7), 3.42-3.50 (m, 2H, H-4, H-9b), 3.54-3.63 (m, 3H, H-5, H-
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6, H-8), 4.28, 4.49 (A, B of AB, J = 10.9 Hz, 2H, CH2Ph), 7.10-7.17 (m, 5H, Ar-H); 
13C NMR (125 MHz, D2O): δ 13.9 (C-10´), 22.4 (C-9´), 22.5 (NHCOCH3), 25.9 (C-
8´), 28.7 (C-7´), 29.0 (2C, C-5´, C-6´), 29.2 (C-4´), 31.6 (C-3´), 36.2 (C-2´), 41.0 
(C-3), 42.4 (C-9), 52.2 (C-5), 68.0 (CH2Ph), 68.7 (C-4), 70.3 (C-7), 70.7 (C-8), 
72.9 (C-6), 101.2 (C-2), 128.6, 129.0, 129.2, 137.4 (6C, C6H5), 173.6, 175.3, 
177.3 (3CO). 
 
Sodium [benzyl 5-acetamido-9-(4-chlorobenzamido)-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid]onate (12h). 
O
OHHN OH CO2Na
OAcHN
HO
O
Cl
 
According to the general method II, compound 11h (32.0 mg, 0.047 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12h was obtained as a fluffy solid (21.0 mg, 75%). 
α[ ]D25= - 1.95 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.68 (t, J = 12.2 Hz, 
1H, H-3a), 1.99 (s, 3H, NHAc), 2.76 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.45 (dd, J 
= 8.0, 14.4 Hz, 1H, H-9a), 3.51 (d, J = 8.9 Hz, 1H, H-7), 3.64-3.84 (m, 5H, H-4, 
H-5, H-6, H-8, H-9b) 4.51, 4.69 (A, B of AB, J = 11.2 Hz, 2H, CH2Ph), 7.26-7.36, 
7.46, 7.69 (m, 9H, Ar-H); 13C NMR (125 MHz, D2O): δ 22.3 (NHCOCH3), 40.9 (C 
3), 43.0 (C-9), 52.2 (C-5), 67.7 (CH2Ph), 68.6 (C-4), 70.3 (C-7), 70.6 (C-8), 73.0 
(C-6), 101.6 (C-2), 128.5, 128.9, 129.0, 129.0, 129.1, 132.4, 137.6, 137.9 (12 C, 
C6H5, C6H4), 170.4, 173.5, 176.5 (3CO). 
 
Sodium [benzyl 5-acetamido-3,5,9-trideoxy-9-(4-methoxybenzamido)-D-
glycero-α-D-galacto-2-nonulopyranosid]onate (12i). 
O
OHHN OH CO2Na
OAcHN
HO
O
O
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According to the general method II, compound 11i (25.0 mg, 0.037 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12i was obtained as a fluffy solid (16.0 mg, 80%). 
α[ ]D25= - 3.22 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.68 (t, J = 12.2 Hz, 
1H, H-3a), 1.98 (s, 3H, NHAc), 2.76 (dd, J = 4.7, 12.4 Hz, 1H, H-3e), 3.44 (dd, J 
= 8.2, 14.6 Hz, 1H, H-9a), 3.51 (dd, J = 1.7, 8.7 Hz, 1H, H-7), 3.64-3.84 (m, 8H, 
H-4, H-5, H-6, H-8, H-9b, OCH3), 4.51, 4.68 (A, B of AB, J = 11.2 Hz, 2H, 
CH2Ph), 7.01, 7.24-7.36, 7.74 (m, 9H, Ar-H); 13C NMR (125 MHz, D2O): δ 22.4 
(NHAc), 40.9 (C-3), 42.9 (C-9), 52.2 (C-5), 55.8 (PhOCH3), 67.7 (CH2Ph), 68.6 
(C-4), 70.3 (C-7), 70.7 (C-8), 73.0 (C-6), 101.6 (C-2), 114.3, 126.3, 128.5, 128.9, 
129.0, 129.5, 137.6, 162.3 (12 C, C6H5, C6H4), 170.6, 173.8, 175.4 (3CO). 
 
Sodium [benzyl 5-acetamido-3,5,9-trideoxy-9-(4-methylbenzamido)-D-
glycero-α-D-galacto-2-nonulopyranosid]onate (12j). 
O
OHHN OH CO2Na
OAcHN
HO
O
 
According to the general method II, compound 11j (26.0 mg, 0.039 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12j was obtained as a fluffy solid (20.0 mg, 87%). 
α[ ]D25= - 2.07 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.68 (t, J = 12.2 Hz, 
1H, H-3a), 1.98 (s, 3H, NHAc), 2.38 (s, 3H, PhCH3), 2.76 (dd, J = 4.6, 12.4 Hz, 
1H, H-3e), 3.33- 3.51 (m, 2H, H-7, H-9a), 3.67 (m, 1H, H-4), 3.72-3.83 (m, 4H, H-
5, H-6, H-8, H-9b), 4.53, 4.69 (A, B of AB, J = 11.3 Hz, 2H, CH2Ph), 7.267.36, 
7.69 (m, 9H, Ar-H); 13C NMR (125 MHz, D2O): δ 20.9 (PhCH3), 22.3 (NHCOCH3), 
40.9 (C-3), 42.9 (C-9), 52.2 (C-5), 67.7 (CH2Ph), 68.6 (C-4), 70.2 (C-7), 70.6 (C-
8), 73.0 (C-6), 101.7 (C-2), 127.5, 128.5, 128.9, 129.0, 129.7, 131.0, 137.6, 
143.6 (12C, C6H5, C6H4), 171.3, 173.8, 175.4 (3CO). 
 
Sodium [benzyl 5-acetamido-9-(3,4-dichlorobenzamido)-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid]onate (12k). 
 116
O
OHHN OH CO2Na
OAcHN
HO
O
Cl
Cl
 
According to the general method II, compound 11k (31.0 mg, 0.043 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12k was obtained as a fluffy solid (20.0 mg, 75%). 
α[ ]D25= - 2.45 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.68 (t, J = 12.1 Hz, 
1H, H-3a), 2.01 (s, 3H, NHAc), 2.76 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.39 (dd, J 
= 14.4, 8.5, Hz, 1H, H-9a), 3.52 (m, 1H, H-7), 3.64-3.85 (m, 5H, H-4, H-5, H-6, H-
8, H-9b), 4.47, 4.69 (A, B of AB, J = 11.1 Hz, 2H, CH2Ph), 7.21-7.32, 7.43, 7.53, 
7.75 (m, 8H, Ar-H); 13C NMR (125 MHz, D2O): δ 22.4 (NHCOCH3), 41.0 (C-3), 
43.2 (C-9), 52.2 (C-5), 67.6 (CH2Ph), 68.6 (C-4), 70.4 (C-7), 70.7 (C-8), 73.0 (C-
6), 101.5 (C-2), 126.9, 128.5, 128.9, 129.4, 130.9, 132.5, 133.7, 135.8, 137.4 
(12C, C6H5, C6H3), 168.5, 173.7, 175.4 (3CO). 
 
Sodium [benzyl 5-acetamido-9-(3-chlorobenzamido)-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid]onate (12l). 
O
OHHN OH CO2Na
OAcHN
HO
O
Cl
 
According to the general method II, compound 11l (28.0 mg, 0.041 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12l was obtained as a fluffy solid (16.0 mg, 69 %). 
α[ ]D25  = -1.77 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.69 (t, J = 11.8 Hz, 1H, 
H-3a), 2.00 (s, 3H, NHAc), 2.77 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.49 (m, 2H, H-
7, H-9a), 3.63-3.83 (m, 5H, H-4, H-5, H-6, H-8, H-9), 4.53, 4.71 (A, B of AB, J = 
11.2 Hz, 2H, CH2Ph), 7.29-7.39, 7.44, 7.53, 7.62 (m, 9H, Ar-H); 13C NMR (125 
MHz, D2O): δ 21.9 (NHAc), 40.5 (C-3), 42.6 (C-9), 51.8 (C-5), 67.2 (CH2Ph), 68.2 
(C-4), 69.8 (C-7), 70.1 (C-8), 72.6 (C-6), 101.2 (C-2), 125.3, 127.1, 128.1, 128.5, 
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128.5, 130.2, 131.8, 134.0, 135.3, 137.2 (12C, C6H5, C6H4), 169.5, 173.4, 175.0 
(3CO).  
 
Sodium [benzyl 5-acetamido-3,5,9-trideoxy-9-(4-trifluoromethylbenzamido)-
D-glycero-α-D-galacto-2-nonulopyranosid]onate (12m). 
O
OHHN OH CO2Na
OAcHN
HO
O
F3C
 
According to the general method II, compound 11m (36.0 mg, 0.050 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12m was obtained as a fluffy solid (21.0 mg, 70%). 
α[ ]D25  = -2.37 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.68 (t, J = 12.2 Hz, 1H, 
H-3a), 2.00 (s, 3H, NHAc), 2.76 (dd, J = 4.7, 12.5 Hz, 1H, H-3e), 3.44-3.52 (m, 
2H, H 7, H-9a), 3.68 (m, 1H, H-4), 3.75-3.84 (m, 4H, H-5, H-6, H-8, H-9b), 4.49, 
4.68 (A, B of AB, J = 11.2 Hz, 2H, CH2Ph), 7.24-7.35, 7.75, 7.84 (m, 9H, Ar-H); 
13C NMR (125 MHz, D2O): δ 22.4 (NHCOCH3), 40.9 (C-3), 43.1 (C-9), 52.3 (C-5), 
67.6 (CH2Ph), 68.6 (C-4), 70.3 (C-7), 70.6 (C-8), 73.0 (C-6), 101.6 (C-2), 126.0, 
(CF3), 128.0, 128.5, 128.9, 129.0, 129.5, 129.6, 132.5, 137.5 (12C, C6H5, C6H4), 
170.0, 173.8, 175.4 (3CO). 
 
Sodium [benzyl 5-acetamido-9-(2,4-dichorobenzamido)-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid] onate (12n). 
O
OHHN OH CO2Na
OAcHN
HO
O
Cl
Cl
 
According to the general method II, compound 11n (31.0 mg, 0.043 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup and 
purification 12n was obtained as a fluffy solid (18.0 mg, 72%). 
α[ ]D25  = -1.17 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.66 (t, J = 12.1 Hz, 1H, 
H-3a), 2.01 (s, 3H, NHAc), 2.75 (dd, J = 4.7, 12.3 Hz, 1H, H-3e), 3.53-3.83 (m, 
6H, H-4, H-5, H-6, H-7, H-9), 3.89 (m, 1H, H-8), 4.49, 4.71 (A, B of AB, J = 11.0 
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Hz, 2H, CH2Ph), 7.33-7.41, 7.55 (m, 8H, Ar-H); 13C NMR (125 MHz, D2O): δ 20.0 
(NHCOCH3), 38.5 (C-3), 40.1 (C-9), 49.9 (C-5), 65.1 (CH2Ph), 66.1 (C-4), 67.4 
(C-7), 67.9 (C-8), 70.5 (C-6), 98.9 (C-2), 125.4, 126.2, 126.6, 126.7, 127.1, 
127.4, 127.6, 129.0, 131.3, 134.1, 135.0 (12C, C6H5, C6H3), 167.6, 171.4, 173.0 
(3XCO). 
 
Benzyl 5-acetamido-3,5,9-trideoxy-9-(4-nitrobenzamido)-D-glycero-α-D-
galacto-2-nonulopyranoside (12o). 
O
OHHN OH CO2Na
OAcHN
HO
O
N+
OŠ
O
 
According to the general method II, compound 11o (28.0 mg, 0.040 mmol) was 
deprotected by treatment with 10% NaOH (0.2 mL). After the workup (this 
compound was not passed through the Dowex 50X8 (Na) column) and 
purification 12o was obtained as a fluffy solid (21.0 mg, 95%). 
α[ ]D25  = -2.45 (c = 1.00, H2O); 1H NMR (500 MHz, D2O): δ 1.67 (t, J = 12.2 Hz, 1H, 
H-3a), 1.99 (s, 3H, NHAc), 2.74 (dd, J = 4.7, 12.4 Hz, 1H, H-3e), 3.46 (dd, J = 
7.7, 14.0 Hz, 1H, H-9a), 3.52 (dd, J = 1.7, 8.8 Hz, 1H, H-7), 3.67 (m, 1H, H-4), 
3.74-3.84 (m, 4H, H-5, H-6, H-8, H-9b), 4.48, 4.67 (A, B of AB, J = 11.2 Hz, 2H, 
CH2Ph), 7.23-7.34, 7.88, 8.25 (m, 9H, Ar-H); 13C NMR (125 MHz, D2O): δ 20.4 
(NHCOCH3), 39.0 (C-3), 41.3 (C-9), 50.3 (C-5), 65.7 (CH2Ph), 66.6 (C-4), 68.4 
(C-7), 68.6 (C-8), 71.1 (C-6), 99.6 (C-2), 122.3, 126.6, 126.8, 127.0, 127.0, 
135.6, 138.1, 147.8 (12C, Ar-C), 172.4, 173.5, 176.5 (3CO). 
 
benzyl 5-acetamido-9-{4-methyl-(1H-benzotriazole)[1,2,3]-triazole}-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (13a) 
O
OHN OH COOMe
OAcHN
HO
N
N
N
N
N
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To solution of compound 8 (25 mg, 57.0 µmol) and 1-Propargyl-1H-benzotriazole 
(9.00 mg, 57.0 µmol) in tBuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (1.20 
mg, 6.00 µmol, 6 µl of freshly prepared solution of 1M in H2O), followed by 
CuSO4.5H2O (0.15 mg, 0.61 µmol) in H2O. This heterogeneous mixture was 
stirred for 36 h during which at intervals was added the 2 portions of Na-
ascorbate (2.20 mg, 12.0 µmol) and 2 portions of CuSO4.5H2O (0.30 mg, 1.20 
µmol). After 36 h TLC in DCM:MeOH (7:3) system showed completion of 
reaction. Solvents removed under high vaccum to dryness. This was purified by 
column chromatography on silica gel in DCM:MeOH system to get a foamy solid 
of 13a (25.0 mg, 75%). 
1H NMR (500 MHz, CD3OD): δ 1.79 (t, J = 12.7 Hz, 1H, H-3a), 1.94 (s, 3H, 
NHAc), 2.70 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 3.37 (dd, J = 1.5, 8.5 Hz, 1H, H-7), 
3.55-3.68 (m, 2H, H-4, H-6), 3.72 (s, 3H, CO2CH3), 3.77 (q, J = 10.2 Hz, 1H, H-
5), 4.10 (m, 1H, H-8), 4.42 (dd, J = 4.2, 8.0 Hz, 1H, H-9a), 4.46, 4.74 (A, B of AB, 
J = 11.8 Hz, 2H, CH2Ph), 4.81 (dd, J = 2.5, 4.1 Hz, 1H, H-9b), 6.04 (s, 2H, -CH2-
N), 7.19-7.28 (m, 5H, Ar-H), 7.40, 7.53, 7.85, 7.96 (m, 4H, Ar-H), 7.98 (s, 1H, Ar-
H). 13C NMR (125 MHz, CD3OD): δ 23.0 (NHCOCH3), 42.1 (C-3), 44.6 (-CH2-N) 
53.7 (CO2CH3), 54.2 (C-5), 55.3 (C-9), 67.8 (CH2Ph), 68.7 (C-4), 71.5 (C-8), 71.9 
(C-7), 75.2 (C-6), 100.7 (C-2), 112.12, 120.37, 126.1, 127.0, 129.1, 129.2, 129.3, 
129.6, 130.3, 134.6, 139.3, 143.1, 147.2 (14C, Ar-C), 171.2, 175.6 (2CO). 
 
Methyl [benzyl 5-acetamido-9-{4-(3-pyridyl)1,2,3-triazole}-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid] onate (13b) 
O
OHN OH COOMe
OAcHN
HO
N
N
N
 
To solution of compound 8 (25 mg, 57.0 µmol) and 3-ethynyl pyridine (5.78 mg, 
57.0 µmol) in tBuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (1.20 mg, 6.00 
µmol, 6 µl of freshly prepared solution of 1M in H2O), followed by CuSO4.5H2O 
(0.15 mg, 0.61 µmol) in H2O. This heterogeneous mixture was stirred for 36 h 
during which at intervals was added the 2 portions of Na-ascorbate (2.20 mg, 
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12.0 µmol) and 2 portions of CuSO4.5H2O (0.30 mg, 1.20 µmol). After 36 h, 
according to TLC (EA:MeOH 7:3), reaction was complete. Solvents removed 
under high vaccum to dryness and the residue purified by column 
chromatography on silica gel (EA:MeOH) to get 13b (23 mg, 74%) as a foam.  
1H NMR (500 MHz, CD3OD): δ 1.73 (t, J = 12.4 Hz, 1H, H-3a), 1.88 (s, 3H, 
NHAc), 2.64 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 3.35 (dd, J = 1.4, 8.5 Hz, 1H, H-7), 
3.59 (m, 2H, H-4, H-6), 3.64 (s, 3H, CO2CH3), 3.72 (q, J = 10.2 Hz, 1H, H-5), 
4.15 (m, 1H, H-8), 4.44 (m, 2H, H-9a, A of AB CH2Ph), 4.72 (B of AB, J = 11.7 
Hz, 2H, CH2Ph), 4.83 (dd, J = 2.7, 14.0 Hz, 1H, H-9b), 7.42, 7.12-7.20, 8.92, 
8.39, 8.18 (m, 10H, Ar-H). 13C NMR (125 MHz, CD3OD): δ 23.0 (NHCOCH3), 
42.2 (C-3), 53.7 (CO2CH3), 54.3 (C-5), 55.5 (C-9), 67.8 (CH2Ph), 68.7 (C-4), 71.5 
(C-8), 72.0 (C-7), 75.3 (C-6), 100.7 (C-2), 124.9, 126.0, 129.1, 129.3, 129.7, 
135.3, 139.3, 145.4, 147.6, 149.9 (13C, Ar-C), 171.3, 175.6 (2CO). 
 
Methyl [benzyl 5-acetamido-9-(4-methylphenoxy)[1,2,3]-triazole}-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (13c) 
O
OHN OH COOMe
OAcHN
HO
N
N
O
 
To solution of 8 (25 mg, 57.0 µmol) and Phenyl propargyl ether (7.52 mg, 57.0 
µmol) in tertBuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (1.20 mg, 6.00 
µmol, 6 µl of freshly prepared solution of 1M in H2O), followed by CuSO4.5H2O 
(0.15 mg, 0.61 µmol) in H2O. This heterogeneous mixture was stirred for 36 h 
during which at intervals was added the 2 portions of Na-ascorbate (2.20 mg, 
12.0 µmol) and 2 portions of CuSO4.5H2O (0.30 mg, 1.20 µmol). After 36 h, 
according to TLC (EA:MeOH 7:3), reaction was complete. Solvents removed 
under high vaccum to dryness and the residue purified by column 
chromatography on silica gel (EA:MeOH) to get 13c (26 mg, 81%) as a solid. 
1H NMR (500 MHz, CD3OD): δ 1.82 (t, J = 12.4 Hz, 1H, H-3a), 1.99 (s, 3H, 
NHAc), 2.73 (dd, J = 4.7, 12.7 Hz, 1H, H-3e), 3.41 (dd, J = 1.4, 8.4 Hz, 1H, H-7), 
3.62-3.68 (m, 2H, H-4, H-6), 3.75 (s, 3H, CO2CH3), 3.80 (q, J = 10.2 Hz, 1H, H-
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5), 4.17 (m, 1H, H-8), 4.45-4.53 (m, 2H, H-9a, A of AB CH2Ph), 4.80 (B of AB, J = 
11.7 Hz, 2H, CH2Ph), 4.84 (m, 1H, H-9b), 5.16 (s, 2H, -CH2-OPh), 6.92-7.01 (m, 
3H, Ar-H), 7.22-7.33 (m, 7H, Ar-H), 8.05 (s, 1H, Ar-H). 13C NMR (125 MHz, 
CD3OD): δ 23.0 (NHCOCH3), 42.1 (C-3), 53.7 (CO2CH3), 54.2 (C-5), 55.3 (C-9), 
62.7 (-CH2-OPh), 67.8 (CH2Ph), 68.7 (C-4), 71.5 (C-8), 71.9 (C-7), 75.2 (C-6), 
100.7 (C-2), 116.2, 122.6, 127.0, 129.1, 129.2, 129.6, 130.9, 131.6, 139.3, 145.1, 
(14C, Ar-C), 171.3, 175.6 (2CO). 
 
Methyl [benzyl 5-acetamido-9-{4-(3-thiophene)[1,2,3]-triazole}-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (SH-13d) 
O
OH
N OH COOMe
OAcHN
HO
N
N
S
 
To solution of 8 (25 mg, 57.0 µmol) and 3-ethynyl thiophene (6.15 mg, 57.0 
µmol) in tBuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (1.20 mg, 6.00 µmol, 
6 µl of freshly prepared solution of 1M in H2O), followed by CuSO4.5H2O (0.15 
mg, 0.61 µmol) in H2O. This heterogeneous mixture was stirred for 36 h during 
which at intervals was added the two additional portions of Na-ascorbate (2.20 
mg, 12.0 µmol) and two additional portions of CuSO4.5H2O (0.30 mg, 1.20 µmol). 
Reaction was very sluggish as monitored by TLC (EA:MeOH 8:2). Solvents 
removed under high vaccum to dryness and the residue purified by column 
chromatography on silica gel (EA:MeOH) to get 13d (10 mg, 32%) as a solid. 
1H NMR (500 MHz, CDCl3): δ 1.95 (s, 3H, NHAc), 2.02 (m, 1H, H-3a), 2.82 (dd, J 
= 4.6, 13.2 Hz, 1H, H-3e), 3.31 (d, J = 9.0 Hz, 1H, H-7), 3.45 (d, J = 10.4 Hz, 1H, 
H-6), 3.66 (s, 3H, CO2CH3), 3.72 (m, 1H, H-4), 3.84 (m, 1H, H-5), 4.20 (m, 1H, H-
8), 4.41, 4.75 (A, B of AB, J = 11.7 Hz, 2H, CH2Ph), 4.53 (dd, J = 7.0, 14.1 Hz, 
1H, H-9a), 4.83 (dd, J = 2.0, 14.1 Hz, 1H, H-9b), 7.23-7.43 (m, 7H, Ar-H), 7.66, 
7.92 (s, 2H, Ar-H). 13C NMR (125 MHz, CDCl3): δ 23.3 (NHCOCH3), 40.5 (C-3), 
53.6 (C-5), 53.7 (2C, C-9, CO2CH3), 67.7 (CH2Ph), 67.7 (C-4), 70.1 (C-8), 70.4 
(C-7), 74.1 (C-6), 99.2 (C-2), 121.7, 126.1, 127.0, 128.0, 128.2, 128.7, 137.2 
(11C, Ar-C), 170.5, 174.5 (2CO). 
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Methyl [benzyl 5-acetamido-9-{4-(3-chloro phenyl)[1,2,3]-triazole}-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (13e) 
O
OH
N OH COOMe
OAcHN
HO
N
N
Cl
 
To solution of 8 (25 mg, 57.0 µmol) and 3-chloro-1-ethynyl benzene (7.75 mg, 
57.0 µmol) in tBuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (1.20 mg, 6.00 
µmol, 6 µl of freshly prepared solution of 1M in H2O), followed by CuSO4.5H2O 
(0.15 mg, 0.61 µmol) in H2O. This heterogeneous mixture was stirred for 36 h 
during which at intervals was added the two additional portions of Na-ascorbate 
(2.20 mg, 12.0 µmol) and two additional portions of CuSO4.5H2O (0.30 mg, 1.20 
µmol). Reaction was sluggish as monitored by TLC (EA:MeOH 8:2). Solvents 
removed under high vaccum to dryness and the residue purified by column 
chromatography on silica gel (EA:MeOH) to get 13e (18 mg, 56%) as a solid. 
1H NMR (500 MHz, CDCl3): δ 1.97 (m, 3H, H-3a, NHAc), 2.83 (dd, J = 4.2, 12.9 
Hz, 1H, H-3e), 3.32 (d, J = 8.5 Hz, 1H, H-7), 3.47 (m, 1H, H-6), 3.67 (s, 3H, 
CO2CH3), 3.72 (m, 1H, H-4), 3.82 (q, J = 9.4 Hz, 1H, H-5), 4.19 (m, 1H, H-8), 
4.41, 4.73 (A, B of AB, J = 11.7 Hz, 2H, CH2Ph), 4.53 (dd, J = 6.8, 14.0 Hz, 1H, 
H-9b), 4.84 (d, J = 13.5 Hz, 1H, H-9b), 6.86 (d, J = 7.2 Hz, 1H, NH-5), 7.22-7.34, 
7.67 (m, 8H, Ar-H), 7.70, 7.96 (s, 2H, Ar-H). 13C NMR (125 MHz, CDCl3): δ 23.1 
(NHCOCH3), 40.8 (C-3), 53.4 (C-5), 53.7 (C-9, CO2CH3), 66.8 (CH2Ph), 67.8 (C-
4), 70.0 (C-8), 70.4 (C-7), 74.1 (C-6), 99.2 (C-2), 122.6, 124.1, 126.1, 128.1, 
128.3, 128.6, 128.7, 130.6, 132.5, 137.1, 146.7 (14C, Ar-C), 170.5, 174.6 (2CO). 
 
Methyl [benzyl 5-acetamido-9-{4-(4-trifluormethyl phenyl)[1,2,3]-triazole}-
3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (13f). 
O
OH
N OH COONa
OAcHN
HO
N
N
F3C
 
To solution of 8 (25 mg, 57.0 µmol) and 4-trifluoromethyl benzene acetylene 
(9.69 mg, 57.0 µmol) in tBuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (1.20 
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mg, 6.00 µmol, 6 µl of freshly prepared solution of 1M in H2O), followed by 
CuSO4.5H2O (0.15 mg, 0.60 µmol) in H2O. This heterogeneous mixture was 
stirred for 36 h during which at intervals was added two additional portions of Na-
ascorbate (2.20 mg, 12.0 µmol) and two additional portions of CuSO4.5H2O (0.30 
mg, 1.20 µmol). After 36 h, according to TLC (EA:PE:MeOH 7:2:1), reaction was 
complete. Solvents removed under high vacuum to dryness and the residue 
purified by column chromatography on silica gel to get 13f (22 mg, 64%) as solid.  
1H NMR (500 MHz, CD3OD): δ 1.82 (t, J = 12.4 Hz, 1H, H-3a), 1.97 (s, 3H, 
NHAc), 2.73 (dd, J = 4.7, 12.8 Hz, 1H, H-3e), 3.43 (dd, J = 1.4, 8.5 Hz, 1H, H-7), 
3.68 (m, 2H, H-4, H-6), 3.73 (s, 3H, CO2CH3), 3.80 (q, J = 10.2 Hz, 1H, H-5), 
4.23 (m, 1H, H-8), 4.53 (m, 2H, H-9a, B of AB CH2Ph), 4.81 (d, J = 11.7 Hz, 2H, 
B of AB CH2Ph), 4.90 (m, 1H, H-9b), 7.25 (m, 5H, Ar-H), 7.72 (d, J = 8.2 Hz, 2H, 
Ar-H), 8.01 (d, J = 8.1 Hz, 2H, Ar-H), 8.43 (s, 1H, Ar-H). 13C NMR (125 MHz, 
CD3OD): δ 23.0 (NHCOCH3), 42.2 (C-3), 53.7 (CO2CH3), 54.2 (C-5), 55.4 (C-9), 
67.8 (CH2Ph), 68.7 (C-4), 71.4 (C-8), 71.9 (C-7), 75.3 (C-6), 100.7 (C-2), 125.0, 
127.3, 127.4, 129.1, 129.2, 129.6, 136.1, 139.3, 147.4 (12C, Ar-C), 171.3, 175.6 
(2CO). 
 
 
Sodium [benzyl 5-acetamido-9-{4-methyl (1-H-benzotriazole)[1,2,3]-triazole}-
3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (14a) 
O
OHN OH COONa
OAcHN
HO
NN
N
N
N
 
To a solution of compound 13a (25 mg, 0.042 mmol) in methanol (2 mL) was 
added 10% aq. NaOH (0.2 mL). The mixture was stirred at r.t. for 3 h. After 
neutralization with 10 % HCl till pH=7, the solution was concentrated and the 
residue purified by reversed phase chromatography (RP-18 column, 5% gradient 
MeOH in water), Dowex 50X8 (Na+ type) ion-exchange chromatography, and P2 
size exclusion chromatography to afford 14a (25 mg, 98%) as a white solid after 
a final lyophilization from water. 
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1H NMR (500 MHz, D2O): δ 1.44 (t, J = 12.7 Hz, 1H, H-3a), 1.92 (s, 3H, NHAc), 
2.56 (dd, J = 4.5, 12.4 Hz, 1H, H-3e), 3.45 (dd, J = 1.2, 9.1 Hz, 1H, H-7), 3.30-
3.51 (m, 6H, H-4, H-5, H-6, H-8, A, B of AB CH2Ph), 4.32 (dd, J = 9.5, 14.4 Hz, 
1H, H-9a), 4.69-4.81 (m, 1H, H-9b), 5.59 (q, J = 16.0 Hz, 2H, -CH2-N), 6.33 (t, J = 
7.5 Hz, 1H, Ar-H), 6.61 (t J = 7.4 Hz, 2H, Ar-H), 6.80 (m, 2H, Ar-H), 6.88 (t, J = 
7.4 Hz, Ar-H), 6.86 (t, J = 7.3 Hz, 1H, Ar-H), 7.18 (d, J = 8.3 Hz, 1H, Ar-H), 8.21 
(s, 1H, Ar-H). 13C NMR (125 MHz, D2O): δ 22.3 (NHCOCH3), 40.9 (C-3), 42.7 (-
CH2-N), 52.1 (C-5), 53.7 (C-9), 67.3 (CH2Ph), 68.4 (C-4), 69.9 (C-7), 1.5 (C-8), 
72.7 (C-6), 101.3 (C-2), 110.1, 118.0, 124.5, 126.5, 128.0, 128.1, 128.2, 128.9, 
132.1, 136.4, 141.9, 144.1 (14C, Ar-C), 173.3, 175.4 (2CO). 
 
Sodium [benzyl 5-acetamido-9-{4-(3-pyridyl) triazole}-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid] onate (14b) 
O
OHN OH COONa
OAcHN
HO
N
N
N
 
To a solution of compound 13b (25 mg, 0.042 mmol) in methanol (2 mL) was 
added 10% aq. NaOH (0.2 mL). The mixture was stirred at r.t. for 3 h. After 
neutralization with 10 % HCl till pH=7, the solution was concentrated and the 
residue purified by reversed phase chromatography (RP-18 column, 5% gradient 
MeOH in water), Dowex 50X8 (Na+ type) ion-exchange chromatography, and P2 
size exclusion chromatography to afford 14b (23 mg, 98%) as a white solid after 
a final lyophilization from water. 
1H NMR (500 MHz, CD3OD): δ 1.69 (t, J = 12.2 Hz, 1H, H-3a), 2.00 (s, 3H, 
NHAc), 2.75 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.46 (dd, J = 1.6, 9.0 Hz, 1H, H-7), 
3.68 (m, 1H, H-4), 3.74 (dd, J = 1.7 Hz, 10.4 Hz, 1H, H-6), 3.80 (m, 2H, H-5, H-
8), 4.44 (m, 2H, H-9a, A of AB CH2Ph), 4.57 (B of AB, J = 11.7 Hz, 1H, CH2Ph), 
4.75 (m, 1H, H-9b), 7.10-7.26, 7.37(m, 6H, Ar-H), 7.84 (d, J = 8.0 Hz, Ar-H), 8.22 
(d, J = 4.0 Hz, 1H, Ar-H), 8.54 (s, 1H, Ar-H). 13C NMR (125 MHz, D2O): δ 21.8 
(NHCOCH3), 40.5 (C-3), 51.7 (C-5), 52.9 (C-9), 7.3 (CH2Ph), 68.0 (C-4), 69.2 (C-
7), 70.3 (C-8), 72.3 (C-6), 101.3 (C-2), 111.9, 123.3, 124.3, 125.9, 127.8, 128.1, 
128.2, 133.8, 137.1, 143.8, 145.2, 148.0 (13C, Ar-C), 171.3, 175.6 (2CO). 
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Methyl [benzyl 5-acetamido-9-{4-(3-thiophene)[1,2,3]-triazole}-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (14c) 
O
OHN OH COONa
OAcHN
HO
N
N
S
 
To a solution of compound 13c (10 mg, 0.018 mmol) in methanol (2 mL) was 
added 10% aq. NaOH (0.2 mL). The mixture was stirred at r.t. for 3 h. After 
neutralization with 10 % HCl till pH=7, the solution was concentrated and the 
residue purified by reversed phase chromatography (RP-18 column, 5% gradient 
MeOH in water), Dowex 50X8 (Na+ type) ion-exchange chromatography, and P2 
size exclusion chromatography to afford 14c (7.50 mg, 75%) as a white solid 
after a final lyophilization from water. 
1H NMR (500 MHz, CDCl3): δ 1.69 (m, 1H, H-3a), 1.93 (s, 3H, NHAc), 2.75 (dd, J 
= 4.6, 12.5 Hz, 1H, H-3e), 3.38 (d, J = 1.8, 9.0 Hz, 1H, H-7), 3.62-3.71 (m, 3H, H-
4, H-6, H-8), 3.78 (m, 1H, H-5), 4.44 (dd, J = 7.9, 14.5 Hz, 1H, H-9a), 4.55, 4.62 
(d, J = 11.8 Hz, 2H, A, B of AB, CH2Ph), 4.71 (m, 1H, H-9b), 7.18-7.25 (m, 3H, 
Ar-H), 7.33 (m, 2H, Ar-H), 7.52, 7.57, 7.81 (m, 3H, Ar-H), 8.32 (s, 1H, Ar-H). 
 
Sodium [benzyl 5-acetamido-9-{4-(methylphenoxy)[1,2,3]-triazole}-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (14d) 
O
OHN OH COONa
OAcHN
HO
N
N
O
 
To a solution of compound 13d (26 mg, 0.045 mmol) in methanol (2 mL) was 
added 10% aq. NaOH (0.2 mL). The mixture was stirred at r.t. for 3 h. After 
neutralization with 10 % HCl till pH=7, the solution was concentrated and the 
residue purified by reversed phase chromatography (RP-18 column, 5% gradient 
MeOH in water), Dowex 50X8 (Na+ type) ion-exchange chromatography, and P2 
size exclusion chromatography to afford 14d (26 mg, 98%) as a white solid after 
a final lyophilization from water. 
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1H NMR (500 MHz, D2O): δ 1.67 (t, J = 12.7 Hz, 1H, H-3a), 1.99 (s, 3H, NHAc), 
2.75 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.38 (dd, J = 1.8, 9.0 Hz, 1H, H-7), 3.65 (m, 
3H, H-4, H-6, H-8), 3.77 (m, 1H, H-5), 4.37 (dd, J = 8.5, 14.5 Hz, 1H, H-9a), 4.53 
(q, J = 11.7 Hz, 2H, A, B of AB CH2Ph), 4.68 (dd, J = 2.2, 14.5 Hz, 1H, H-9b), 
5.24 (s, 2H, -CH2-O-Ph), 6.33 (t, J = 7.5 Hz, 1H, Ar-H), 7.01 (m, 3H, Ar-H), 7.20 
(m, 3H, Ar-H), 7.30 (m, 4H, Ar-H), 8.05 (s, 1H, Ar-H). 13C NMR (125 MHz, D2O): 
δ 19.9 (NHCOCH3), 38.6 (C-3), 49.7 (C-5), 50.8 (C-9), 59.0 (-CH2-O-Ph), 65.5 
(CH2Ph), 66.1 (C-4), 67.3 (C-7), 68.3 (C-8), 70.4 (C-6), 99.5 (C-2), 113.4, 120.0, 
124.0, 126.0, 126.3, 126.4, 127.8, 135.4, 141.2, 155.1 (14C, Ar-C), 171.2, 173.0 
(2CO). 
 
Sodium [benzyl 5-acetamido-9-{4-(3-chloro phenyl)[1,2,3]-triazole}-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (14e) 
O
OHN OH COONa
OAcHN
HO
NN
Cl
 
To a solution of compound 13e (18 mg, 0.031 mmol) in methanol (2 mL) was 
added 10% aq. NaOH (0.2 mL). The mixture was stirred at r.t. for 3 h. After 
neutralization with 10 % HCl till pH=7, the solution was concentrated and the 
residue purified by reversed phase chromatography (RP-18 column, 5% gradient 
MeOH in water), Dowex 50X8 (Na+ type) ion-exchange chromatography, and P2 
size exclusion chromatography to afford 14e (12 mg, 99%) as a white solid after 
a final lyophilization from water. 
1H NMR (500 MHz, CDCl3): δ 1.68 (t, J = 12.1 Hz, 1H, H-3a), 1.99 (s, 3H, NHAc), 
2.75 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.44 (d, J = 1.8, 9.0 Hz, 1H, H-7), 3.67 (m, 
1H, H-4), 3.72-3.82 (m, 3H, H-5, H-6, H-8), 4.41 (dd, J = 8.3, 14.5 Hz, 1H, H-9a), 
4.48, 4.60 (d, J = 11.6 Hz, 2H, A, B of AB, CH2Ph), 4.74 (m, 1H, H-9b), 7.12-
7.52, 7.55 (m, 9H, Ar-H), 8.16 (s, 1H, Ar-H). 13C NMR (125 MHz, D2O): δ 22.2 
(NHCOCH3), 40.9 (C-3), 52.1 (C-5), 53.4 (C-9), 67.8 (CH2Ph), 68.4 (C-4), 69.7 
(C-7), 70.8 (C-8), 72.7 (C-6), 99.2 (C-2), 123.5, 124.0, 125.4, 128.2, 128.5, 
128.6, 128.7, 130.7, 131.4, 134.4, 137.6, 146.3 (13C, Ar-C), 173.5, 175.4 (2CO). 
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Sodium [benzyl 5-acetamido-9-{4-(4-trifluormethyl phenyl) triazole}-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate (14f). 
O
OHN OH COONa
OAcHN
HO
N
NF3C
 
To a solution of compound 13f (22 mg, 0.036 mmol) in methanol (2 mL) was 
added 10% aq. NaOH (0.2 mL). The mixture was stirred at r.t. for 3 h. After 
neutralization with 10 % HCl till pH=7, the solution was concentrated and the 
residue purified by reversed phase chromatography (RP-18 column, 5% gradient 
MeOH in water), Dowex 50X8 (Na+ type) ion-exchange chromatography, and P2 
size exclusion chromatography to afford 14f (16 mg, 73%) as a white solid after a 
final lyophilization from water. 
1H NMR (500 MHz, CD3OD): δ 1.68 (t, J = 12.1 Hz, 1H, H-3a), 1.99 (s, 3H, 
NHAc), 2.74 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.44 (dd, J = 1.8, 9.0 Hz, 1H, H-7), 
3.63 (m, 1H, H-4) 3.73 (dd, J = 1.9, 10.5 Hz, 1H, H-6), 3.78 (m, 2H, H-5, H-8), 
4.39 (dd, J = 8.4, 14.6 Hz, 1H, H-9a) 4.45 (d, J = 11.5 Hz, 1H, A of AB CH2Ph), 
4.58 (d, J = 11.6 Hz, 1H, B of AB CH2Ph), 4.71 (d, J = 2.0, 14.6 Hz, 1H, H-9b), 
7.10-7.18 (m, 3H, Ar-H), 7.24 (m, 2H, Ar-H), 7.54 (d, J = 8.2 Hz, 2H, Ar-H), 7.63 
(d, J = 8.3 Hz, 2H, Ar-H), 8.22 (s, 1H, Ar-H). 13C NMR (125 MHz, D2O): δ 20.0 
(NHCOCH3), 38.7 (C-3), 49.9 (C-5), 51.1 (C-9), 65.6 (CH2Ph), 66.2 (C-4), 67.5 
(C-7), 68.6 (C-8), 70.5 (C-6), 99.5 (C-2), 121.6, 123.7, 123.8, 126.0, 126.4, 
126.5, 130.9, 135.3, 144 (14C, Ar-C), 171.3, 173.2 (2CO). 
 
Methyl (methyl 5-acetamido-3,5-dideoxy-2-thio-D-glycero-α-D-galacto-2-
nonulopyranosid)onate. (15) 
SMeO
HO
AcHN
HO
OH
OH CO2Me
 
A solution of 3 (6.00 g, 11.5 mmol) in dry methanol (220 mL) was treated with 1 
M methanolic NaOMe (24.0 mL) at r.t. for 2 h. The reaction mixture was 
neutralized with Amberlyst 15 (H+) ion-exchange resin and filtered through a pad 
of Celite. The Celite was washed thoroughly with methanol (3 × 5 mL), and the 
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combined filtrates were evaporated to give 15 as anomeric mixture (α:β X:X) 
(2.70 g, 68%). 
β-isomer:  
1H NMR (500MHz, CD3OD): δ 1.92 (t, J = 13.8 Hz, 1H, H-3a), 2.04 (s, 3H, 
NHAc), 2.02 (s, 3H, SMe), 2.42 (dd, J = 4.9, 13.8 Hz, 1H, H-3e), 3.49 (dd, J = 
1.0, 9.4 Hz, 1H, H-7), 3.63 (dd, J = 4.9, 11.5 Hz, 1H, H-9a), 3.78 (m, 6H, H-5, H-
8, H-9b, CO2CH3), 4.05 (m, H-4), 4.10 (dd, J = 1.2, 10.7 Hz, H-6). 13C NMR (125 
MHz, CD3OD): δ 12.9 (SCH3), 23.8 (NHCOCH3), 42.1 (C-3), 53.9 (CO2CH3), 54.7 
(C-5), 66.2 (C-9), 69.3 (C-4), 71.2 (C-7), 72.3 (C-8), 73.6 (C-6), 86.5 (C-2), 172.0, 
176.2 (2CO). α-Isomer:  1H NMR (500MHz, CD3OD): δ 1.76 (t, J = 12.8 Hz, 1H, 
H-3a), 1.98 (s, 3H, NHAc), 2.13 (s, 3H, SMe), 2.73 (dd, J = 4.7, 12.8 Hz, 1H, H-
3e), 3.40 (dd, J = 1.6, 10.4 Hz, H-6), 3.49 (dd, J = 1.6, 9.1 Hz, 1H, H-7), 3.59-
3.67 (m, 2H, H-4, H-9a), 3.74-3.84 (m, 6H, H-5, H-8, H-9b, CO2CH3). 13C NMR 
(125 MHz, CD3OD): δ 12.3 (SCH3), 23.1 (NHCOCH3), 42.2 (C-3), 54.0 (CO2CH3), 
54.1 (C-5), 64.9 (C-9), 69.3 (C-4), 71.6 (C-7), 73.0 (C-8), 77.4 (C-6), 84.0 (C-2), 
172.2, 175.7 (2CO). 
 
Methyl [methyl 5-acetamido-3,5-dideoxy-9-O-(4-toluenesulfonyl)-2-thio-D-
glycero-D-galacto-2-nonulo-pyranosid]onate: (16) 
SMeO
TsO
AcHN
HO
OH
OH CO2Me
 
To a anomeric mixture of 15 (2.70 g, 7.64 mmol) in pyridine (80 ml) was added p-
TsCl (1.45 gm, 7.64 mmol) at 0°C. After 2 h, p-TsCl (725 mg, 3.82 mmol) was 
added and stirring continued for 16 h at 5°C. The reaction mixture was warmed 
to r.t., diluted with methanol (40 mL) and stirring continued for 30 min. After 
removal of the solvents the remaining syrup was purified by chromatography on 
silica gel (DCM/MeOH 19:1) to yield 16 as anomeric mixture (α:β X:X) (2.13 gm, 
56%). 
β-Isomer:  1H NMR (500MHz, CD3OD): δ 1.90 (t, J = 13.9 Hz, 1H, H-3a), 1.97 (s, 
3H, NHAc), 1.99 (s, 3H, SMe), 2.41 (m, 1H, H-3e), 2.43 (s, 3H, PhCH3), 3.45 (dd, 
J = 1.1, 9.1 Hz, 1H, H-7), 3.71 (t, J = 10.4 Hz, 1H, H-5), 3.75 (s, 3H, CO2CH3), 
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3.95 (m, 1H, H-8), 4.01-4.07 (m, 3H, H-4, H-6, H-9a), 4.28 (dd, J = 2.2, 10.0 Hz, 
1H, H-9b), 7.43 (d, J = 8.1 Hz, 2H, Ar-H), 7.79 (d, J = 8.4 Hz, 2H, Ar-H). 13C NMR 
(125 MHz, CD3OD): δ 11.6 (SCH3), 22.0 (PhCH3), 23.1 (NHCOCH3), 41.4 (C-3), 
53.6 (CO2CH3), 54.4 (C-5), 68.4 (C-4), 69.3 (C-8), 70.2 (C-7), 72.7 (C-6), 74.5 
(C-9), 85.9 (C-2), 129.5, 131.5, 134.5, 146.9 (Ar-C), 171.2, 175.6 (2CO). α-
Isomer:  1H NMR (500MHz, CD3OD): δ 1.72 (t, J = 12.8 Hz, 1H, H-3a), 1.97 (s, 
3H, NHAc), 2.07 (s, 3H, SMe), 2.43 (s, 3H, PhCH3), 2.71 (dd, J = 4.7, 12.9 Hz, 
1H, H-3e), 3.36 (dd, J = 1.4, 10.3 Hz, H-6), 3.41 (dd, J = 1.4, 8.8 Hz, 1H, H-7), 
3.62 (m, 1H, H-4), 3.70 (t, J = 10.1 Hz, 1H, H-5), 3.79 (s, 3H, CO2CH3), 3.96 (m, 
1H, H-8), 4.05 (dd, J = 6.1, 10.2 Hz, 1H, H-9a), 4.28 (dd, J = 2.0, 10.2 Hz, 1H, H-
9b), 7.43 (d, J = 8.2 Hz, 2H, Ar-H), 7.82 (d, J = 8.3 Hz, 2H, Ar-H). 13C NMR (125 
MHz, CD3OD): δ 12.2 (SCH3), 21.8 (PhCH3), 22.9 (NHCOCH3), 42.0 (C-3), 53.9 
(CO2CH3), 54.0 (C-5), 69.0 (C-4), 70.2 (C-7), 70.3 (C-8), 73.7 (C-6), 84.0 (C-2), 
129.3, 131.3, 134.4, 146.7 (Ar-C), 171.7, 175.6 (2CO). 
 
Methyl (methyl 5-acetamido-9-azido-2-thio-3,5,9-trideoxy-D-glycero-D-
galacto-2-nonulo-pyranosid)onate: (17) 
SMeO
N3
AcHN
HO
OH
OH CO2Me
 
A mixture of SH-16 (2.13 gm, 4.21 mmol), crown ether 18-C-6 (447 mg, 1.68 
mmol) and NaN3 (1.37 gm, 21.1 mmol) was stirred in DMF (60 mL) at 60°C for 24 
h. TLC analysis (DCM/acetone 1:1) showed completion of the reaction. The 
mixture was filtered through a pad of Celite and then washed with methanol 
several times. The filtrate was collected and evaporated to dryness. Purification 
by column chromatography on silica gel (DCM/acetone 7:3) yielded 17 as a 
mixture (1.42 gm, 89%) of α:β isomer (0.8:1). 
 
Methyl (methyl 5-acetamido-4,7,8-tri-O-acetyl-9-azido-2-thio-3,5,9-trideoxy-
D-glycero-α-D-galacto-2-nonulopyranosid)onate: (18) 
SMeO
N3
AcHN
AcO
OAc
OAc CO2Me
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Compound 17 (1.42 gm, 3.75 mmol) was dissolved in dry pyridine (1.60 gm, 157 
mmol) and stirred at 0°C for 15 min under argon before DMAP (73.0 mg, 0.60 
mmol) and Ac2O (1.47 gm, 187 mmol) were added simultaneously at 0°C. After 
stirring at r.t. for 14 h, TLC analysis showed completion of the reaction. After 
evaporation of the solvents, chromatography on silica gel (DCM/MeOH 20:1) 
yielded 18 as a white foam (1.69 gm, 90%) with a mixture of α:β isomer (0.8:1). 
 
Methyl [(3-NHCbz-propyl) 5-acetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid]onate: (19) 
O
OAc
N3 OAc COOMe
OAcHN
AcO
N
H
O
O
 
Compound 18 (450 mg, 0.865 mmol), Cbz-amino propanol (271 mg, 1.297 mmol) 
and 3Å molecular sieves (450 mg) were suspended in dry MeCN (10 mL) and 
stirred under argon atmosphere with cooling, until temperature reached –40°C. 
NIS (231 mg, 12.0 mmol) and trifluoromethane sulfonic acid (52 mg, 0.346 mmol) 
were added successively. After stirring for 30 min, the reaction was warmed to –
30°C and stirring was continued at this temperature for additional 14 h. The 
mixture was diluted with DCM and filtered through a pad of Celite. After 
subsequent washing with 20% aqueous Na2S2O3 (20 mL) and sat. aqueous 
NaHCO3 (20 mL), the organic layer was dried over Na2SO4, filtered and 
concentrated to give a syrup. Purification by column chromatography on silica gel 
(petrol ether/DCM/2-propanol 8:4:1) yielded 19 (624 mg) as a crude mixture of 
α:β isomer (1:0.4) and some residual impurities. 
 
Methyl [(3-NHCbz-propyl) 5-acetamido-4,7,8-tri-O-acetyl-9-benzamido-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid] onate: (20) 
O
OAcH
N OAc COOMe
OAcHN
AcO
NHZO
 
According to the general method I, 19 (624 mg, 0.938 mmol) was reacted with 
benzoyl chloride (525 mg, 3.75 mmol) and triphenyl phosphine (540 mg, 2.06 
 131
mmol) in DCE (20 mL) for 14 h. After workup 20 was obtained as a crude solid 
(620 mg, 94%) with a mixture of α:β isomer (1:0.7). 
 
(3-NHCbz-propyl) 5-acetamido-4,7,8-tri-O-acetyl-9-benzamido-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranoside: (21) 
O
OHH
N OH COOH
OAcHN
HO
NHZO
 
To a solution of 20 (624 mg) in methanol (25 mL) was added 10% aq. NaOH (2.4 
mL). The mixture was stirred at r.t. for 3 h. The solution was neutralized with 10% 
aq. HCL (2.4 ml) and then concentrated. The residue was purified by reversed 
phase chromatography (RP-18 column, 5% gradient MeOH in water) to give first 
21 as α-isomer (85 mg, 17%) and in later fractions the β isomer. 
1H NMR (500MHz, D2O): δ 1.67 (m, 2H, H-3a, H-2’), 2.00 (s, 3H, NHAc), 2.72 
(dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.13 (m, 2H, H-3’), 3.44 (m, 2H, H-9a, H-1’a), 
3.53 (dd, J = 1.1, 8.9 Hz, 1H, H-7), 3.64-3.76 (m, 4H, H-4, H-6, H-9a, H-1’b), 3.74 
(m, 1H, H-5), 3.92 (m, 1H, H-8), 4.90 (s, 2H, H-1”) 7.25, 7.31, 7.41, 7.52, 7.65 
(m, 10H, Ar-H). 
 
(3-Amino-propyl) 5-acetamido-4,7,8-tri-O-acetyl-9-benzamido-3,5,9-trideoxy-
D-glycero-α-D-galacto-2-nonulopyranoside: (22) 
O
OHH
N OH COOH
OAcHN
HO
NH2O
 
The compound 21 (85 mg, 0.140 mmol) was dissolved in MeOH (5 ml) and 
stirred under argon atmosphere for 10 min. The flask was saturated with H2 
atmosphere and stirred for 2 hrs. According to TLC, hydrogenation was 
complete. The reaction mixture was filtered through a pad of celite and a 
microfilter to get the compound 22 (66 mg, 95 %) as a white solid. 
1H NMR (500MHz, D2O): δ 1.66 (m, 1H, H-3a), 1.76 (m, 2H, H-2’), 1.97 (s, 3H, 
NHAc), 2.71 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 2.82 (m, 2H, H-3’), 3.51 (m, 3H, H-
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7, H-9a, H-1’a), 3.65 (m, 1H, H-4), 3.79 (m, 4H, H-5, H-6, H-9b, H-1’b), 4.03 (m, 
1H, H-8), 7.49, 7.58, 7.74 (m, 5H, Ar-H). 
 
[3-Amino-(4-carboxy-TEMPO)-propyl] 5-acetamido-4,7,8-tri-O-acetyl-9-
benzamido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranoside: (12a*) 
O
OHH
N OH COOH
OAcHN
HO
N
H
O
O
N
O 
Dhbt-OH (33.7 mg, 0.207) and DIC (26.08 mg, 0.207mmol) were added to the 
solution of the 1-Oxyl-4-carboxyl-2,2,6,6-tetramethylpiperidine (41.4 mg, 
0.207mmol) in dry THF (2 mL). The mixture was stirred at 0°C for 2 h. The 
solvent was evaporated and quickly dried in vacuum. Dry DMF (1 mL) was added 
to the solid followed by N,N-Diisopropylethylamine (DIPEA, 26.7 mg, 0.207 
mmol) and the 22 (65 mg, 0.138 mmol). After stirring the reaction mixture for 3 
hours at room temperature, the TLC (DCM:MeOH 10:5) showed completion of 
reaction. The solvents were removed under high vaccum and the residue was 
purified by reversed phase chromatography on LiCroPrep RP-8 (5% gradient of 
MeOH:H2O) coulmn. After P2 size exclusion chromatography and lyophilization 
from water, 23 (52.0 mg, 57%) was obtained as a white solid 
 
For analysis purposes phenyl hydrazine (0.005 mL) was added to the sample (2 
mg) in CD3OD. The solvent was evaporated and the sample D2O exchanged. 
Impurity peaks were estimated at less than 5%. 
1H NMR (500MHz, D2O): δ 1.14-1.27 (m 12H, 4XCH3), 1.64 (m, 2H, H-3a, H-
2’’a), 1.72 (m, 2H, H-2’, H-2’’b), 1.98 (s, 3H, NHAc), 2.69 (m, 1H, H-1’’), 2.72 (dd, 
J = 4.8, 12.5 Hz, 1H, H-3e), 3.23 (m, 2H, H-3’), 3.49-3.57 (m, 3H, H-7, H-9a, H-
1’a), 3.67 (m, 1H, H-4), 3.75 (m, 3H, H-6, H-9a, H-1’b), 3.82 (m, 1H, H-5), 4.02 
(m, 1H, H-8), 7.51, 7.60, 7.75 (m, 5H, Ar-H). 
 
Methyl (5-acetamido-4,7,8,9-tetra-O-acetyl-2-chloro-3,5-dideoxy-D-glycero-D-
galacto-2-nonulopyranosid)onate: (24) 
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O
AcO
AcHN
AcO
OAc
OAc
CO2Me
Cl
 
To a stirred solution of 2 (800 mg, 1.500 mmol) l) was addedand AcCl (1.8 ml) 
in DCM (5 ml) in a “bombenrohr”, 32% HCl (213 at -20°C. After stirring for 16 h at 
r.t., the mixture was diluted with cold DCM and subsequently washed with H2O, 
5% NaHCO3 and brine. The organic layer was dried over Na2SO4 and 
evaporated to give 24 (700 mg, 91 %) as a fluffy solid. 
1H NMR (500 MHz, CDCl3): δ 1.95 (s, 3H, NHAc), 2.08, 2.09, 2.11, 2.16 (4s, 12H, 
OAc), 2.32 (t, J = 13.9 Hz, 1H, H-3a), 2.82 (dd, J = 4.8, 13.9 Hz, 1H, H-3e), 3.91 
(s, 3H, CO2CH3), 4.10 (dd, J = 5.7, 12.5 Hz, 1H, H-9a), 4.24 (q, J = 10.5, 1H, H-
5), 4.38 (dd, J = 2.4, 10.8 Hz, 1H, H-6),  4.45 (dd, J = 2.7, 12.6 Hz, 1H, H-9b),  
5.21 (m, 1H, H-8), 5.36 (d, J = 10.2 Hz, 1H, NH), 5.45 (m, 1H, H-4), 5.51 (dd, J = 
2.4, 7.1 Hz, 1H, H-7).  
 
Methyl (2-propynyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α- and β-D-galacto-2-nonulopyranosid) onate: (25a) 
OO
AcO
AcHN
AcO
OAc
OAc CO2Me
 
Compound 24 (1.40 g, 2.75 mmol) was dissolved in dry CH3CN (30 ml) 
containing propargyl alcohol (308 mg, 5.50 mmol) and molecular sieves 3Å (4.0 
g). The mixture was stirred at r.t. for one hour with light exclusion. Then AgOTf 
(1.41 g, 5.50 mmol) was added in one portion and stirring continued at r.t. for 16 
h. The mixture was filtered through a pad of celite and the celite was washed 
thoroughly with DCM. The filtrate was subsequently washed with 10% NaHCO3, 
sat. Na2S2O3  and water. The organic layer was dried with Na2SO4 and the DCM 
evaporated. The residue was purified by silica gel column chromatography 
(PE:DCM:iPrOH 8:4:1) system. The compound 25a (1.150 g, 79%) was obtained 
as anomeric mixture (αβ 1:1), together with approximately 20% of glycal. MS-
ESI: 552.27(M++Na) 
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Methyl (2-propynyl 5-acetamido-3,5-dideoxy-D-glycero-α- and β-D-galacto-2-
nonulopyranosid) onate: (26a) 
OO
HO
AcHN
HO
OH
OH CO2Me
 
A solution of 25a (1.15 g, 2.20 mmol) in dry methanol (30 mL) was treated with 1 
M methanolic NaOMe (5 mL) at r.t. for 2 h. The reaction mixture was neutralized 
with Amberlyst 15 (H+) ion-exchange resin and filtered through a pad of celite. 
The celite was thoroughly washed with methanol (3 × 10 mL), and the combined 
filtrates were evaporated to dryness. The residue was purified by silica gel 
column chromatography (DCM:MeOH 7:3) to afford anomeric mixture of 26a, α-
isomer (263 mg, 33%) and β-isomer as a mixture with glycal (500 mg, 62%). MS-
ESI: 360.14, 384.10 (M++Na) 
α-isomer: 1H NMR (500 MHz, CD3OD): δ 1.71 (t, J = 12.6 Hz, 1H, H-3a), 1.97 (s, 
3H, NHAc), 2.67 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 2.83 (X of ABX, J = 2.4 Hz, 1H, 
C≡CH), 3.47 (dd, J = 1.3, 9.0 Hz, 1H, H-7,), 3.56 (dd, J = 1.3, 10.5 Hz, 1H, H-6), 
3.60-3.65 (m, 2H, H-4, H-9a), 3.73-3.83 (m, 3H, H-5, H-8, H-9b), 3.81 (s, 3H, 
CO2CH3), 4.32 (AB of ABX, J = 2.4, 15.9 Hz, 2H, H-1’), 13C NMR (125 MHz, 
D2O): δ 23.2 (NHCOCH3), 41.9 (C-3), 53.3 (C-1’), 53.9 (CO2CH3), 54.1 (C-5), 
65.1 (C-9), 68.9 (C-4), 70.5 (C-7), 72.6 (C-8), 75.3 (C≡CH), 75.3 (C-6), 80.7 
(C≡CH), 99.9 (C-2), 170.9, 175.6 (2CO). 
 
Methyl [2-propynyl 5-acetamido-3,5-dideoxy-9-O-(4-toluenesulfonyl)-D-
glycero-α-D-galacto-2-nonulo-pyranosid] onate: (27a) 
OO
TsO
AcHN
HO
OH
OH CO2Me
 
To the solution of a-isomer of 26a (263 mg, 0.728 mmol) in pyridine (15 ml) was 
added p-TsCl (138 mg, 0.728 mmol) at 0°C. After 2 h, p-TsCl (69 mg, 0.364 
mmol) was added and stirring continued for 16 h at 5°C. The reaction mixture 
was warmed to r.t., then diluted with methanol (20 mL) and stirring continued for 
30 min. After removal of solvents, the remaining syrup was purified by 
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chromatography on silica gel (DCM/MeOH 19:1) to yield 27a as a solid (223 mg, 
60%).  
MS-ESI: 538.20 (M++Na) 1H NMR (500MHz, CD3OD): δ 1.69 (t, J = 12.8 Hz, 1H, 
H-3a), 1.99 (s, 3H, NHAc), 2.46 (s, 3H, Ph-CH3), 2.67 (dd, J = 4.6, 12.8 Hz, 1H, 
H-3e), 2.84 (X of ABX, J = 2.5 Hz, 1H, C≡CH) 3.44 (dd, J = 1.4, 8.8 Hz, 1H, H-7),  
3.55 (dd, J = 1.4, 10.5 Hz, 1H, H-6),  3.63 (m, 1H, H-4), 3.71 (m, 1H, H-5), 3.81 
(s, 3H, CO2CH3), 3.97 (m 1H, H-8), 4.08 (m, 1H, H-9a), 4.23-4.32 (m, 3H, H-9b, 
H-1’), 7.45 (AA’ of AA’BB’, 2H, J = 8.0 Hz, Ar-H), 7.80 (BB’ of AA’BB’, 2H, J = 8.3 
Hz, Ar-H), 13C NMR (125 MHz, D2O): δ 22.0 (Ph-CH3), 23.1 (NHCOCH3), 41.9 
(C-3), 53.4 (C-1’),  53.7 (CO2CH3), 54.0 (C-5), 68.7 (C-4), 70.1 (C-8),  70.4 (C-7), 
74.1 (C-9), 75.0 (C-6), 76.1 (C≡CH), 80.8 (C≡CH), 100.0 (C-2), 129.5, 131.4, 
134.7, 146.8 (6C, C6H5), 170.5, 175.5 (2CO). 
 
Methyl (2-propynyl 5-acetamido-9-azido-3,5,9-trideoxy-D-glycero-α-D-
galacto-2-nonulo pyranosid) onate: (28a ) 
OO
N3
AcHN
HO
OH
OH CO2Me
 
A mixture of 27a (223 mg, 0.433 mmol), crown ether 18-C-6 (44.8 mg, 0.170 
mmol) and NaN3 (140 mg, 2.15 mmol) was stirred in DMF (4 mL) at 60°C for 24 
h. TLC analysis (DCM:MeOH 9:1) showed completion of the reaction. The 
mixture was filtered through a pad of celite and the filtrate was evaporated to 
dryness. Purification by column chromatography on silica gel (DCM:MeOH 7:3) 
yielded 28a as a white solid (110 mg, 66%).  
MS-ESI: 387.11, 385.09.1H NMR (500 MHz, CD3OD): δ 1.76 (t, J = 12.6 Hz, 1H, 
H-3a), 2.03 (s, 3H, NHAc), 2.72 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 2.87 (X of ABX, 
J = 2.5 Hz, 1H, C≡CH), 3.41 (dd, J = 6.2, 12.8 Hz, 1H, H-9a), 3.49 (dd, J = 1.4, 
9.0 Hz, 1H, H-7), 3.57 (dd, J = 2.6, 12.8 Hz, 1H, H-9b), 3.64 (dd, J = 1.5, 10.5 
Hz, 1H, H-6), 3.68 (m, 1H, H-4), 3.79 (m, 1H, H-5), 3.87 (s, 3H, CO2CH3), 4.01 
(m, 1H, H-8), 4.38 (AB of ABX, J = 2.5 Hz, 15.8 Hz, 2H, H-1’). 13C NMR (125 
MHz, D2O): δ 23.1 (NHCOCH3), 41.9 (C-3), 53.5 (C-1’), 53.9 (CO2CH3), 54.1 (C-
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5), 55.9 (C-9), 68.8 (C-4), 71.3 (C-7), 71.6 (C-8), 75.1 (C-6), 76.1 (C≡CH), 80.8 
(C≡CH), 100.0 (C-2), 170.7, 175.6 (2CO). 
 
Methyl (2-propynyl 5-acetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulo-pyranosid) onate: (29a) 
OO
N3
AcHN
AcO
OAc
OAc CO2Me
 
Compound 28a (110 mg, 0.284 mmol) was dissolved in dry pyridine (1.17 ml, 
14.8 mmol) and stirred at 0°C for 15 min under argon before DMAP (4.90 mg, 
0.040 mmol) and Ac2O (1.28 ml, 12.6 mmol) were added simultaneously at 0°C. 
After stirring at r.t. for 14 h, the solvent was evaporated. The residual solid was 
purified by column chromatography on silica gel (DCM/MeOH 9:1) to get 29a as 
white foam (90 mg, 62%). 
1H NMR (500 MHz, CDCl3): δ 1.84 (s, 3H, NHAc), 1.95 (t, J = 12.5 Hz, 1H, H-3a), 
2.00, 2.12, 2.14 (3s, 9H, 3OAc), 2.43 (X of ABX, J = 2.4 Hz, 1H, C≡CH), 2.60 
(dd, J = 4.7, 12.9 Hz, 1H, H-3e), 3.25 (dd, J = 2.9, 5.2 Hz, 1H, H-9a), 3.55 (dd, J 
= 2.5, 14.7 Hz, 1H, H-9b), 3.78 (s, 3H, CO2CH3),  4.06 (m, 2H, H-5, H-6), 4.12, 
4.35 (AB of ABX, J = 2.4, 15.7 Hz, 2H, H-1’), 4.83 (m, 1H, H-4), 5.28 (m, 2H, H-7, 
H-8), 5.48 (d, J = 9.3 Hz, 1H, NH), 13C NMR (125 MHz, D2O): δ 21.2, 21.2, 21.4 
(3OCOCH3), 23.5 (NHCOCH3), 38.1 (C-3), 49.5 (C-5), 51.2 (C-9), 53.1 
(CO2CH3), 53.3 (C-1’), 68.2 (C-8), 69.1 (C-4), 70.2 (C-7), 73.3 (C-6), 75.0 
(C≡CH), 79.2 (C≡CH), 98.5 (C-2), 168.1, 170.6, 170.6 170.7, 171.3 (5CO). 
 
Methyl (2-propynyl 5-acetamido-4,7,8-tri-O-acetyl-9-benzamido-3,5,9-
trideoxy)-D-glycero-α-D-galacto-2-nonulo-pyranosid) onate: (30a) 
OO
H
N
AcHN
AcO
OAc
OAc CO2Me
O
 
Compound 29a (90.0 mg, 0.175 mmol) was reacted with benzoyl chloride (95.0 
mg, 0.678 mmol) and triphenyl phosphine (97.0 mg, 0.370 mmol) in DCE (4 mL) 
at r.t. for 16 h. The reaction mixture was diluted with DCM and subsequently 
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washed with 10% NaHCO3 and water. The organic layer was dried with Na2SO4. 
The solvent was evaporated and the residue was purified by column 
chromatography on silica gel (DCM:MeOH 97:3) to get 30a as a white solid (54 
mg, 52 %). 
1H NMR (500 MHz, CDCl3): δ 1.88 (s, 3H, NHAc), 1.98 (t, J = 12.6 Hz, 1H, H-3a), 
2.03, 2.09, 2.24 (3s, 9H, 3OAc), 2.43 (X of ABX, J = 2.4 Hz, 1H, C≡CH), 2.64 
(dd, J = 4.6, 12.7 Hz, 1H, H-3e), 2.97 (m, 1H, H-9a), 3.73 (s, 3H, CO2CH3), 3.99 
(dd, J = 2.1, 10.8 Hz, 1H, H-6), 4.16 (m, 2H, H-5, H-1’a), 4.32 (m, 1H, H-9b), 4.39 
(dd, J = 2.5, 15.6 Hz, 1H, H-1’a), 4.85 (m, 1H, H-4), 5.16 (dd, J = 2.0, 9.8 Hz, 1H, 
H-7), 5.27 (m, 1H, H-8), 5.60 (d, J = 10.1 Hz, 1H, NH-5), 7.11 (m, 1H, NH-9), 
7.44, 7.58, 7.81 (m, 5H, C6H5), 13C NMR (125 MHz, D2O): δ 21.2, 21.4, 21.5 
(3OCOCH3), 23.4 (NHCOCH3), 38.1 (C-3), 38.8 (C-9), 49.7 (C-5), 53.2 (2C, 
CO2CH3, C-1’), 68.2 (C-7), 68.7 (C-8), 69.3 (C-4), 72.6 (C-6), 74.9 (C≡CH), 79.2 
(C≡CH), 98.4 (C-2), 127.3, 128.8, 130.4, 133.8 (6C, C6H5), 167.9, 167.9, 170.8 
171.1, 171.6, 172.7 (6CO). 
 
Sodium (2-propynyl 5-acetamido-9-benzamido-3,5,9-trideoxy-D-glycero-α-D-
galacto-2-nonulo-pyranosid) onate: (31a) 
OO
H
N
AcHN
HO
OH
OH CO2Na
O
 
To a solution of compound 30a (54 mg, 0.091 mmol) in methanol (2 mL) was 
added 10% aq. NaOH (0.2 mL). The mixture was stirred at r.t. for 3 h. After 
neutralization with 10 % HCl (0.2 ml), the solution was concentrated and the 
residue purified by reversed phase chromatography (RP-18 column, 5% gradient 
MeOH in water), Dowex 50X8 (Na+ type) ion-exchange chromatography, and P2 
size exclusion chromatography to afford 31a (41 mg, 95%) as a white solid after 
a final lyophilization from water. 
α[ ]D25  = - 0.5 (c = 0.10, H2O); 1H NMR (500 MHz, D2O): δ 1.67 (t, J = 12.2 Hz, 1H, 
H-3a), 1.98 (s, 3H, NHAc), 2.73 (dd, J = 4.7, 12.5 Hz, 1H, H-3e), 3.54 (m, 2H, H 
7, H-9a), 3.67 (m, 1H, H-4), 3.75 (m, 2H, H-6, H-9b), 3.83 (m, 1H, H-5), 4.06 (m 
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1H, H-8), 4.35, 4.21 (A, B, of AB, J = 15.6 Hz, 2H, of H-1’), 7.50, 7.58, 7.74 (m, 
5H, C6H5). 13C NMR (125 MHz, D2O): δ 22.3 (NHCOCH3), 40.6 (C-3), 43.0 (C-9), 
52.1 (C-5), 52.9 (C-1’), 68.4 (C-4), 70.1 (C-7), 70.4 (2C, C-8, C≡CH), 73.1 (C-6), 
79.8 (C≡CH), 101.0 (C-2), 127.4, 129.1, 132.4, 133.9 (C6H5), 171.6, 173.1, 175.3 
(3CO). 
 
Methyl (3-butynyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-α- and β-D-
glycero-D-galacto-2-nonulopyranosid) onate: (25b) 
OO
AcO
AcHN
AcO
OAc
OAc CO2Me
 
Compound 24 (910 mg, 1.78 mmol) was dissolved in dry CH3CN (15 ml) 
containing 3-butynyl alcohol (270 mg, 3.85 mmol) and molecular sieves 3Å (1.80 
g). The mixture was stirred at r.t. for 1 hr with light exclusion. Then AgOTf (914 
mg, 3.55 mmol) was added in one portion and stirring continued at r.t. for 16 h. 
The suspension was filtered through a pad of celite and the celite was washed 
thoroughly with DCM. The filtrate was subsequently washed with 10% NaHCO3, 
sat. Na2S2O3 and water. The organic layer was dried with Na2SO4 and the 
solvent was evaporated to get compound 25b (547 mg, 56%) as an anomeric 
mixture (α:β 1:1) along with glycal impurities. The residue was purified by silica 
gel column chromatography (PE:DCM:iPrOH 8:4:1) system. The early fractions 
were collected to get a mixture of α:β isomers (422 mg), which were taken as 
such for further reaction.  
MS-ESI: 566.14 (M++Na) β-isomer: 1H NMR (500 MHz, CDCl3): δ 1.87 (m, 4H, 
H-3a, NHAc), 2.01, 2.03, 2.07 (3s, 9H, 3OAc), 2.13 (m, 1H, C≡CH), 2.14 (s, 3H, 
OAc), 2.44-2.51(m, 3H, H-3e, H-2’), 3.49 (m, 1H, H-1’a), 3.61 (m, 1H, H-1’b), 
3.80 (s, 3H, CO2CH3), 4.11 (m, 2H, H-5, H-9a), 4.20 (dd, J = 1.9, 10.6 Hz, H-6), 
4.82 (dd, J = 2.2, 12.5 Hz, 1H, H-9b), 5.21-5.32 (m, 2H, H-4, H-8), 5.40 (m, 2H, 
H-7, NH). 13C NMR (125 MHz, D2O): δ 20.0 (C-2’), 21.1, 21.2, 21.3, 21.5 
(4OCOCH3), 23.5 (NHCOCH3), 37.7 (C-3), 49.6 (C-5), 53.1 (CO2CH3), 62.5 (C-
1’), 62.7 (C-9), 68.6 (C-7), 69.2 (C-4), 70.6 (C≡CH), 72.0 (C-6), 72.5 (C-8), 81.8 
(C≡CH), 98.7 (C-2), 167.0, 170.6, 170.7, 171.0, 171.1, 171.4 (6CO). α-isomer:  
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1H NMR (500 MHz, CDCl3): δ 1.79 (s, 3H, NHAc), 1.87 (m, 2H, H-3a, C≡CH), 
1.94, 1.96, 2.05, 2.06 (4s, 12H, 4OAc), 2.38 (m, 2H, H-2’), 2.52 (dd, J = 4.6, 12.8 
Hz, 1H, H-3e), 3.32 (m, 1H, H-1’a), 3.72 (m, 3H, CO2CH3), 3.78 (m, 1H, H-1’b), 
4.05 (m, 3H, H-5, H-6, H-9a), 4.21 (dd, J = 2.6, 12.4 Hz, 1H, H-9b), 4.78 (m, 1H, 
H-4), 5.07 (d, J = 9.4 Hz, 1H, NH), 5.23 (dd, J = 1.8, 8.4 Hz, 1H, H-7), 5.31 (m, 
1H, H-8). 13C NMR (125 MHz, D2O): δ 20.0 (C-2’), 21.1, 21.2, 21.3, 21.4 
(4OCOCH3) 23.5 (NHCOCH3), 38.4 (C-3), 49.6 (C-5) 53.1 (CO2CH3), 62.7 (C-9), 
63.7 (C-1’), 67.7 (C-7), 69.1 (C-8), 69.4 (C≡CH), 69.7 (C-4), 72.9 (C-6),  81.1 
(C≡CH), 99.1 (C-2), 168.6, 170.5, 170.6, 170.7, 171.0, 171.3 (6CO). 
 
Methyl (3-butynyl 5-acetamido -3,5-dideoxy-D-glycero-α- and β-D-galacto-2-
nonulopyranosid) onate: (26b) 
OO
HO
AcHN
HO
OH
OH CO2Me
 
A solution of 25b (422 mg, 0.777 mmol) in dry methanol (10 mL) was treated with 
1 M methanolic NaOMe (1.5 mL) at r.t. for 2 h. The reaction mixture was 
neutralized with Amberlyst 15 (H+) ion-exchange resin and filtered through a pad 
of celite. The celite was washed thoroughly with methanol (3 × 5 mL), and the 
combined filtrates were evaporated and the residue purified by silica gel column 
chromatography (DCM:MeOH 7:3) system. The initial fractions collected gave α-
isomer 26b (165 mg, 56%) and the remaining fractions gave β (145 
mg, 49%) with some impurities.  
MS-ESI: 374.08, 376.10. α-isomer: 1H NMR (500 MHz, CD3OD): δ 1.73 (t, J = 
12.4 Hz, 1H, H-3a), 2.00 (s, 3H, NHAc), 2.26 (m, 1H, C≡CH), 2.41 (m, 2H, H-2’), 
2.69 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 3.51 (m, 3H, H-7, H-9a, H-1’a), 3.57 (d, J = 
10.5 Hz, 1H, H-6), 3.65 (m, 2H, H-4, H-9b), 3.76 (m, 1H, H-5), 3.87 (m, 6H, H-8, 
H-9b, H-1’b, CO2CH3), 13C NMR (125 MHz, D2O): δ 21.03 (C-2’), 23.0 
(NHCOCH3), 42.0 (C-3), 53.8 (CO2CH3), 54.2 (C-5), 64.1 (C-1’), 65.1 (C-9), 68.9 
(C-4), 70.5 (C-7), 71.0 (C≡CH), 72.8 (C-8),75.3 (C-6), 82.5 (C≡CH), 100.6 (C-2), 
171.2, 175.6 (2CO). β-isomer: 1H NMR (500 MHz, CD3OD): δ 1.80 (t, J = 12.8 
Hz, 1H, H-3a), 2.01 (s, 3H, NHAc), 2.26 (m, 1H, C≡CH), 2.43 (m, 2H, H-2’), 2.39 
 140
(dd, J = 4.9, 13.0 Hz, 1H, H-3e), 3.37 (m, 1H, H-1’a), 3.51 (d, J = 9.3 Hz, 1H, H-
7), 3.65 (dd, J = 5.1, 11.2 Hz, 1H, H-9a), 3.80-3.99 (m, 8H, H-5, H-6, H-8, H-9b, 
H-1’b, CO2CH3), 4.06 (m, H-4). 13C NMR (125 MHz, CD3OD): δ 19.5 (C-2’), 23.1 
(NHCOCH3), 40.8 (C-3), 52.3 (CO2CH3), 53.0 (C-5), 62.1 (C-1’), 64.4 (C-9), 66.8 
(C-4), 69.2 (C-7), 69.8 (C≡CH), 70.6 (C-8), 71.7 (C-6), 81.0 (C≡CH), 99.2 (C-2), 
169.8, 174.1 (2CO). 
 
Methyl [(3-butynyl 5-acetamido-3,5-dideoxy-9-O-(4-toluenesulfonyl)-D-
glycero-α-D-galacto-2-nonulo-pyranosid] onate: (27b) 
OO
TsO
AcHN
HO
OH
OH CO2Me
 
To the solution of a-isomer of 26b (165 mg, 0.440 mmol) in pyridine (10 ml) was 
added p-TsCl (83.6 mg, 0. 440 mmol) at 0°C. After 2 h, p-TsCl (41.8 mg, 0.220 
mmol) was added and stirring continued for 16 h at 5°C. The reaction mixture 
was warmed to r.t., diluted with methanol (20 mL) and stirring continued for 30 
min. After removal of the solvents the remaining syrup was purified by 
chromatography on silica gel (DCM/MeOH 19:1) to yield 27b as a white solid 
(167 mg, 72%).  
MS-ESI: 552.17(M++Na), 528.31. 1H NMR (500 MHz, CD3OD): δ 1.69 (t, J = 12.4 
Hz, 1H, H-3a), 1.99 (s, 3H, NHAc), 2.26 (m, 1H, C≡CH,) 2.38 (m, 2H, H-2’), 2.46 
(s, 3H, Ph-CH3), 2.65 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 3.44 (d, J = 1.3, 8.8 Hz, 
1H, H-7), 3.48 (m, 1H, H-1’a), 3.55 (dd, J = 1.3, 10.4 Hz, 1H, H-6), 3.63 (m, 1H, 
H-4), 3.71 (m, H-5), 3.80 (m, 4H, H-1’b, CO2CH3), 3.97 (m 1H, H-8), 4.08 (m, 1H, 
H-9a), 4.31 (dd, 1H, J = 2.1, 10.1 Hz, H-9b), 7.45, 7.80 (AA’BB’, J = 8.3 Hz, 4H, 
C6H5), 13C NMR (125 MHz, CD3OD): δ 21.0 (C-2’), 22.0 (Ph-CH3), 23.1 
(NHCOCH3), 42.0 (C-3), 53.6 (CO2CH3), 54.1 (C-5), 64.1 (C-1’), 68.8 (C-4), 70.2 
(C-8), 70.4 (C-7), 71.0 (C≡CH), 74.0 (C-9), 74.9 (C-6), 82.0 (C≡CH), 100.7 (C-2), 
129.5, 131.4, 134.7, 146.8 (6C, C6H4), 170.9, 175.6 (2CO). 
 
Methyl (3-butynyl 5-acetamido-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-
2-nonulo-pyranosid) onate: (28b) 
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OO
N3
AcHN
HO
OH
OH CO2Me
 
A mixture of 27b (167 mg, 0.315 mmol), crown ether 18-C-6 (31.6 mg, 0.120 
mmol) and NaN3 (100 mg, 1.55 mmol) was stirred in DMF (6 mL) at 60°C for 24 
h. The solvent was evaporated and the residue purified by column 
chromatography on silica gel (DCM:acetone 7:3) to give 28b as a white solid (90 
mg, 71 %).  
MS-ESI: 401.15, 399.19. 1H NMR (500 MHz, CD3OD): δ 1.74 (t, J = 12.3 Hz, 1H, 
H-3a), 2.03 (s, 3H, NHAc), 2.28 (t, J = 2.6 Hz, 1H, C≡CH), 2.43 (m, 2H, H-2’), 
2.70 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 3.40 (dd, J = 6.2, 12.8 Hz, 1H, H-9a), 3.43-
3.56 (m, 3H, H-7, H-9b, H-1’a), 3.64 (m, 2H, H-4, H-6), 3.77 (m, 1H, H-5), 3.87 
(s, 4H, H-1’b, CO2CH3), 3.99 (m 1H, H-8). 13C NMR (125 MHz, D2O): δ 21.0 (C-
2’), 23.1 (NHCOCH3), 42.0 (C-3), 53.9 (CO2CH3), 54.2 (C-5), 55.8 (C-9), 64.1 (C-
1’), 68.9 (C-4), 71.1 (C-7), 71.2 (C≡CH), 71.8 (C-8), 75.0 (C-6), 82.0 (C≡CH), 
100.6 (C-2), 171.5, 175.6 (2CO). 
 
Methyl (3-butynyl 5-acetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulo-pyranosid) onate: (29b) 
OO
N3
AcHN
AcO
OAc
OAc CO2Me
 
The compound 28b (90 mg, 0.22 mmol) was dissolved in dry pyridine (903 mg, 
11.4 mmol) and stirred at 0°C for 15 min under argon before DMAP (3.66 mg, 
0.03 mmol) and Ac2O (1.00 g, 9.90 mmol) were added simultaneously at 0°C and 
stirring continued at r.t. for 14 h. The reaction mixture was diluted with DCM and 
subsequently washed with 10% HCl, 10% NaHCO3 and water. The organic layer 
was dried with Na2SO4. After evaporating the solvent, the residue was purified on 
silica gel (DCM/MeOH 20:1) to get 29b as a white solid (90mg, 76%).  
MS-ESI: 571.18 (M++Na). 1H NMR (500 MHz, CDCl3): δ 1.88 (s, 3H, NHAc), 1.98 
(m, 2H, H-3a, C≡CH), 2.02, 2.16, 2.17 (3s, 9H, 3OAc), 2.45 (m, 2H, H-2’), 2.60 
(dd, J = 4.6, 12.9 Hz, 1H, H-3e), 3.29 (dd, J = 3.6, 5.7 Hz, 1H, H-9a), 3.42 (m, 
1H, H-1’b), 3.59 (dd, J = 2.7, 13.3 Hz, 1H, H-9b), 3.81 (s, 3H, CO2CH3),  3.85 (m, 
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1H, H-1’b), 4.09 (m, 2H, H-5, H-6), 4.85 (m, 1H, H-4), 5.30 (m, 3H, H-7, H-8, 
NH), 13C NMR (125 MHz, D2O): δ 20.3 (C-2’), 21.2, 21.2, 21.4 (3C, OCOCH3), 
23.5 (NHCOCH3), 38.2 (C-3), 49.7 (C-5), 51.2 (C-9), 53.2 (CO2CH3), 63.5 (C-1’), 
68.4 (C-7), 69.3 (C-4), 69.8 (C≡CH), 70.4 (C-8), 73.3 (C-6), 81.0 (C≡CH), 99.2 
(C-2), 168.6, 170.5, 170.6 170.7, 171.4 (5CO). 
 
Methyl (3-butynyl 5-acetamido-4,7,8-tri-O-acetyl-9-benzamido-3,5,9-
trideoxy)-D-glycero-α-D-galacto-2-nonulo-pyranosid) onate: (30b) 
OO
H
N
AcHN
AcO
OAc
OAc CO2Me
O
 
Compound 29b (90.0 mg, 0.171 mmol) was reacted with benzoyl chloride (95.0 
mg, 0.678 mmol) and triphenyl phosphine (97.0 mg, 0.370 mmol) in DCE (3 mL). 
After stirring at r.t. for 16 h, diluted with DCM and washed with 10% NaHCO3. 
The organic layer was dried with Na2SO4. After evaporating the solvent, the 
residue was purified by column chromatography on silica gel (DCM/MeOH 
9.7:0.3) to get 30b (72 mg, 69%) as a white solid.  
MS-ESI: 627.26 (M++Na), 603.27. 1H NMR (500 MHz, CDCl3): δ 1.87 (s, 3H, 
NHAc), 1.97 (m, 2H, H-3a, C≡CH), 2.02, 2.10, 2.24 (3s, 9H, 3OAc), 2.44 (m, 2H, 
H-2’), 2.61 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 2.94 (m, 1H, H-9a), 3.40 (m, 1H, H-
1’a), 3.75 (s, 3H, CO2CH3), 3.88 (m, 1H, H-1’b), 4.00 (dd, J = 2.0, 10.7 Hz, 1H, 
H-6), 4.17 (q, J = 10.7 Hz, 1H, H-5), 4.34 (m, 1H, H-9b), 4.82 (m, 1H, H-4), 5.14 
(dd, J = 2.0, 9.7 Hz, 1H, H-7), 5.25 (m, 1H, H-8), 5.37 (d, J = 10.1 Hz, 1H, NH-5), 
7.09 (m, 1H, NH-9), 7.40, 7.49, 7.81 (m, 5H, C6H5), 13C NMR (125 MHz, D2O): δ 
20.4 (C-4’), 21.2, 21.4, 21.5 (OCOCH3), 23.5 (NHCOCH3), 38.2 (C-3), 38.7 (C-9), 
49.8 (C-5), 53.1 (COOCH3), 63.4 (C-1’), 68.3 (C-7), 68.8 (C-8), 69.4 (C-4), 69.8 
(C≡CH), 72.5 (C-6), 81.2 (C≡CH), 99.0 (C-2), 127.3, 128.9, 131.8, 134.6 (6C, 
C6H5), 167.6, 168.4, 170.6 170.7, 171.5, 172.7 (6CO). 
 
Sodium (3-butynyl 5-acetamido-9-benzamido-3,5,9-trideoxy-D-glycero-α-D-
galacto-2-nonulo-pyranosid) onate: (31b) 
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OO
H
N
AcHN
HO
OH
OH CO2Na
O
 
To a solution of compound 30b (72 mg, 0.119 mmol) in methanol (5 mL) was 
added 10% aq. NaOH (0.5 mL). The mixture was stirred at r.t. for 3 h. After the 
evaporating the solvents, the residue purified by reversed phase chromatography 
(RP-18 column, 5% gradient MeOH in water), Dowex 50X8 (Na+ type) ion-
exchange chromatography, and P2 size exclusion chromatography to afford 31b 
(41 mg, 72%) as a colorless solid after a final lyophilization from water.  
α[ ]D25  = - 1.7 (c = 0.10, H2O); MS-ESI: 627.26 (M++Na), 603.27. 1H NMR (500 
MHz, D2O): δ 1.69 (t, J = 12.2 Hz, 1H, H-3a), 2.00 (s, 3H, NHAc), 2.34 (m, 3H, 
C≡CH), 2.36 (m, 2H, H-2’), 2.74 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.55 (m, 3H, H-
7, H-9a, H-1’a), 3.69 (m, 1H, H-4), 3.75-3.86 (m, 4H, H-5, H-6, H-9b, H-1’b), 4.05 
(m 1H, H-8), 7.50, 7.60, 7.65 (m, 5H, C6H5). 13C NMR (125 MHz, D2O): δ 19.6 (C 
2’), 23.3 (NHCOCH3), 40.6 (C-3), 43.0 (C-9), 52.2 (C-5), 63.2 (C-1’), 68.5 (C-4), 
70.2 (C-7), 70.5 (C-8), 70.7 (C≡CH), 72.9 (C-6), 82.6 (C≡CH), 101.1 (C-2), 127.4, 
129.1, 132.4, 133.9 (6C, C6H5), 171.5, 173.7, 175.7 (3CO). 
 
Methyl (4-pentynyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α- and β-D-galacto-2-nonulopyranosid) onate: (25c) 
OO
AcO
AcHN
AcO
OAc
OAc CO2Me
 
Compound 24 (1.40 g, 2.75 mmol) was dissolved in dry CH3CN (30 ml) 
containing 3-pentynyl alcohol (462 mg, 5.50 mmol) and molecular sieves 3Å 
(1.80 g). This was stirred at r.t. for 1 hr with light exclusion. Then AgOTf (1.41 g, 
5.50 mmol) was added in one portion and stirring continued at r.t. for 16 h. The 
mixture was diluted with DCM (30 ml) and the residue filtered through a pad of 
celite. The celite was washed thoroughly with DCM and the filtrate was 
subsequently washed with 10% NaHCO3, sat. Na2S2O3 and water. The organic 
layer was dried with Na2SO4 and the DCM. After evaporating the solvent, the 
residue was purified by silica gel column chromatography (PE:DCM:iPrOH 8:4:1)  
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to get a compound 25c (1.11 g, 56%) as anomeric mixture (αβ 1:1) with 
approximately 25% of glycal. 
 
Methyl (3-pentynyl 5-acetamido-3,5-dideoxy-D-glycero-α- and β-D-galacto-2-
nonulopyranosid) onate: (26c) 
OO
HO
AcHN
HO
OH
OH CO2Me
 
A solution of 25c (775 mg, 1.39 mmol) in dry methanol (20 mL) was treated with 
1 M methanolic NaOMe (3 mL) at r.t. for 2 h. The reaction mixture was 
neutralized with Amberlyst 15 (H+) ion-exchange resin and filtered through a pad 
of celite. The celite was thoroughly washed with methanol (3 × 10 mL) and the 
filtrate was evaporated. The residue was purified by silica gel column 
chromatography (DCM:MeOH 7:3) to yield anomeric mixture of 26c with α-
isomer (242 mg, 44%) and β-isomer (120 mg, 22%).  
α-isomer: 1H NMR (500 MHz, CD3OD): δ 1.72 (m, 3H, H-3a, H-2’), 2.00 (s, 3H, 
NHAc), 2.23 (m, 3H, H-3’, C≡CH) 2.68 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 3.48 (m, 
1H, H-1’a), 3.51 (dd, J = 1.6, 8.8 Hz, 1H, H-7), 3.58 (d, J = 1.6, 10.4 Hz, H-6), 
3.63 (m, 2H, H-4, H-9a), 3.76 (m, 1H, H-5), 3.84 (m, 3H, CO2CH3), 3.85 (m, 3H, 
H-8, H-9b, H-1’b). 13C NMR (125 MHz, CD3OD): δ 16.0 (C-3’), 23.0 (NHCOCH3), 
30.2 (C-2’), 42.1 (C-3), 53.8 (CO2CH3), 54.2 (C-5), 64.0 (C-1’), 65.0 (C-9), 68.9 
(C-4), 70.2 (C≡CH), 70.6 (C-7), 72.9 (C-8), 75.3 (C-6), 84.7 (C≡CH), 100.6 (C-2), 
171.5, 175.6 (2XCO). β-Isomer: 1H NMR (500MHz, CD3OD): δ 1.63 (t, J = 12.7 
Hz, 1H, H-3a), 1.69-1.80 (m, 2H, H-2’), 2.01 (s, 3H, NHAc), 2.22 (m, 1H, C≡CH), 
2.24-2.35 (m, 2H, H-3’), 2.39 (dd, J = 4.8, 12.8 Hz, 1H, H-3e), 3.31 (m, 1H, H-
1’a), 3.49 (d, J = 9.1 Hz, 1H, H-7), 3.69 (m, 1H, H-9a), 3.69-3.89 (m, 8H, H-5, H-
6, H-8, H-9b, H-1’b, CO2CH3), 3.96 (m, 1H, H-4). 13C NMR (125 MHz, CD3OD): δ 
16.3 (C-3’), 23.2 (NHCOCH3), 30.4 (C-2’), 42.1 (C-3), 53.9 (CO2CH3), 54.1 (C 5), 
63.5 (C-1’), 65.6 (C-9), 68.1 (C-4), 70.1 (C≡CH), 70.5 (C-7), 71.8 (C-8), 72.7 (C-
6), 85.1 (C≡CH), 100.4 (C-2), 171.4, 175.2 (2CO). 
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Methyl [4-pentynyl 5-acetamido-3,5-dideoxy-9-O-(4-toluenesulfonyl)-D-
glycero-α-D-galacto-2-nonulopyranosid] onate: (27c). 
OO
TsO
AcHN
HO
OH
OH CO2Me
 
To a solution of 26c (225 mg, 0.578 mmol) in pyridine (15 ml) was added p-TsCl 
(108 mg, 0.578 mmol) at 0°C. After 2 h, p-TsCl (53.0 mg, 0.289 mmol) was 
added and stirring continued for 16 h at 5°C. The reaction mixture was warmed 
to r.t., then diluted with methanol (20 mL) and stirring continued for 30 min. After 
removal of solvents the remaining syrup was purified by chromatography on 
silica gel (DCM:MeOH 19:1) to yield 27c (240 mg, 76%) as a white solid. 
MS-ESI: 566.34 (M++Na), 542.35. 1H NMR (500 MHz, CD3OD): δ 1.70 (m, 3H, H-
3a, H-2’), 2.02 (s, 3H, NHAc), 2.24 (m, 3H, H-3’, C≡CH), 2.47 (s, 3H, Ph-CH3), 
2.68 (dd, J = 4.7, 12.7, Hz, 1H, H-3e), 3.45 (m, 1H, H-1’a), 3.48 (dd, J = 1.4, 8.7 
Hz, 1H, H-7), 3.59 (dd, J = 1.2, 10.4 Hz, 1H, H-6), 3.65 (m, 1H, H-4), 3.74 (m, 1H, 
H-5), 3.81 (m, 1H, H-1’b), 3.83 (s, 3H, CO2CH3), 4.04 (m, 1H, H-8), 4.10 (dd, J = 
6.3, 10.0 Hz, 1H, H-9a), 4.35 (dd, J = 2.0, 10.0 Hz, 1H, H-9b), 7.46, 7.81 (AA’, 
BB’ of AA’BB’, 4H, J = 8.4 Hz, C6H4). 13C NMR (125 MHz, CD3OD): δ 16.0 (C-3’), 
22.1 (Ph-CH3), 23.2 (NHCOCH3), 30.21 (C-2’), 42.1 (C-3), 53.9 (CO2CH3), 54.2 
(C-5), 64.1 (C-1’), 68.7 (C-4), 70.4 (C-7), 70.5 (2C, C-8, C≡CH), 74.0 (C-9), 75.0 
(C-6), 84.9 (C≡CH), 100.7 (C-2), 129.5, 131.5, 134.5, 146.9 (6C, C6H4), 171.3, 
175.7 (2CO). 
 
Methyl (4-pentynyl 5-acetamido–9-azido-3,5,9-trideoxy-D-glycero-α-D-
galacto-2-nonulopyranosid) onate: (28c). 
OO
N3
AcHN
HO
OH
OH CO2Me
 
A mixture of 27c (235 mg, 0.432 mmol), crown ether 18-C-6 (45.0 mg, 0.170 
mmol) and NaN3 (140 mg, 2.15 mmol) was stirred in DMF (7 mL) at 60°C for 24 
h. The solvent was evaporated and the residual solid purified by column 
chromatography on silica gel (DCM:acetone 7:3) to give 28c (150 mg, 83 %) as a 
white solid. 
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MS-ESI: 413.22, 415.23. 1H NMR (500 MHz, CD3OD): δ 1.73 (m, 3H, H-3a, H-2’), 
2.01 (s, 3H, NHAc), 2.24 (m, 3H, H-3’, C≡CH), 2.68 (dd, J = 4.6, 12.8, Hz, 1H, H-
3e), 3.39 (dd, J = 6.4, 12.8 Hz, 1H, H-9a), 3.48 (m, 2H, H-7, H-1’a), 3.55 (dd, J = 
2.6, 12.8 Hz, 1H, H-9b), 3.63 (m, 2H, H-4, H-6), 3.75 (m, 1H, H-5), 3.85 (s, 3H, 
CO2CH3), 3.86 (m, 1H, H-1’b), 4.00 (m, 1H, H-8), 13C NMR (125 MHz, CD3OD): δ 
16.0 (C-3’), 23.2 (NHCOCH3), 30.2 (C-2’), 42.1 (C-3), 53.9 (CO2CH3), 54.3 (C-5), 
55.7 (C-9), 64.0 (C-1’), 68.9 (C-4), 70.4 (C≡CH), 71.3 (C-7), 71.9 (C-8),  75.0 (C-
6), 84.9 (C≡CH), 100.7 (C-2), 171.4, 175.7 (2CO). 
 
Methyl (4-pentynyl 5-acetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosid) onate: (29c). 
OO
N3
AcHN
AcO
OAc
OAc CO2Me
 
Compound 28c (150 mg, 0.362 mmol) was dissolved in dry pyridine (1.50 g, 19.0 
mmol) and stirred at 0°C for 15 min under argon before DMAP (7.32 mg, 0.060 
mmol) and Ac2O (1.65 g, 16.2 mmol) were added simultaneously at 0°C. After 
stirring at r.t. for 14 h, the reaction mixture was diluted with DCM. The reaction 
mixture was the subsequently washed with 10% HCl, 10% NaHCO3 and water. 
The organic layer was dried with Na2SO4. After evaporating the solvent the 
residue was purified by column chromatography on silica gel (DCM:MeOH 20:1) 
to give 29c (180 mg, 92%) as a white solid. 
MS-ESI: 563.26 (M++Na). 1H NMR (500 MHz, CDCl3): δ 1.67 (m, 3H, H-2’), 1.79 
(s, 3H, NHAc), 1.81-1.89 (m, 2H, H-3a, C≡CH), 1.94, 2.07, 2.08 (3s, 9H, 3OAc), 
2.18 (m, 2H, H-3’) 2.50 (dd, J = 4.7, 12.9, Hz, 1H, H-3e), 3.22 (dd, J = 6.4, 12.8 
Hz, 1H, H-9a), 3.28 (m, 1H, H-1’a), 3.55 (dd, J = 2.9, 13.5 Hz, 1H, H-9b), 3.69 
(m, 1H, H-1’b),  3.71 (s, 3H, CO2CH3), 4.03 (m, 2H, H-5, H-6), 4.75 (m, 1H, H-4), 
5.19 (m, 1H, H-8),  5.25 (dd, J = 1.6, 6.6 Hz, 1H, H-7), 5.82 (d, J = 9.5 Hz, 1H, 
NH). 13C NMR (125 MHz, CDCl3): δ 15.2 (C-3’), 21.1, 21.3, 21.6 (3OCOCH3), 
23.4 (NHCOCH3), 28.8 (C-2’), 38.1 (C-3), 49.4 (C-5) 51.0 (C-9), 53.1 (CO2CH3),  
63.5 (C-1’), 68.4 (C-7), 69.0 (C-4), 69.5 (C≡CH), 71.1 (C-8),  73.3 (C-6), 84.0 
(C≡CH), 99.2 (C-2), 168.7, 170.5, 170.7, 170.7, 171.3 (5CO). 
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Methyl (4-pentynyl 5-acetamido-4,7,8-tri-O-acetyl-9-benzamido-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid) onate: (30c). 
OO
H
N
AcHN
AcO
OAc
OAc CO2Me
O
 
Compound 29c (180 mg, 0.333 mmol) was reacted with benzoyl chloride (184 
mg, 1.32 mmol) and triphenyl phosphine (189 mg, 0.721 mmol) in DCE (2 mL). 
After stirring at r.t. for 16 h, the solvent was evaporated. Purification by column 
chromatography on silica gel (DCM:MeOH 100:1 to 20:1) yielded 30c as a white 
solid (146 mg, 70%). 
MS-ESI: 641.32 (M++Na), 617.37. 1H NMR (500 MHz, CDCl3): δ 1.71 (m, 2H, H 
2’), 1.83 (s, 3H, NHAc), 1.89 (m, 2H, H-3a, C≡CH), 1.98, 2.05, 2.20 (3s, 9H, 
3OAc), 2.22 (m, 2H, H-3’), 2.55 (dd, J = 4.6, 12.7 Hz, 1H, H-3e), 2.94 (ddd, J = 
3.7, 7.6, 11.2 Hz, 1H, H-9a), 3.30 (m, 1H, H-1’a), 3.69 (s, 3H, CO2CH3), 3.80 (m, 
1H, H-1’b), 4.02 (dd, J = 2.0, 10.7 Hz, 1H, H-6), 4.14 (q, J = 10.7 Hz, 1H, H-5), 
4.28 (ddd, J = 3.1, 6.7, 8.5 Hz, 1H, H-9b), 4.78 (m, 1H, H-4), 5.12 (dd, J = 2.0, 
9.7 Hz, 1H, H-7), 5.23 (m, 1H, H-8), 5.67 (d, J = 10.0 Hz, 1H, NH-5), 7.11 (m, 1H, 
NH-9), 7.37, 7.44, 7.77 (m, 5H, C6H5). 13C NMR (125 MHz, CDCl3): δ 15.3 (C-3’), 
21.2, 21.4, 21.5 (3OCOCH3), 23.4 (NHCOCH3), 28.9 (C-2’), 38.3 (C-3), 38.8 (C-
9), 49.7 (C-5), 53.0 (CO2CH3), 63.5 (C-1’), 68.3 (C-7), 68.9 (2C, C-8, C≡CH), 
69.5 (C-4), 72.4 (C-6), 84.1 (C≡CH), 99.0 (C-2), 127.3, 128.7, 128.9, 130.3, 
131.8, 134.5 (6C, C6H5), 167.7, 168.6, 170.6, 170.9, 171.4, 172.6 (6CO). 
 
Sodium (4-pentynyl 5-acetamido-9-benzamido-3,5,9-trideoxy-D-glycero-α-D-
galacto-2-nonulopyranosid) onate: (31c). 
OO
H
N
AcHN
HO
OH
OH CO2Na
O
 
To a solution of compound 30c (146 mg, 0.236 mmol) in methanol (10 mL) was 
added 10% aq. NaOH (0.6 mL). The mixture was stirred at r.t. for 3 h. The 
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solution was concentrated and the residue purified by reversed phase 
chromatography (RP-18 column, 5% gradient MeOH in water), Dowex 50X8 (Na+ 
type) ion-exchange chromatography, and P2 size exclusion chromatography to 
afford 31c (116 mg, 98%) as a white solid after a final lyophilization from water. 
α[ ]D25  = - 1.2 (c = 0.10, H2O); 1H NMR (500 MHz, D2O): δ 1.65-1.73 (m, 3H, H-3a, 
H-2’), 1.99 (s, 3H, NHAc), 2.19-2.26 (m, 2H, H-3’), 2.73 (dd, J = 4.7, 12.4 Hz, 1H, 
H-3e), 3.45-3.52 (m, 2H, H-9a, H-1’a), 3.55 (d, J = 1.4, 8.9 Hz, 1H, H-7), 3.67 (m, 
1H, H-4), 3.75 (dd, J = 1.3, 10.5 Hz, 1H, H-6), 3.78-3.84 (m, 3H, H-5, H-9b, H 
1’b), 4.05 (m 1H, H-8), 7.45, 7.55, 7.69 (m, 5H, C6H5). 13C NMR (125 MHz, D2O): 
δ 14.7 (C-3’), 22.4 (NHCOCH3), 28.3 (C-2’), 40.8 (C-3), 43.0 (C-9), 52.3 (C-5), 
63.7 (C-1’), 68.6 (C-4), 70.3 (C-7), 70.8 (C-8), 72.9 (C-6), 85.0 (C≡CH), 101.1 (C-
2), 127.4, 129.1, 132.5, 133.8 (6C, C6H5), 171.2, 173.9, 175.4 (3CO). 
 
Methyl (5-hexynyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-
D-galacto-2-nonulopyranosid) onate: (25d) 
OO
AcO
AcHN
AcO
OAc
OAc CO2Me
 
Compound 24 (970 mg, 1.90 mmol) was dissolved in dry CH3CN (25 ml) 
containing 3-hexynyl alcohol (372 mg, 3.80 mmol) and molecular sieves 3Å (2.00 
g). This was stirred at r.t. for 1 hr with light exclusion. Then AgOTf (976 mg, 3.80 
mmol) was added in one portion and stirring continued at r.t. for 16 h. Diluted 
with DCM (30 ml). The mixture was filtered through a pad of celite and the celite 
was washed thoroughly with DCM. The filtrate was subsequently washed with 
10% NaHCO3, sat. Na2S2O3 and water. The organic layer was dried with Na2SO4 
and the DCM was evaporated. The residue was purified with silica gel column 
chromatography (PE:DCM:iPrOH 8:4:1) to give compound 25d (678 mg, 62%) as 
anomeric mixture (αβ 1:1) with approximately 20% of . 
MS-ESI: 594.26 (M++Na). 
α-isomer: 1H NMR (500 MHz, CDCl3): δ 1.55-1.65 (m, 4H, H-2’, H-3’), 1.86 (s, 
3H, NHAc), 1.92 (m, 2H, H-3a, C≡CH), 2.00, 2.01, 2.02, 2.03 (4s, 12H, 4OAc), 
2.20 (m, 2H, H-4’), 2.55 (dd, J = 3.3, 12.8 Hz, 1H, H-3e), 3.23 (m, 1H, H-1’a), 
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3.76 (m, 4H, H-1’b, CO2CH3), 4.06 (m, 3H, H-5, H-6, H-9a), 4.29 (d, J = 12.4 Hz, 
1H, H-9b), 4.82 (m, 1H, H-4), 5.31 (m, 2H, H-7, NH-5), 5.36 (m, 1H, H-8). 13C 
NMR (125 MHz, CDCl3): δ 18.3 (C-4’), 21.1, 21.2, 21.3, 21.5 (4OCOCH3), 23.5 
(NHCOCH3), 25.3 (C-3’), 28.9 (C-2’), 38.4 (C-3), 49.8 (C-5), 53.0 (CO2CH3), 62.7 
(C-9), 64.7 (C-1’), 67.7 (C-7), 68.7 (C-8), 69.0 (C≡CH), 69.5 (C-4), 72.8 (C-6), 
84.7 (C≡CH), 99.0 (C-2), 168.9, 170.4, 170.5, 170.6, 171.0, 171.4 (6CO). β-
isomer: 1H NMR (500 MHz, CDCl3): δ 1.59 (m, 2H, H-3’), 1.70 (m, 2H, H-2’), 
1.85 (m, 1H, H-3a), 1.86 (s, 3H, NHAc), 1.91 (m, 1H, C≡CH) 2.00, 2.01, 2.05, 
2.12 (4s, 12H, 4OAc), 2.22 (m, 2H, H-4’), 2.43 (dd, J = 4.9, 12.9 Hz, 1H, H-3e), 
3.33 (m, 1H. H-1’a), 3.49 (m, 1H, H-1’b), 3.73 (s, 3H, CO2CH3), 3.87 (dd, J = 2.0, 
10.5 Hz, 1H, H-6), 4.11 (m, 2H, H-5, H-9a), 4.79 (dd, J = 2.1, 12.4 Hz, H-9b), 
5.16 (m, 1H, H-8), 5.24 (m, 1H, H-4), 5.38 (m, 1H, H-7), 5.44 (d, J = 10.2 Hz, 1H, 
NH), 13C NMR (125 MHz, CDCl3): δ 18.5 (C-4’), 21.1, 21.2, 21.3, 21.4 
(4OCOCH3), 23.5 (NHCOCH3), 25.3 (C-3’), 28.8 (C-2’), 37.8 (C-3), 49.7 (C-5) 
53.0 (CO2CH3), 62.7 (C-9), 63.9 (C-1’), 68.8 (C-7), 69.1 (C-4), 69.3 (C≡CH), 72.1 
(C-6), 72.5 (C-8), 84.4 (C≡CH), 98.9 (C-2), 167.9, 170.5, 170.6, 170.9, 171.0, 
171.4 (6CO). 
 
Methyl (5-hexynyl 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosid) onate: (26d). 
OO
HO
AcHN
HO
OH
OH CO2Me
 
A solution of 25d (374 mg, 0.654 mmol) in dry methanol (8.0 mL) was treated 
with 1 M methanolic NaOMe (0.8 mL) at r.t. for 2 h. The reaction mixture was 
neutralized with Amberlyst 15 (H+) ion-exchange resin and filtered through a pad 
of celite. The celite was thoroughly washed with methanol (3 × 5 mL), and the 
combined filtrates were evaporated. The residue was purified by silica gel column 
chromatography (DCM:MeOH 7:3) to yield anomeric mixture of 26d with α-
isomer  (200 mg, 76%) and β (50 mg, 19%).  
MS-ESI: 426.18 (M++Na), 402.22. α-isomer: 1H NMR (500 MHz, CD3OD): δ 1.58 
(m, 2H, H-3’), 1.67 (m, 2H, H-2’), 1.77 (t, J = 12.4 Hz, 1H, H-3a), 2.04 (s, 3H, 
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NHAc), 2.20 (m, 3H, H-4’, C≡CH), 2.70 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 3.42 (m, 
1H, H-1’a), 3.55 (d, J = 9.0 Hz, 1H, H-7), 3.60 (d, J = 1.4, 10.4 Hz, 1H, H-6), 3.66 
(m, 2H, H-4, H-9a), 3.77–3.90 (m, 4H, H-5, H-8, H-9b, H-1’b), 3.88 (m, 3H, 
CO2CH3). 13C NMR (125 MHz, CD3OD): δ 19.0 (C-4’), 23.0 (NHCOCH3), 26.6 (C-
3’), 30.0 (C-2’), 42.1 (C-3), 53.8 (CO2CH3), 54.2 (C-5), 65.0 (C-1’), 65.1 (C-9), 
68.9 (C-4), 70.1 (C-7), 70.6 (C≡CH), 72.9 (C-8), 75.3 (C-6), 85.2 (C≡CH), 100.6 
(C-2), 171.6, 175.6 (2CO). β-isomer: 1H NMR (500 MHz, CD3OD): δ 1.60-1.72 
(m, 5H, H-3a, H-2’, H-3’), 2.04 (s, 3H, NHAc), 2.22 (m, 3H, H-4’, C≡CH), 2.41 
(dd, J = 4.9, 12.9 Hz, 1H, H-3e), 3.24 (m, 1H, H-1’a), 3.53 (d, J = 8.9 Hz, 1H, H-
7), 3.69 (m, 1H, H-9a), 3.84 (m, 8H, H-5, H-6, H-8, H-9b, H-1’b, CO2CH3), 4.04 
(m, H-4). 13C NMR (125 MHz, CD3OD): δ 19.3 (C-4’), 23.1 (NHCOCH3), 26.6 (C 
3’), 30.1 (C-2’), 42.2 (C-3), 53.6 (CO2CH3), 54.2 (C-5), 64.4 (C-1’), 65.6 (C-9), 
68.1 (C-4), 70.0 (C-7), 70.5 (C≡CH), 71.8 (C-8), 72.7 (C-6), 85.3 (C≡CH), 100.4 
(C-2), 171.6, 175.2 (2CO). 
 
Methyl (5-hexynyl 5-acetamido-3,5-dideoxy-9-O-(4-toluenesulfonyl)-D-
glycero-α-D-galacto-2-nonulo-pyranosid) onate: (27d) 
OO
TsO
AcHN
HO
OH
OH CO2Me
 
To a solution of 26d (200 mg, 0.496 mmol) in pyridine (10 ml) was added p-TsCl 
(93.0 mg, 0. 496 mmol) at 0°C. After 2 h, p-TsCl (46.0 mg, 0.248 mmol) was 
added and stirring continued for 16 h at 5°C. The reaction mixture was warmed 
to r.t., then diluted with methanol (10 mL) and stirring continued for 30 min. After 
removal of solvents the remaining syrup was purified by chromatography on 
silica gel (DCM:MeOH 19:1) to yield 27d (182 mg, 66%) as a white solid. 
MS-ESI: 580.18 (M++Na), 556.24. 1H NMR (500 MHz, CD3OD): δ 1.52 (m, 2H, H-
3’), 1.60 (m, 2H, H-2’), 1.68 (t, J = 12.4 Hz, 1H, H-3a), 1.98 (s, 3H, NHAc), 2.20 
(m, 3H, H-4’, C≡CH), 2.45 (s, 3H, Ph-CH3), 2.63 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 
3.33 (m, 1H, H-1’b), 3.45 (d, J = 8.5 Hz, 1H, H-7), 3.54 (d, J = 10.4 Hz, 1H, H-6), 
3.60 (m, 1H, H-4), 3.72 (m, 2H, H-5, H-1b’), 3.80 (s, 3H, CO2CH3), 4.06 (m 1H, 
H-8), 4.09 (dd, J = 6.2, 10.0 Hz, 1H, H-9a), 4.31 (dd, J = 2.9, 10.0 Hz, 1H, H-9b), 
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7.47, 7.82 (AA’, BB’ of AA’BB’, 4H, J = 8.2 Hz, Ar-H), 13C NMR (125 MHz, 
CD3OD): δ 19.0 (C-4’), 22.0 (Ph-CH3), 23.1 (NHCOCH3), 26.5 (C-3’), 30.0 (C-2’), 
42.0 (C-3), 53.7 (CO2CH3), 54.2 (C-5), 65.1 (C-1’), 68.8 (C-4), 70.1 (C-7), 70.4 
(C≡CH), 70.5 (C-8), 74.0 (C-9), 74.9 (C-6), 85.3 (C≡CH), 100.7 (C-2), 129.5, 
131.5, 134.6, 146.8 (6C, C6H4), 171.3, 175.7 (2CO). 
 
Methyl (5-hexynyl 5-acetamido-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-
2-nonulo-pyranosid) onate: (28d) 
OO
N3
AcHN
HO
OH
OH CO2Me
 
A mixture of 27d (180 mg, 0.323 mmol), crown ether 18-C-6 (32.0 mg, 0.121 
mmol) and NaN3 (104 mg, 1.60 mmol) was stirred in DMF (8 mL) at 60°C for 24 
h. The solvent was evaporated and the residual solid was purified by column 
chromatography on silica gel (DCM:acetone 7:3) to give 28d (112 mg, 81 %) as a 
white solid. 
MS-ESI: 427.22, 451.19 (M++Na). 1H NMR (500 MHz, CD3OD): δ 1.58 (m, 2H, H-
3’), 1.66 (m, 2H, H-2’), 1.76 (t, J = 12.4 Hz, 1H, H-3a), 2.04 (s, 3H, NHAc), 2.22 
(m, 3H, H-4’, C≡CH), 2.70 (dd, J = 4.7, 12.8 Hz, 1H, H-3e), 3.41 (m, 2H, H-9a, H 
1’a), 3.58 (dd, J = 2.6, 12.8 Hz, 1H, H-7), 3.61 (dd, J = 1.5, 10.4 Hz, 1H, H-9b), 
3.66 (m, 1H, H-4, H-6), 3.81 (m, 2H, H-5, H-1’b), 3.87 (s, 3H, CO2CH3), 4.01 (m 
1H, H-8), 13C NMR (125 MHz, CD3OD): δ 19.1 (C-4’), 23.1 (NHCOCH3), 26.5 (C 
3’), 30.1 (C-2’), 42.1 (C-3), 53.8 (CO2CH3), 54.2 (C-5), 55.7 (C-9), 65.1 (C-1’), 
68.9 (C-4), 70.2 (C≡CH), 71.3 (C-7), 71.9 (C-8), 75.0 (C-6), 85.2 (C≡CH), 100.6 
(C-2), 171.5, 175.7 (2CO). 
 
Methyl (5-hexynyl 5-acetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulo-pyranosid) onate: (29d) 
OO
N3
AcHN
AcO
OAc
OAc CO2Me
 
Compound 28d (121 mg, 0.282 mmol) was dissolved in dry pyridine (1.10 g, 14.0 
mmol) and stirred at 0°C for 15 min under argon before DMAP (6.00 mg, 0.049 
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mmol) and Ac2O (1.22 g, 12.0 mmol) were added simultaneously at 0°C. After 
stirring at r.t. for 14 h, The reaction mixture was diluted with DCM and 
subsequently washed with 10% HCl, 10% NaHCO3 and water. The organic layer 
was dried with Na2SO4. After evaporating the solvent, the residue was purified on 
silica gel (DCM/MeOH 20:1) to get 29d (140 mg, 89%) as a white solid. 
MS-ESI: 577.30 (M++Na). 1H NMR (500MHz, CDCl3): δ 1.53 (m, 2H, H-3’), 1.62 
(m, 2H, H-2’), 1.82 (s, 3H, NHAc), 1.90 (m, 2H, H-3a, C≡CH), 1.98, 2.11, 2.12 
(3s, 9H, 3OAc), 2.16 (m, 2H, H-4’), 2.53 (dd, J = 4.6, 12.8 Hz, 1H, H-3e), 3.20-
3.27 (m, 2H, H-9a, H-1’a), 3.56 (dd, J = 2.9, 13.5 Hz, 1H, H-9b), 3.70 (m, 1H, H-
1’b), 3.75 (s, 3H, CO2CH3), 4.01-4.06 (m, 1H, H-5, H-6), 4.78 (m, 1H, H-4), 5.23 
(m, 1H, H-8), 5.27 (m, 1H, H-7), 5.58 (m, 1H, NH-5). 13C NMR (125 MHz, CDCl3): 
δ 18.3 (C-4’), 21.1, 21.2, 21.3 (3OCOCH3), 23.4 (NHCOCH3), 25.3 (C-3’), 28.8 
(C-2’), 38.3 (C-3), 49.5 (C-5), 51.1 (C-9), 53.0 (CO2CH3), 64.6 (C-1’), 68.4 (C-7), 
68.8 (C≡CH), 69.4 (C-4), 70.9 (C-8), 73.2 (C-6), 84.6 (C≡CH), 99.1 (C-2), 168.8, 
170.60, 170.64 170.7, 171.3 (5CO). 
 
Methyl (5-hexynyl 5-acetamido-4,7,8-tri-O-acetyl-9-benzamido-3,5,9-
trideoxy)-D-glycero-α-D-galacto-2-nonulo-pyranosid) onate: (30d) 
OO
H
N
AcHN
AcO
OAc
OAc CO2Me
O
 
Compound 29d (140 mg, 0.252 mmol) was reacted with benzoyl chloride (140 
mg, 1.00 mmol) and triphenyl phosphine (145 mg, 0.554 mmol) in DCE (5 mL). 
After stirring at r.t. for 16 h, the reaction mixture was diluted with DCM and 
washed with 10% NaHCO3 and water. The organic layer was dried with Na2SO4 
and evaporated. Purification by column chromatography on silica gel 
(DCM:MeOH 100:1 to 20:1) yielded 30d (100 mg, 64%) as a white solid. 
MS-ESI: 631.33, 633.38. 1H NMR (500 MHz, CDCl3): δ 1.52-1.63 (m, 4H, H-3’, H-
2’), 1.84 (s, 3H, NHAc), 1.91-1.94 (m, 2H, H-3a, C≡CH), 1.99, 2.07, 2.22 (3s, 9H, 
OAc), 2.13-2.20 (m, 2H, H-4’), 2.56 (dd, J = 4.6, 12.7 Hz, 1H, H-3e), 2.93 (m, 1H, 
H-9a), 3.22 (m, 1H, H-1’a), 3.72 (s, 3H, CO2CH3), 3.76 (m, 1H, H-1’b), 4.00 (dd, J 
= 2.0, 10.8 Hz, 1H, H-6), 4.14 (q, J = 10.8 Hz, 1H, H-5), 4.30 (m, 1H, H-9b), 4.77 
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(m, 1H, H-4), 5.12 (dd, J = 2.0, 9.6 Hz, 1H, H-7), 5.23 (m, 1H, H-8), 5.45 (m, 1H, 
NH-5), 7.09 (m, 1H, NH-9), 7.38-7.48, 7.86 (m, 5H, C6H5). 13C NMR (125 MHz, 
CDCl3): δ 18.3 (C-4’), 21.2, 21.4, 21.5 (3OCOCH3), 23.4 (NHCOCH3), 25.3 (C-
3’), 28.9 (C-2’), 38.4 (C-3), 38.7 (C-9), 49.8 (C-5), 53.0 (CO2CH3), 64.6 (C-1’), 
68.3 (C-7), 68.8 (2C, C-8, C≡CH), 69.5 (C-4), 72.4 (C-6), 84.7 (C≡CH), 98.9 (C 
2), 127.3, 128.5, 128.9, 131.8, 134.65 (6C, C6H5), 167.6, 168.7, 170.6 170.7, 
171.4, 172.7 (6CO).  
 
Sodium (5-hexynyl 5-acetamido-9-benzamido-3,5,9-trideoxy-D-glycero-α-D-
galacto-2-nonulo-pyranosid) onate: (31d) 
OO
H
N
AcHN
HO
OH
OH CO2Na
O
 
To a solution of compound 30d (100 mg, 0.158 mmol) in methanol (4 mL) was 
added 10% aq. NaOH (0.4 mL). After stirring at r.t. for 3 h, the reaction mixture 
was neutralized with 10% HCl (0.4 mL). Then solution was concentrated and the 
residue purified by reversed phase chromatography (RP-18 column, 5% gradient 
MeOH in water), Dowex 50X8 (Na+ type) ion-exchange chromatography, and P2 
size exclusion chromatography to afford 31d (76 mg, 95%) as a colorless solid 
after a final lyophilization from water. 
α[ ]D25  = - 0.7 (c = 0.10, H2O); 1H NMR (500 MHz, D2O): δ 1.43-1.52 (m, 2H, H-3’), 
1.58-1.67 (m, 3H, H-3a, H-2’), 1.99 (s, 3H, NHAc), 2.14 (m, 2H, H-4’), 2.73 (dd, J 
= 4.6, 12.4 Hz, 1H, H-3e), 3.43 (m, 1H, H-1’a), 3.30 (dd, J = 4.6, 12.4 Hz, 1H, H-
9a), 3.55 (dd, J = 1.7, 8.9 Hz, 1H, H-7), 3.67 (m, 1H, H-4), 3.72-3.84 (m, 4H, H-5, 
H-6, H-9b, H-1’b), 4.02 (m 1H, H-8), 7.47, 7.57, 7.72 (m, 5H, C6H5). 13C NMR 
(125 MHz, D2O): δ 17.5 (C-4’), 22.4 (NHCOCH3), 24.5 (C-3’), 28.5 (C-2’), 40.8 
(C-3), 43.0 (C-9), 52.3 (C-5), 64.7 (C-1’), 68.6 (C-4), 70.3 (C-7), 70.8 (C-8), 72.9 
(C-6), 85.7 (C≡CH), 101.1 (C-2), 127.4, 129.1, 132.4, 133.9 (6C), 171.3, 173.9, 
175.4 (3CO). 
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3-Carboxaldehyde-5-Nitro-1H-Indole: (33) 
N
H
H
N+
OŠ
O
O
 
Dimethyl formamide (3.0 mL) was cooled to 0°C in an ice-salt bath and 
phosphorous oxychloride (0.8 mL) was added slowly over 30 min. The 5-nitro 
indole (1.40 gm, 8.64 mmol) in DMF (1.0 mL) was added slowly to the cooled 
solution over a period of 10 min and the resulting slurry heated at 35°C for 60 
min until the clear yellow solution became yellowish paste. To this was added ice 
and 3.5 mL of 10% NaOH solution. This was heated to boil and late cooled in ice 
bath. The residual solid cake was filtered and vaccum dried to get 33 (1.52 gm, 
92%). 
1H NMR (500 MHz, DMSO-d6): δ 7.72 (d, J = 9.0 Hz, 1H, Ar-H), 8.15 (m, 1H, Ar-
H), 8.57 (s, 1H, Ar-H), 8.94 (s, 1H, Ar-H), 10.02 (s, 1H, Ar-H), 12.71 (s, 1H, NH). 
13C NMR (125 MHz, DMSO-d6): δ 113.6, 117.4, 119.1, 119.4, 123.9, 140.5, 
1141.8, 143.2 (Ar-C), 185.9 (CO). 
 
5-Nitro-3-(1H-Indole)Carbinol - (34) 
N
H
OH
N+
OŠ
O
 
To a solution of compound 33 (1.52 gm, 8.00 mmol) in methanol (10 mL) was 
added NaBH4 till the starting material is consumed as observed by TLC. This was 
added to ice cold water (50 mL). The residual yellow coloured solid was filtered 
and dried by vacccum to get compound 34 (1.42 mg, 92%). 
1H NMR (500 MHz, DMSO-d6): δ 4.70 (d, J = 4.8 Hz, 2H, CH2), 5.04 (t, J = 5.0 
Hz, 1H, OH), 7.52 (m, 1H, Ar-H), 8.00 (dd, J = 2.2, 9.0 Hz, 1H, Ar-H), 8.63 (d, J = 
2.2 Hz, 1H, Ar-H), 11.64 (bs, 1H, NH). 13C NMR (125 MHz, DMSO-d6): δ 55.7 
(CH2), 112.1, 117.0, 117.5, 119.2, 126.7, 127.6, 128.0, 140.4 (Ar-C). 
 
5-Nitro-3-(N-tertBOC-indole)carbinol: (35) 
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N
OH
N+
OŠ
O
O
O
 
To a suspension of compound 34 (1.42 gm, 7.39 mmol) in dichoromethane (20 
mL) was added tert-BOC anhydride (1.93 gm, 8.86 mmol) and DMAP (450 mg, 
3.69 mmol). The reaction mixture was stirred for 60 min after which the TLC 
showed complete consumption of starting material. Solvents were evaporated 
and the residual solid was purified by silica gel column chromatography (EA:Pet-
ether 1:4) to get 35 (1.33 gm, 61%).  
1H NMR (500 MHz, CDCl3): δ 1.68 (s, 9H, 3XCH3), 4.91 (s, 2H, CH2), 7.72 (s, 1H, 
Ar-H), 8.23 (m, 2H, Ar-H), 8.58 (d, J = 1.8 Hz, 1H, Ar-H). 13C NMR (125 MHz, 
CDCl3): δ 28.5 (3XCH3), 57.1 (CH2), 85.6 [C(CH3)], 115.8, 116.3, 120.3, 121.4, 
126.8, 129.5 (Ar-C). 
 
3-bromomethyl-5-Nitro-NtBOC-indole: (37) 
N
Br
N+
OŠ
O
O
O
 
To a solution of compound 35 (660 mg, 2.26 mmol) in chloroform was added 
halo-enamine 36 under Argon atmosphere. This was stirred for 60 min after 
which the TLC showed complete consumption of 35. Solvent was evaporated 
and the residual solid purified by silica gel column chromatography (EA:Pet-ether 
1:9) to get compound 37 (475 mg, 60%) as a solid. 
1H NMR (500 MHz, CDCl3): δ 1.68 (s, 9H, 3XCH3), 4.67 (s, 2H, CH2), 7.81 (s, 1H, 
Ar-H), 8.27 (m, 2H, Ar-H), 8.60 (d, J = 1.0 Hz, 1H, Ar-H). 13C NMR (125 MHz, 
CDCl3): δ 23.1 (CH2), 28.5 (3XCH3), 75.6 [C(CH3)], 116.1, 116.2, 120.7, 128.0 
(Ar-C). 
 
3-(azidomethyl)-5-nitro-NtBOC-indole: (38) 
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Compound 37 (475 mg, 1.34 mmol) was added to a solution of sodium azide 
(104 mg, 1.60 mmol) and 15-C-5-crown ether (116 mg, 0.53 mmol) in DMF (10 
mL). The reaction mixture was stirred for 16 h after solvent was evaporated and 
the residual solid purified by silica gel chromatography (EA:Pet-ether 1:9) to get 
38 (412 mg, 97%) as a solid. 
1H NMR (500 MHz, CDCl3): δ 2.00 (s, 9H, 3XCH3), 4.53 (s, 2H, CH2), 7.75 (s, 1H, 
Ar-H), 8.27 (m, 2H, Ar-H), 8.53 (d, J = 0.8 Hz, 1H, Ar-H).  
 
3-(azidomethyl)-5-nitro-1H-indole: (39) 
N
H
N3
N+
OŠ
O
 
To a solution of compound 38 (470 mg, 1.48 mmol) in dichloromethane (20 mL) 
was added TFA (1 mL). This was stirred for 16 h at r.t. after which the solvents 
were evaporated. To this residual liquied was added ice-cold water. The solid 
was filtered and dried under high vaccum. The solid was further purified by silica 
gel column chromatography (EA:Pet-ether 9:1) to get 39 (190 mg, 70%). 
1H NMR (500 MHz, DMSO-d6): δ 4.50 (s, 2H, CH2), 7.39 (d, J = 8.9 Hz, 1H, Ar-
H), 7.55 (d, J = 2.4 Hz, 1H, 1H, Ar-H), 7.84 (dd, J = 2.3, 9.0 Hz, 1H, Ar-H), 8.45 
(d, J = 2.3 Hz, 1H, Ar-H), 11.69 (bs, 1H, NH). 13C NMR (125 MHz, DMSO-d6): δ 
45.9 (CH2), 112.4, 113.2, 116.6, 117.9, 126.7, 130.3, 140.3, 141.7 (Ar-C). 
 
Ethyl 5-nitro-3-(1H-indole)propionate: (40) 
N
H
OO
N+
OŠ
O
 
A solution of 5-nitroindole (200 g, 1.22 mmol), Meldrum's acid (210 mg, 1.46 
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mmol), 37% aqueous formaldehyde (43.8 mg, 1.46 mmol) and proline (14.9 mg, 
0.06 mmol) in 0.8 mL of acetonitrile was stirred at room temperature for 18 h. 
The resulting thick yellow slurry was filtered and the filtercake was washed with 
acetonitrile, then acetone and finally with ether. This material was dried in vacuo 
to give [5-(5-nitroindol-3-yl)methyl]-2,2-dimethyl-1,3-dioxane-4,6-dione (355 mg, 
81%) as a bright yellow solid.  
To the solution of above crude compound (465 mg, 1.46 mmol) in a mixture of 
pyridine (34.6 mg, 0.438 mmol) and absolute ethanol (0.644 mg, 0.014) was 
added 4.65 mg of copper powder and the mixture was heated to reflux under Ar 
for 2 h. The cooled mixture was filtered and the filtrate was evaporated. The 
resulting residue was purified by silica gel chromatography (EA:Pet-ether 0.5:9.5) 
to give 40 (162 mg, 42%) as a solid. 
1H NMR (500 MHz, DMSO-d6): δ 1.14 (t, J = 7.2 Hz, 3H, CH3), 2.68 (d, J = 7.4 
Hz, 2H, H-1’), 3.03 (t, J = 7.4 Hz, 1H, H-2’), 4.04 (q, J = 7.2 Hz, 1H, CH2), 7.41 
(d, J = 2.0 Hz, 1H, Ar-H), 7.50 (d, J = 8.9 Hz, 1H, Ar-H), 7.98 (dd, J = 2.2, 8.9 Hz, 
1H, Ar-H), 8.53 (d, J = 2.1 Hz, 1H, Ar-H), 11.60 (s, 1H, NH). 13C NMR (125 MHz, 
DMSO-d6): δ 14.2 (C-CH3), 20.1 (C-1’), 34.8 (C-2’), 60.1 (CH2), 112.1, 116.0, 
116.6, 116.8, 126.6, 126.8 (C-9), 139.6, 140.5 (Ar-C), 172.8 (CO). 
 
5-Nitro-3-(3-hydroxypropyl)-1H-indole: (41) 
N
H
OH
N+
OŠ
O
 
To a suspension of 95% LiAlH4 (46.3 mg, 1.22 mmol) in 4 mL of dry THF was 
added a solution of ethyl 5-nitro-3-(1H-indole)propionate 40 (160 mg, 0.61 mmol) 
in 6 mL of dry THF, at 0 under Ar. After stirring for 20 min, the mixture was 
quenched by the cautious addition of 3 mL of H2O. The resulting suspension was 
stirred for 10 min and then it was filtered and the filtercake was washed with 
additional THF. The filtrate was evaporated and the residue was taken up in 
ether, dried by Na2SO4 and evaporated. The resulting solid was triturated with 
hexane to give 41 (110 mg, 82%) as a yellow solid. 
1H NMR (500 MHz, MeOD): δ 1.92 (m, 2H, H-2’), 2.84 (t, J = 7.7 Hz, 2H, H-1’), 
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3.62 (t, J = 6.5 Hz, 2H, H-3’), 7.22 (s, 1H, Ar-H), 7.39 (d, J = 9.0 Hz, 1H, Ar-H), 
7.99 (dd, J = 2.2, 9.0 Hz, 1H, Ar-H), 8.52 (d, J = 2.1 Hz, 1H, Ar-H), 13C NMR (125 
MHz, MeOD): δ 22.4 (C-1’), 34.6 (C-2’), 62.8 (C-3’), 112.6, 117.1, 118.1, 119.5, 
126.9, 128.5, 141.6, 142.5 (Ar-C). 
 
3-(3-bromopropyl)- 5-Nitro-1H-indole: (42) 
N
H
Br
N+
OŠ
O
 
To a solution of compound 41 (110 mg, 0.50 mmol) in chloroform (4 mL) was 
added halo-enamine 36 (106.8 mg, 0.6 mmol) under Argon atmosphere. This 
was stirred for 60 min after which the TLC showed complete consumption of 41. 
Solvent was evaporated and the residual solid purified by silica gel column 
chromatography (EA:Pet-ether 1:9) to get compound 42 (120 mg, 85%) as a 
solid. 
1H NMR (500 MHz, CDCl3): δ 2.25 (m, 2H, H-2’), 2.97 (t, J = 7.4 Hz, 2H, H-1’), 
3.44 (t, J = 6.4 Hz, 2H, H-3’), 7.21 (s, 1H, Ar-H), 7.41(d, J = 9.0 Hz, 1H, Ar-H), 
8.11 (dd, J = 2.2, 9.0 Hz, 1H, Ar-H), 8.57 (m, 2H, Ar-H, NH). 13C NMR (125 MHz, 
MeOD): δ 23.4 (C-1’), 33.0 (C-2’), 33.6 (C-3’), 111.6, 116.6, 117.7, 118.2, 125.2, 
127.2, 139.7, 141.9 (Ar-C). 
 
3-(3-Azidopropyl)- 5-Nitro-1H-indole: (43) 
N
H
N3
N+
OŠ
O
 
Compound 42 (120 mg, 0.425 mmol) was added to a solution of sodium azide 
(33.1 mg, 0.51 mmol) and 15-C-5-crown ether (37.4 mg, 0.17 mmol) in DMF 
(3.00 mL). The reaction mixture was stirred for 16 h after solvent was evaporated 
and the residual solid purified by silica gel chromatography (EA:Pet-ether 1:9) to 
get 43 (97.0 mg, 93%) as a solid. 
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1H NMR (500 MHz, CDCl3): δ 2.02 (m, 2H, H-2’), 2.90 (t, J = 7.6 Hz, 2H, H-1’), 
3.36 (t, J = 6.7 Hz, 2H, H-3’), 7.18 (s, 1H, Ar-C), 7.40(d, J = 9.0 Hz, 1H, Ar-C), 
8.11 (dd, J = 2.1, 9.0 Hz, 1H, Ar-C), 8.48 (s, 1H, NH), 8.57 (d, J = 1.8 Hz, 1H, Ar-
C). 13C NMR (125 MHz, MeOD): δ 22.2 (C-1’), 29.5 (C-2’), 51.1 (C-3’), 111.5, 
116.6, 118.1, 118.2, 124.9, 127.2, 139.7, 141.9 (Ar-C). 
 
1-(5-nitro-1H-indole-3-yl-methyl-)-4-{sodium [5-acetamido-9-benzamido-
3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulo-pyranosynate-2-O-yl]}methyl-
[1,2,3]-triazole: (SA1NI1) 
OO
H
N
AcHN
HO
OH
OH CO2Na
O
N N
N
H
N
N O
O  
To a solution of 31a (10.0 mg, 21.0 µmol) and 39 (4.55 mg, 21.0 µmol) in tert-
BuOH:H2O (1:1) (0.1 ml) was added Na-ascorbate (1.20 mg, 6.10 µmol, 6 µl of a 
freshly prepared 1M solution in H2O), followed by CuSO4.5H2O (0.15 mg, 0.61 
µmol) in H2O. This heterogeneous mixture was stirred for 36 h during which 
period at intervals four additional portions of Na-ascorbate (4.80 mg, 24.4 µmol in 
total) and three additional portions of CuSO4.5H2O (0.45 mg, 1.83 µmol) were 
added. After 36 h, according to TLC, the reaction was not finished. So a catalytic 
amount of CuCl2 was added and stirring continued for 1 h after which TLC 
showed completion of the reaction. The solvents were removed under high 
vaccum and the residue was purified by reversed phase chromatography on 
LiCroPrep RP-8 (5% gradient of MeOH:H2O). After P2 size exclusion 
chromatography and lyophilization from water, SA1NI1 (7.0 mg, 50%) was 
obtained as a white solid 
α[ ]D25  = - 0.4 (c = 0.1, H2O); 1H NMR (500 MHz, D2O): δ 1.66 (t, J = 12.1 Hz, 1H, 
H-3a), 2.00 (s, 3H, NHAc), 2.73 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.21 (m, 1H, H-
9a), 3.47 (t, J = 7.4 Hz, 1H, H-7), 3.54 (m, 1H, H-9b), 3.64-3.76 (m, 3H, H-4, H-6, 
H-8), 3.81 (q, J = 10.0 Hz, 1H, H-5), 4.54, 4.84 (A, B of AB, J = 12.1 Hz, 2H, H-
1’), 5.44 (d, J = 3.8 Hz, 2H, H-1’’), 6.89 (d, J = 8.8 Hz, 1H, Ar-H), 7.14 (m, 2H, Ar-
H), 7.25-7.37 (m, 7H, Ar-H), 7.80 (s, 1H, Ar-H), 7.90 (s, 1H, Ar-H). 13C NMR (125 
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MHz, D2O): δ 22.3 (NHCOCH3), 40.6 (C-3), 43.1 (C-9), 45.3 (C-1’’), 52.1 (C-5), 
57.9 (C-1’), 68.6 (C-4), 70.5 (C-7), 70.6 (C-8), 73.0 (C-6), 106.0 (C-2), 110.9, 
111.7, 115.4, 117.4, 125.0, 127.0, 128.6, 129.2, 132.1, 133.0, 139.5, 140.4 (Ar-
C), 170.4, 173.0, 175.3 (3CO). 
 
1-(5-nitro-1H-indole-3-yl-methyl)-4-{sodium [5-acetamido-9-benzamido-
3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulo-pyranosynate-2-O-yl]}-ethyl-
[1,2,3] triazole: (SA2NI1) 
OO
H
N
AcHN
HO
OH
OH CO2Na
O
N N N
H
N
N O
O
 
To a solution of 31b (10.0 mg, 20.0 µmol) and 39 (4.34 mg, 20.0 µmol) in tert-
BuOH:H2O (1:1) (0.1 ml) was added Na-ascorbate (1.2 mg, 6.0 µmol, 6 µl of 
freshly prepared 1M solution in H2O), followed by CuSO4.5H2O (0.15 mg, 0.60 
µmol) in H2O. This heterogeneous mixture was stirred for 36 h during which 
period at intervals seven additional portions of Na-ascorbate (8.40 mg, 42.0 µmol 
in total) and three additional portions of CuSO4.5H2O (0.45 mg, 1.83 µmol in 
total) were added. After 36 h, according to TLC the reaction was not finished. So 
a catalytic amount of CuCl2 was added and stirring continued for 1 h after which 
TLC showed completion of the reaction. The solvents were removed under high 
vaccum and the residue was purified by reversed phase chromatography on 
LiCroPrep RP-8 (5% gradient if MeOH:H2O). After P2 size exclusion 
chromatography and lyophilization from H2O, SA2NI1 (7.0 mg, 50%) was 
obtained as a white solid 
α[ ]D25  = - 0.4 (c = 0.1, H2O); 1H NMR (500 MHz, D2O): δ1.50 (t, J = 12.1 Hz, 1H, 
H-3a), 1.99 (s, 3H, NHAc), 2.64 (dd, J = 4.5, 12.4 Hz, 1H, H-3e), 2.85 (t, J = 6.3 
Hz, 2H, H-2’), 3.32 (dd, J = 7.9, 13.9 Hz, 1H, H-9a), 3.48 (d, J = 8.8 Hz, 1H, H-7), 
3.56 (dd, J = 2.7, 13.9 Hz, 1H, H-9b), 3.59-3.70 (m, 4H, H-4, H-5, H-6, H-1’a), 
3.81 (m, 1H, H-8), 3.90 (m, 1H, H-1’b), 5.41 (d, J = 5.1 Hz, 2H, H-1’’), 7.08 (d, J = 
9.0 Hz, 1H, Ar-H), 7.25 (t, J = 7.7 Hz, 2H, Ar-H), 7.25 (m, 2H, Ar-H), 7.46 (d, J = 
6.4 Hz, 2H, Ar-H), 7.51 (dd, J = 1.4, 9.0 Hz, 1H, Ar-H), 7.76 (s, 1H, Ar-H), 7.91 
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(d, J = 1.2 Hz, 1H, Ar-H). 13C NMR (125 MHz, D2O): δ 22.3 (NHCOCH3), 26.0 (C-
2’), 40.6 (C-3), 43.2 (C-9), 45.4 (C-1’’), 52.1 (C-5), 63.6 (C-1’), 68.6 (C-4), 70.5 
(2C, C-7, C-8), 72.9 (C-6), 101.0 (C-2), 111.1, 112.1, 115.7, 117.7, 124.0, 125.2, 
127.1, 128.8, 129.2, 132.2, 133.4, 136.3, 139.8, 140.9 (Ar-C), 170.9, 173.8, 
175.4 (3CO). 
 
1-(5-nitro-1H-indole-3-methyl)-4-{sodium [5-acetamido-9-benzamido-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulo-pyranosynate-2-O-yl]}-propyl-
[1,2,3]-triazole: (SA3NI1) 
OO
H
N
AcHN
HO
OH
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O  
To solution of 31c (9.0 mg, 18.0 µmol) and 39 (4.30 mg, 19.8 µmol) in tert-
BuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (1.2 mg, 6.0 µmol, 6 µl of 
freshly prepared solution of 1M in H2O), followed by CuSO4.5H2O (0.15 mg, 0.60 
µmol) in H2O. This heterogeneous mixture was stirred for 36 h during which 
period at intervals was added three additional portions of Na-ascorbate (3.6 mg, 
18.0 µmol in total) and one additional portion of CuSO4.5H2O (0.15 mg, 0.60 
µmol) in H2O. After 36 h, according to TLC the reaction was not complete. So a 
catalytic amount of CuCl2 was added and stirring continued for 1 h after which 
TLC showed completion of the reaction. The solvents were removed under high 
vaccum and the residue was purified by reversed phase chromatography on 
LiCroPrep RP-8 (5% gradient of MeOH:H2O). After P2 size exclusion 
chromatography and lyophilization from H2O, SA3NI1 (6.0 mg, 46%) was 
obtained as a white solid. 
α[ ]D25  = -1.1 (c = 0.1, H2O); 1H NMR (500 MHz, D2O): δ 1.61 (t, J = 12.2 Hz, 1H, 
H-3a), 1.73-1.90 (m, 2H, H-2’), 2.00 (s, 3H, NHAc), 2.53-2.59 (m, 1H, H-3’a), 
2.65-2.71 (m, 2H, H-3e, H-3’b), 3.30 (dd, J = 8.5, 13.9 Hz, 1H, H-9a), 3.40-3.52 
(m, 3H, H-7, H-9b, H-1’a), 3.61-3.70 (m, 3H, H-4, H-6, H-1’b), 3.75-3.81 (m, 2H, 
H-5, H-8), 5.42 (d, J = 3.5 Hz, 2H, H-1’’), 7.13 (d, J = 9.0 Hz, 1H, Ar-H), 7.23 (t, J 
= 7.6 Hz, 2H, Ar-H), 7.34-7.37 (m, 2H, Ar-H), 7.46-7.48 (m, 2H, Ar-H), 7.59 (dd, J 
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= 2.1, 9.0 Hz, 1H, Ar-H), 7.69 (s, 1H, Ar-H), 7.93 (d, J = 2.1 Hz, 1H, Ar-H). 13C 
NMR (125 MHz, D2O): δ 21.3 (C-3’), 22.3 (NHCOCH3), 28.9 (C-2’), 40.6 (C-3), 
43.2 (C-9), 45.3 (C-1’’), 52.1 (C-5), 63.9 (C-1’), 68.6 (C-4), 70.5 (2C, C-7, C-8), 
72.8 (C-6), 100.9 (C-2), 111.1, 112.0, 115.6, 117.7, 123.4, 127.1, 128.7, 128.9, 
132.2, 133.2, 140.9, 148.0 (Ar-C), 170.7, 173.8, 175.3 (3CO). 
 
1-(5-nitro-1H-indole-3-yl-methyl)-4-{sodium [5-acetamido-9-benzamido-
3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulo-pyranosynate-2-O-yl]}-butyl-
[1,2,3]-triazole: (SA4NI1) 
OO
H
N
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To a solution of 31d (15.0 mg, 29.0 µmol) and 39 (6.30 mg, 29.0 µmol) in tert-
BuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (1.2 mg, 6.0 µmol, 6 µl of 
freshly prepared 1M solution in H2O), followed by CuSO4.5H2O (0.15 mg, 0.60 
µmol) in H2O. This heterogeneous mixture was stirred for 36 h during which 
period at intervals was added the five additional portions of Na-ascorbate (6.0 
mg, 30.0 µmol) and three additional portions of CuSO4.5H2O (0.45 mg, 1.83 
µmol). After 60 h, according to TLC the reaction was not complete. So a catalytic 
amount of CuCl2 was added and stirring continued for 1 h after which TLC 
showed completion of the reaction. The solvents were removed under high 
vaccum and the residue was purified by reversed phase chromatography on 
LiCroPrep RP-8 (5% gradient of MeOH:H2O). After P2 size exclusion 
chromatography and lyophilization from water, SA4NI1 (13.0 mg, 61%) was 
obtained as a white solid. 
α[ ]D25  = - 0.50 (c = 0.1, H2O); 1H NMR (500 MHz, D2O): δ 1.15-1.26 (m, 2H, H-3’), 
1.29 (m, 2H, H-2’), 1.60 (t, J = 12.3 Hz, 1H, H-3a), 2.02 (s, 3H, NHAc), 2.25 (m, 
2H, H-4’), 2.70 (dd, J = 4.5, 12.2 Hz, 1H, H-3e), 3.24-3.33 (m, 2H, H-9a, H-1’a), 
3.51 (m, 2H, H-7, H-1’b), 3.60-3.76 (m, 3H, H-4, H-6, H-9b), 3.81 (q, J = 10.1 Hz, 
1H, H-5), 3.95 (dt, J = 2.2, 8.8 Hz, 1H, H-8), 5.26 (s, 2H, H-1’’), 6.99 (t, J = 7.6 
Hz, 1H, Ar-H), 7.05 (d, J = 8.8 Hz, 1H, Ar-H), 7.10 (t, J = 7.3 Hz, 1H, Ar-H), 7.21 
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(s, 1H, Ar-H), 7.34 (d, J = 7.7 Hz, 1H, Ar-H), 7.37 (s, 1H, Ar-H), 7.44 (d, J = 8.7 
Hz, 2H, Ar-H), 7.82 (s, 1H, Ar-H). 13C NMR (125 MHz, D2O): δ 22.4 (NHCOCH3), 
24.3 (C-4’), 25.1 (C-3’), 28.7 (C-2’), 40.9 (C-3), 43.3 (C-9), 45.2 (C-1’’), 52.2 (C-
5), 64.7 (C-1’), 68.7 (C-4), 70.7 (C-7), 70.9 (C-8), 72.8 (C-6), 101.0 (C-2), 111.1, 
112.1, 115.4, 117.6, 122.7, 125.1, 127.0, 128.5, 129.2, 131.9, 133.2, 139.6, 
140.7, 148.3 (Ar-C), 170.3, 173.8, 175.3 (3CO). 
 
1-(5-nitro-1H-indole-3-propyl)-4-{sodium [5-acetamido-9-benzamido-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulo-pyranosynate-2-O-yl]}-methyl-
[1,2,3]-triazole: (SA1NI3) 
OO
H
N
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HO
OH
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O
 
To a solution of 31a (10.0 mg, 21.0 µmol) and 49 (5.14 mg, 21.0 µmol) in 
tBuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (1.2 mg, 6.0 µmol, 6 µl of 
freshly prepared 1M solution of H2O), followed by CuSO4.5H2O (0.15 mg, 0.60 
µmol) in H2O. This heterogeneous mixture was stirred for 36 h during which 
period at intervals was added four additional portions of Na-ascorbate (4.8 mg, 
24.0 µmol in total) and three additional portions of CuSO4.5H2O (0.45 mg, 1.83 
µmol in total). After 42 h, according to TLC the reaction was incomplete. So a 
catalytic amount of CuCl2 was added and stirring continued for 1 h after which 
TLC showed completion of the reaction. The solvents were removed under high 
vaccum and the residue was purified by reversed phase chromatography on 
LiCroPrep RP-8 (5% gradient of MeOH:H2O) system. After P2 size exclusion 
chromatography and lyophilization from water, SA1NI3 (9.0 mg, 60%) was 
obtained as a white solid. 
α[ ]D25  = - 1.4 (c = 0.1, H2O); 1H NMR (500 MHz, D2O): δ 1.66 (t, J = 12.1 Hz, 1H, 
H-3a), 1.87 (m, 1H, H-2”), 2.02 (s, 3H, NHAc), 2.16 (m, 2H, H-3”), 2.73 (dd, J = 
4.6, 12.3 Hz, 1H, H-3e), 3.33 (dd, J = 4.0, 8.8 Hz, 1H, H-9a), 3.54 (dd, J = 1.4, 
8.8 Hz, 1H, H-7), 3.69 (dddd, J = 1.9, 4.6, 7.1, 9.8 Hz, 1H, H-4), 3.77-3.87 (m, 
3H, H-5, H-6, H-9b), 3.91 (dt, J = 2.7, 8.8 Hz, 1H, H-8), 4.14 (t, J = 6.3 Hz, 1H, H-
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1”), 4.38, 4.65 (A, B of AB, J = 12.0 Hz, 2H, H-1’b), 6.80 (s, 1H, Ar-H), 6.98 (d, J 
= 8.9 Hz, 1H, Ar-H), 7.16 (t, J = 7.6 Hz, 2H, Ar-H), 7.26 (t, J = 7.4 Hz, 1H, Ar-H), 
7.45-7.51 (m, 4H, Ar-H), 7.54 (s, 1H, Ar-H). 13C NMR (125 MHz, D2O): δ 21.1 (C-
3’’) 22.4 (NHCOCH3), 29.4 (C-2’’), 40.6 (C-3), 43.3 (C-9), 50.1 (C-1’’), 52.1 (C-5), 
57.4 (C-1’), 68.6 (C-4), 70.6 (C-7), 70.9 (C-8), 73.0 (C-6), 101.0 (C-2), 111.2, 
115.7, 116.2, 116.9, 125.2, 125.7, 125.9, 127.1, 128.7, 131.7, 132.9, 139.5, 
139.7 (Ar-C), 170.4, 173.4, 175.3 (3CO). 
 
1-(5-nitro-1H-indole-3-propyl)-4-{sodium [5-acetamido-9-benzamido-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulo-pyranosynate-2-O-yl]}-ethyl-1,2,3]-
triazole: (SA2NI3) 
OO
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To solution of 31b(15 mg, 30.0 µmol) and 43 (6.29 mg, 30.0 µmol) in tBuOH:H2O 
(1:1) (0.5 ml) was added Na-ascorbate (1.2 mg, 6.0 µmol, 6 µl of freshly 
prepared so1M solution in H2O), followed by CuSO4.5H2O (0.15 mg, 0.60 µmol) 
in H2O. This heterogeneous mixture was stirred for 42 h during which period at 
intervals was added five additional portions of Na-ascorbate (6.0 mg, 30.0 µmol) 
and three additional portions of CuSO4.5H2O (0.45 mg, 1.80 µmol). After 42 h 
according to TLC the reaction was not complete. So a catalytic amount of CuCl2 
was added and stirring continued for 1 h after which TLC showed completion of 
the reaction. The solvents were removed under high vaccum and purified by 
reversed phase chromatography on LiCroPrep RP-8 (5% gradient of 
MeOH:H2O) system. After P2 size exclusion chromatography and lyophilization 
from water, SA2NI3 (5.0 mg, 22%) was obtained as a white solid. 
α[ ]D25  = - 0.1 (c = 0.1, H2O); 1H NMR (500 MHz, D2O): δ 1.64 (t, J = 12.2 Hz, 1H, 
H-3a), 2.01 (s, 3H, NHAc), 2.04-2.07 (m, 2H, H-2”), 2.45 (m, 2H, H-3”), 2.72 (dd, 
J = 4.5, 12.4 Hz, 1H, H-3e), 2.75-2.80 (m, 2H, H-2’), 3.31 (m, 1H, H-9a), 3.53 
(dd, J = 1.6, 8.8 Hz, 1H, H-7), 3.60-3.96 (m, 7H, H-4, H-5, H-6, H-8, H-9a, H-1’), 
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4.15 (t, J = 5.9 Hz, 1H, H-1”), 6.80 (s, 1H, Ar-H), 6.93 (s, 1H, Ar-H), 7.18-7.25 (m, 
3H, Ar-H), 7.36 (t, J = 7.5 Hz, 1H, Ar-H), 7.45-7.49 (m, 3H, Ar-H), 7.72 (dd, J = 
2.2, 9.0 Hz, 1H, Ar-H), 7.92 (d, J = 2.2 Hz, 1H, Ar-H). 13C NMR (125 MHz, D2O): 
δ 21.1 (C-3’’) 22.4 (NHCOCH3), 29.4 (C-2’’), 40.6 (C-3), 43.3 (C-9), 50.1 (C-1’’), 
52.1 (C-5), 57.4 (C-1’), 68.6 (C-4), 70.6 (C-7), 70.9 (C-8), 73.0 (C-6), 101.0 (C-2), 
111.2, 115.7, 116.2, 116.9, 125.2, 125.7, 125.9, 127.1, 128.7, 131.7, 132.9, 
139.5, 139.7 (Ar-C), 170.4, 173.4, 175.3 (3CO). 
 
1-(5-nitro-1H-indole-3-propyl)-4-{sodium [5-acetamido-9-benzamido-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulo-pyranosynate-2-O-yl]}-propyl-
[1,2,3] triazole: (SA3NI3) 
OO
H
N
AcHN
HO
OH
OH CO2Na
O
N N
N
H
N
N
O
O
 
To solution of 31c (15.0 mg, 30.0 µmol) and 43 (7.35 mg, 30.0 µmol) in 
tBuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (1.2 mg, 6.0 µmol, 6 µl of 
freshly prepared 1M solution in H2O), followed by CuSO4.5H2O (0.15 mg, 0.60 
µmol) in H2O. This heterogeneous mixture was stirred for 60 h during which 
period at intervals was added nine additional portions of Na-ascorbate (10.8 mg, 
54.0 µmol) and four additional portions of CuSO4.5H2O (0.60 mg, 2.40 µmol). 
After 60 h according to TLC the reaction was not complete. So a catalytic amount 
of CuCl2 was added and stirring continued for 1 h after which TLC showed 
completion of the reaction. The solvents were removed under high and the 
residue was purified by reverse chromatography on LiCroPrep RP-8 (5% 
gradient of MeOH:H2O). After P2 size exclusion chromatography and 
lyophilization from water, SA3NI3 (10.0 mg, 45%) was obtained as a white solid. 
α[ ]D25  = - 0.3 (c = 0.1, H2O); 1H NMR (500 MHz, D2O): δ 1.66 (m, 3H, H-3a, H-2’), 
1.89-2.01 (m, 2H, H-2’’), 2.00 (s, 3H, NHAc), 2.36 (t, J = 7.0 Hz, H-3’’), 2.40-2.54 
(m, 2H, H-3’), 2.72 (dd, J = 4.7, 12.5 Hz, 1H, H-3e), 3.36 (m, 2H, H-9a, H-1’a), 
3.51 (d, J = 8.9 Hz, 1H, H-7), 3.60-3.71 (m, 4H, H-4, H-6, H-9b, H-1’b), 3.84 (m, 
2H, H-5, H-8), 4.07 (t, J = 6.5 Hz, 1H, H-1”), 6.92 (s, 1H, Ar-H), 7.14 (d, J = 8.9 
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Hz, 1H, Ar-H), 7.22 (t, J = 7.6 Hz, 2H, Ar-H), 7.26 (s, 1H, Ar-H), 7.33 (t, J = 7.5 
Hz, 1H, Ar-H), 7.50 (d, J = 7.4 Hz, 2H, Ar-H), 7.6 (dd, J = 1.8, 9.1 Hz, 1H, Ar-H), 
7.86 (d, J = 1.8 Hz, 1H, Ar-H). 13C NMR (125 MHz, D2O): δ 22.1 (C-3’’), 22.2 (C-
3’), 23.2 (NHCOCH3), 29. 6 (C-2’), 30.2 (C-2’’), 41.6 (C-3), 44.2 (C-9), 50.8 (C-
1’’), 53.1 (C-5), 64.8 (C-1’), 69.5 (C-4), 71.5 (C-7), 71.6 (C-8), 73.7 (C-6), 101.8 
(C-2), 112.4, 116.9, 117.2, 118.0, 124.1, 126.9, 127.0, 127.9, 128.0, 129.7, 
133.1, 134.3, 140.6 140.9, 148.3 (Ar-C), 171.5, 174.8, 176.3 (3CO). 
 
1-(3-propyl-5-nitro indole)-4{sodium [5-acetamido-9-benzamido-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulo-pyranosynate-2-O-yl]-butyl}-1H-
[1,2,3] triazole: (SA4NI3) 
OO
H
N
AcHN
HO
OH
OH CO2Na
O
N NN
H
N
N
O
O
 
To solution of 31d (15 mg, 29.0 µmol) and 43 (7.10 mg, 29.0 µmol) in 
tBuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (1.2 mg, 6.00 µmol, 6 µl of 
freshly prepared solution of 1M in H2O), followed by CuSO4.5H2O (0.15 mg, 0.60 
µmol) in H2O. This heterogeneous mixture was stirred for 60 h during which at 
intervals was added the 9 portions of Na-ascorbate (10.8 mg, 54.0 µmol) and 4 
portions of CuSO4.5H2O (0.60 mg, 2.40 µmol). After 60 h according to TLC the 
reaction showed slight presence of starting material still. So a catalytic amount of 
CuCl2 was added and stirred for 1 h after which TLC completion of reaction. 
Solvents removed under high vaccum to dryness. This was taken in H2O and 
purified by reverse chromatography on LiCroPrep RP-8 bed in MeOH:H2O (5% 
gradient) system. After P2 size exclusion chromatography and lyophilization, a 
white solid of SA4NI3 (10 mg, 45%) was obtained. 
α[ ]D25  = - 0.7 (c = 0.1, H2O); 1H NMR (500 MHz, D2O): δ 1.24 (m, 2H, H-3’), 1.36 
(m, 2H, H-2’), 1.66 (t, J = 12.1 Hz, 3H, H-3a), 1.89 (m, 2H, H-2’’), 2.02 (s, 3H, 
NHAc), 2.27 (m, 4H, H-4’, H-3’’), 2.73 (m, 1H, H-3e), 3.31 (m, 2H, H-9a, H-1’a), 
3.54 (d, J = 8.8 Hz, 1H, H-7), 3.60 (m, 1H, H-1’b), 3.67 (m, 1H, H-4), 3.75-3.85 
(m, 3H, H-5, H-6, H-9b), 3.99 (m, 2H, H-8, H-1”), 6.87 (s, 1H, Ar-H), 6.92 (s, 1H, 
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Ar-H), 7.01, 7.09 (m, 4H, Ar-H), 7.26 (s, 1H, Ar-H), 7.37 (d, J = 2.1 Hz, 2H, Ar-H), 
7.54 (d, J = 8.9 Hz, 1H, Ar-H), 7.65 (s, 1H, Ar-H). 13C NMR (125 MHz, D2O): δ 
19.6 (C-3’’), 20.6 (NHCOCH3), 22.5 (C-4’), 23.3 (C-3’), 27.1 (C-2’), 27.6 (C-2’’), 
39.1 (C-3), 41.6 (C-9), 48.1 (C-1’’), 50.5 (C-5), 63.0 (C-1’), 66.9 (C-4), 69.0 (C-7), 
69.2 (C-8), 71.1 (C-6), 99.3 (C-2), 109.8, 114.0, 114.5, 115.2, 120.7, 124.1, 
124.4, 125.2, 126.8, 130.1, 131.5, 137.8, 138.2, 146.1 (Ar-C), 168.3, 172.0, 
173.6 (3CO). 
 
1-Pivaloyl-4{sodium (5-acetamido-9-benzamido-3,5,9-trideoxy-D-glycero-α-
D-galacto-2-nonulo-pyranosynate-2-O-yl)-methyl}-[1,2,3]-triazole: (41) 
OO
H
N
AcHN
HO
OH
OH CO2Na
O
N N
N O
O
 
To solution of 31a (10.0 mg, 21.0 µmol) and 40 (3.92 mg, 25.0 µmol) in 
tBuOH:H2O (1:1) (0.5 ml) was added Na-ascorbate (0.41 mg, 2.1 µmol), followed 
by CuSO4.5H2O (0.052 mg, 0.21 µmol) in H2O. This heterogeneous mixture was 
stirred for 48 h during which period at intervals was added three additional 
portions of Na-ascorbate (1.23 mg, 6.30 µmol) and two additional portions of 
CuSO4.5H2O (0.104 mg, 0.42 µmol). After 48 h according to TLC the reaction 
was not complete. So a catalytic amount of CuCl2 was added and stirring 
continued for 24 h after which TLC showed completion of the reaction. The 
solvents were removed under high and the residue was purified by reverse 
chromatography on LiCroPrep RP-8 (5% gradient of MeOH:H2O). After P2 size 
exclusion chromatography and lyophilization from water, 41 (7.0 mg, 45%) was 
obtained as a white solid. 
1H NMR (500 MHz, D2O): δ 1.11 (s, 9H, C(CH3)3, 1.68 (t, J = 12.2 Hz, 1H, H-3a), 
1.99 (s, 3H, NHAc), 2.73 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.51-3.55 (m, 2H, H-7, 
H-9a), 3.66-3.71 (m, 1H, H-4), 3.77-3.86 (m, 3H, H-5, H-6, H-9b), 3.93-3.97 (m, 
1H, H-8), 4.60, 4.87 (A, B of AB, J = 12.2 Hz, 2H, H-1’), 6.27 (s, 2H, H-1”), 7.48-
7.51 (m, 2H, Ar-H), 7.57-7.60 (m, 1H, Ar-H), 7.74-7.76 (m, 2H, Ar-H), 8.15 (s, 1H, 
Ar-H). 13C NMR (125 MHz, D2O): δ 22.3 (NHCOCH3), 26.2 [C(CH3)3], 40.6 (C-3), 
43.1 (C-9), , 52.2 (C-5), 57.6 (C-1’), 68.5 (C-4), 70.2 (C-7), 70.5 (C-8), 70.6 (C-
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1’’), 73.0 (C-6), 101.1 (C-2), 126.4, 127.4, 129.1, 132.4, 133.9, 144.7 (Ar-C), 
171.5, 173.5, 175.3 (3CO). 
 
4-methyl-(5-acetamido-9-benzamido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-
nonulo-pyranoside-2-O-yl)-[1,2,3]-triazole: (42) 
OO
H
N
AcHN
HO
OH
OH CO2Na
O
N N
NH
 
α[ ]D25  = - 0.9 (c = 0.1, H2O); 1H NMR (500 MHz, D2O): δ 1.70 (t, J = 12.2 Hz, 1H, 
H-3a), 1.98 (s, 3H, NHAc), 2.73 (dd, J = 4.6, 12.4 Hz, 1H, H-3e), 3.53-3.59 (m, 
2H, H-7, H-9a), 3.67-3.72 (m, 1H, H-4), 3.75-3.85 (m, 3H, H-5, H-6, H-9b), 3.96 
(m, 1H, H-8), 4.67, 4.92 (A, B of AB, J = 12.2 Hz, 2H, H-1’), 7.49-7.52 (m, 2H, Ar-
H), 7.59 (m, 1H, Ar-H), 7.75-7.77 (m, 2H, Ar-H), 7.89 (s, 1H, Ar-H). 13C NMR 
(125 MHz, D2O): δ 23.6 (NHCOCH3), 41.9 (C-3), 44.2 (C-9), 53.4 (C-5), 60.3 (C-
1’), 69.7 (C-4), 71.4 (C-7), 71.6 (C-8), 74.2 (C-6), 102.4 (C-2), 128.7, 130.3, 
133.7, 135.2 (Ar-C), 173.5, 174.8, 176.2 (3CO). 
 
General procedure for in-situ click chemistry experiments: 
 
The stock solutions of alkynes (10 mM in H2O) and azides (40 mM in DMSO) 
were prepared. Each alkyne (4 µl) was added to the stock solution of MAG (94 µl 
of 1 mg/ml solution, in PBS buffer) in an eppendorff. After 2 min the azide 
compound (2 µl) was added. It was observed that the azide compound did not 
dissolve completely in the reaction mixture. So the 5 µl of DMSO was added to 
reaction mixture to dissolve the azide compound. Then the eppendorff was 
shaken at 37°C for 3 days. So the final concentrations were: MAG (8.77 µM), 
Alkyne (380 µM) and azide (760 µM). 
 
To cross check the results in parallel two control experiments were also 
performed, one with BSA (94 µl of 1 mg/ml in PBS buffer) and other in ‘absence 
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of protein’. In the case of ‘absence of protein’ only PBS buffer with pH 7.4 was 
used. 
 
 
LC-MS analysis:  
 
The samples were analyzed by reverse phase chromatography with ESI mode 
spectroscopic detection in the negative ion mode with selected ion monitoring of 
only the expected m/z. Samples of the reactions were directly injected (10 µl) into 
the LC-MS instrument to perform LC-MS/SIM analysis. The products were 
identified by their retention times and molecular weights. The components were 
eluted using four different elution solvents: Solvent A1 (0.2% HCOOH in H2O), 
A2 (H2O), B1 (0.2% HCOOH in MeCN) and B2 (MeCN). The presence of 0.2% of 
HCOOH results in fast denaturation of the protein and release of product on the 
column. This allows the detection of compound at relatively low concentrations 
which is an advantage of the LC-MS/SIM analysis.  
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